var title_f12_27_12720="TSH receptor gene mutations";
var content_f12_27_12720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Serum TSH and free T4 in various forms of RTSH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 473px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results shown are from a representative family having each of the four forms of resistance to thyroid stimulating hormone (RTSH). Note that by definition affected family members have high TSH. Free T4 concentrations vary considerably according to the type of defect and within subjects with the same defect. For details,&nbsp;refer to the text&nbsp;of the topic on resistance to thyrotropin.",
"    <div class=\"footnotes\">",
"     TSH: thyroid stimulating hormone (thyrotropin); RTSH: resistance to thyroid stimulating hormone; Chr 15: chromosome 15; FT4: free T4 (free thyroxine).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12720=[""].join("\n");
var outline_f12_27_12720=null;
var title_f12_27_12721="Skin tag thigh PI";
var content_f12_27_12721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin tag on the thigh",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin tags are small growths of normal skin that&nbsp;often grow on a short stalk or stem (as shown). Skin tags tend to form in places where the skin rubs together.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12721=[""].join("\n");
var outline_f12_27_12721=null;
var title_f12_27_12722="Leiomyoma gastric UGI";
var content_f12_27_12722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leiomyoma of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 192px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper gastrointestinal study demonstrates a well circumscribed smooth- appearing mass (large arrows) arising from the wall of the proximal lesser curvature of the stomach. A small central ulcer crater filled with barium (small arrow) along with the well- defined margins of the mass are typically seen with leiomyomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12722=[""].join("\n");
var outline_f12_27_12722=null;
var title_f12_27_12723="Periphepatic packing to control bleeding from the liver";
var content_f12_27_12723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Periphepatic packing to control bleeding from the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 534px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIWAhYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKyNU8RaTpeRfX0Mbj+AHc/8A3yMmk2lqyowlN2irs16K4u2+IugXGqQWImljeZ9iSyJtQt2Gc8Z6fWu0pRkpbMqpSnSdpqwUV5V8RPiXd+GvEb6XYWltKIoUkd5txOWzwMEccCuW/wCF26z/ANAywP8A33/8VWcq8IuzOullterBTitH5nv1FeI2XxwfIF7oYI7tFcYx+BU/zrpLH4xeG7jAuUvrQ+skW4f+Ok01XpvqTPLsTDeH3anpVFcnafEPwpdgGLW7Vc/89d0f/oQFa9tr+jXK5ttVsJh6pcof61alF7M5pUakfii18jVoqKGeKUfupY3/AN1galqjMKKKKACio5ZEjXMjqo9WOBVCbXNJgz9o1Oxjx/fuFH8zSbS3GoylsjTorm7jxv4bg+/rFqcf3CX/AJA1mXPxN8MR/cvJZv8AcgYf+hAVLqQW7N44SvLaD+5nb0V5xN8XNCTIitdQkP8A1zUD9WqjJ8YbIf6rSbhv96VR/jUOvTXU2WW4qW0Geq0V5E/xkGfk0Mkepu8f+yVGfjJJ20RR9bon/wBkpfWafcv+ysX/ACfiv8z2GivHR8ZJe+iKfpdY/wDZalT4yD+PQyPdbvP/ALJR9Zp9w/srF/yfiv8AM9dory2D4w2DY8/S7pB/sOrfzxWzp3xN8O3hCyS3NoT08+L/AOJJqlXpvqZTy/Ew1cGdzRVTT7601CATWNxFcRdN8bhh+lW613ORpp2YUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKimlSGJpZWCRoCWYnAA9aAJa5PxP430vQlaMOLq7H/ACyjYYU/7TdB9OT7Vw3j74iedFJbaZI8Fn0aXlXk9h6D9T+leNajrTXDER5CdhXHUxPSB7mEyjmSnX08v8zv/EXxK1O/dwbk28JyBFASo/E9TXEXGsTzkiP5Qe9ZEStM+5jmtGCD2rjnJyerPoaNCFNWgrIpX0rrbvNMksqDqsa7jjvxXv8A8AfG9r4l8MjTJLwzanppKN5jEvJFn5H55OAQp9COeorxuKMAdK4TU7/UfB/jGPWNHkkt3R1mXYxUSDILI2OoOOR3BrTD1OWRyZphPbUtOh6J8ZNdsn+Mup2xkKokENu7MMASBd3X0w2M+tZwtUx0ry/x94zfxv4wvtaks1083RTMCvvwVRV+9gZztz0rqfAeuPOsOnXoJkI/cyddwAztPvgU8RF81wy2cXRUOyOnNqpHAqCS1K8jmttEpWiBHIrnO/Q5t4j6YNMVnibchKt0+o9DW7Pag8gVnzQY4xRcORPYX7Ol3AZrJdk8YzJAO49VH9P8l9jfXMJGy7uEX/ZkI/rVe1lezukmT7w7eo7g1p6zbRyRx6haD9xJ98d1b3/z/OquYtcrtLYvrrWpBQF1S+x2H2hv8ail1S9k4kvbl/8AelY/1rFhJ6dqsAUm2aqnFdETu7O25mLN6k5NNzTOaOam5pYfzScetNAJpwQmi4WEyKNwp4jpfLouFiPdSbjUhjppTFFxjeaAcUuKMUgHBgKGbuDTCOKjyQfamS0XtO1i90a4Fzp95LbyjqUbG4ehHcexr6W8FatLrnhbTtSuY/Lmnj3OAMDIJGR7HGa+e/AHhSTxfr4hYldOtsPcyDg47KPc4/AZNfTdpbw2ttFBbxrHDEoREUYCqOABXoYWMrNvY+ZzqpTbUF8RPRRRXYeEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4l8U/HCzNLY2sgFjE2CQf9cw/wDZf59fSux+KfiT+x9J+yQSbLi4UlmBwUj749z0/OvmDVr5767dyfkBwo7YrjxFV35Ee9lOCv8Av5r0/wAw1G/lvpSznCdhUMEZY0yNSxxWvZW/QkVxvRH0EVcltIAACRV9VAojXAwKlCiszdaDAcVk+KrFL/RLtWXLqhdPUMATW1sz0qO8hP2G4I5IiYgfgaFvdA2rNM+dh9/zFHOa73wJcGTVrNjjbuI/HacVxVjbPODs/hb5vYetdlo1usAs5kOwRyBvQttOf6V14jVWPMyqMlzS6NfeevAU6jhlDKcgjIIorlO0Yyg1UuIQcmr1RuuRQNOxiTxcHHXtVjQrkb3sp+YJ/lPscYzU1xF3FZcgMU4deCCGFCHOPNEsLC0M8kL/AH42Kn/GrCR5qXVV/wBJtbxPuXMYDH/aA/z+VT2yA4pMdN3iRLb+tPFuKvBB6U4RZpFlEQCneSKvCEU4QigCh5QpRCPStAQrTvKWgDN8gHtSG1JHStQIB2ocALQBiPbkVA8ZBrXkAzVadRimgM4iq10+xDjqeBVpz1q14M0g+IvGGnWBG6BpA0vp5a8t+YGPxqoq7sjGrUUIuT2R718ItBGheDbYyLi6vcXMueo3AbR+C4/HNdxSABQAowBxgdqWvZjFRVkfCVajqzc5bsKKKKZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTHdY0ZmICqMknsKfXM/EO//s3wfqMynDsnlL/wI4P6ZpSlypsulB1JqC6nzz8UvEb6trNyysdsj/KP7qDhR/nvXCKvQVNfTG5vZZG5yeKIVywrym7u7PuIQUEox2RbsoMkVtQoFUCqtnHgCr6CspHRFWHqMCnqpNCjNWIkpDCKLNWWgEkDp03KVz1xxilRcCpVOKaM5M8f8ReF4/CzwMLvzILvKyZTaQwGcgZ6c1jpcsLeDPHlucjj/PSvSvibYPc6ILuIBnsyZCp6FTwT9e9eO284F6iuxKS+vrWiTndhSqRoKMF3/P8A4J7T4KvVvNBt1L5kgXynGckbeBn8K22FefWFxNourq7Hz4kYWzSRtlZIwAFI4GRjlT6fWvQLeaK5gSaBw8bjcCPSsjStTdKVmLTcU84pKZjcgkXNZV/CVw3pWywqtdxh4mHfHFItMksUF94ZljH+ttmLr+HOPyJFOsWDIp9RTfB0gFzcxNypAJHqM4/rUVuhtZ57YnmCQoM9xng/lTZFN2k4myqjGadimQtuQVLUm4UoWkpVNAmO2ikOKCaSqBBTJDhaUkCoZmOKQyBjk1VumGMVPIwVSazriXOaESypdyBEI7mvWv2fNBKpfa7OvL/6NAT6Dlj+e0fga8ejilv7+G2t13TTyCKNfUkgAfrX1r4b0iHQdDstMt+Y7eMLu/vN3P4kk12YWF5c3Y8XOcR7Ol7Nby/I1aKKK9A+WCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8w/aAvja+DooVODNcDPuAp/+tXp9eI/tLzYstEgB4LSsR/3wB/Wsq7tBnbl0ebEwX9bHgyDvV2zXJqoo4rRsV6V5rPsUa0AwBVpBxUEQ4FWEFZM36E0S5q3GvNQQirKUEPYkp4pq9adTRmY3jFS/hfUwvU27/lg5rwK5RvsMUiffhO79a+hPEeP7B1AucKIHyfbaa8MS2LWTREfMcjFaQnyidD23NFdn/mvxOz0FG1KKJnd3QqASzE4wABj8ABXUaVY3GkaybUN/oVxB5yqeSr5xz6ZAz6EVw/gnUU0yyEFwMSJIWLk9sDAxj2bn3rrm15Jby3libzGXKsgOMDHOPfFKUVFncpPFUE7ar+mdMCaWoraZLiCOaI5R1DA9OKlqLHEIRTSoIpxpKLAUPDrGHxC0X99WX9N39K0PEEYh11JlGFuogx/314P6BazrcG38TWT54aRf1OD/Ot3xcg/s6CX+K3uACfZgc/0qjKTtUTK9kxxg1azVG2bBq6KzOxbC5pQaSgUASZ4prNikLYFQu9ADi2ahlbihpAKpXM/UCmIiupewNZl1NhcZ5NS3MwVcn8BS+HdGvfEutQafYJulkOSx+7Gndm/z7VUYt6IyqTUU5PZHofwH8MG+1WXXbuPNvafJb7hw0p6n/gIP5n2r36szw9pNvoWjWmm2g/c26BQT1Y92PuSSa069alDkjY+KxmJeJqufTp6BRRRWhyhRRRQAUVTvr+Cz2iVi0jfdjQZZvoP61mzX97Pny/KtEzwSN7kfyH60AbjMEUsxAUc5PGKpHV9PG7F7buRyQkgY/kKxzaLKd10zXLA5BmbcM+w6D8AKsxW4AwAg9gMCnYdiy+twoodre68o/xiInH1X736VKNYsGQtHcpIR1SPLuPqoyf0qutuR0OAOuKSewgumD8xzqMLLGdrD2yO3saQWJ/7UJ+7Y3ZU9CQi5/AsD+lOTU8nD2d1GPVlUj9GNU83tmD5oNzGo4dCQ/4r3/D8qdDOLlA8Loy8gkckH0PHWgLF+K/gkOF80f70LgfmRUn2qDvIFxz83H86oohxjjrzx/8AWqVInBDKf6f0oCxbhnhmJEMsbkddjA4qWs2e1SVldsxzL92VDgj/AOt7HiljvWgdYr4gEnCzKMKfr6H9KAsaNFIDkZByD6UtAgooooAKKKq3l9aWSb7y6gt09ZZAg/WgNy1RXHaj8SfCNhuEutW8xHa2DT/h8gIrm7v43eH4lP2ax1O4bt8iID+bZ/SodSC3Z0Qwlefwwf3HqtFeHXHx1fJFr4dGOxkvMfoE/rWZP8b9cbPkaXpsY7bt7/8AswqHiKa6nRHKsU/s/ij6Eor5yf41eKm+7baOv0t5D/7Upn/C5/Fn/PLSP/AaT/45U/WaZosnxL6L7z6Qor5vHxm8V/8APHSD/wBu0n/xyrMXxq8SADzLHSG9Sscg/wDZ6PrNMP7HxPZfefQ9FeF2nxxu0wL3QoZB3aK5KY/Aqc/nW/YfGzw/MVW9s9RtGJwW2LIg/I5/SrVem+pjPLcTDeH6nqtFYmg+J9F8QLnR9Rt7psZMath1Huhww/EVt1onfVHFKLi7SVmFFFFMQV4T+0rnzdFHbbJ/Na92rw79peM7NCkxwfOUn/vj/GscR8DPQyv/AHmPz/I8MHWtKw7Vmd60rBuRXms+ujubMfSrEdV4+lWYhxWZs9i1F0qdKoXdut3aS27s6LIpUlGII+hrk9S8JXL4K315dIBtCSTElfoaaS6synKW0Vc9BAxVLUdVsdNQtfXUUPoHYAn6CvIbnwtrEUTmSa+SBD8vDEAevB/WucutIu0LPveYd3Q7vzraMIvqcs6tWK0h+J6R4v8AHVlcaXNa6bvdpRtZ3GAB3wO9edwXpneOJOGHJP41l/ZpWLKCd3oatWdlLBcI+Ccgg4zxWqpQRzwxddv3Vo9zs/DKLeX5+zxwGaKKWUpNGZFYIhZgVwc8Z5PA65GM1oeEreyu9REGotJCCrmBokyZJ/8AlmjcH5ScDNc9pUzm4jBKKFQqCqgEjJJyQOTyeTzjjoK7PS4I3jJEYR1OB65zwQa56+59DlkHUpt3s3obXhaYS6Uwz80crqR6Endj/wAerXzWD4UtpLZtRWUku8vmkk5JLZ5z3rdqTinFxbi+gtIaKKCClc4XUtPkxkLKM/mDXT+KIRJoeoYOWUJKB6YIz/WuX1T5YFk/uMG/UGu8eNL2ykiOCs8RUn2I/wDr00c9d2aZxdpJvhR/UA1oRvxzWFpshjRoZOHjYqwPY5rVjcEdahrU7ou6Lm4UnmCoM01nC96RRM78VWklAqGW496pyTE96dibk805PSqM8wUEk/hUFxdBeFOWrrfAvw61TxTLHdXYey0okEzuMNKPRB3+p4+vStIQcnZHPWrwox5puyOb8PaJqPijVUstNh3yHlnbhI1/vMf857V9KeA/Btl4Q09obYma7lwZ7hgAXPoPRR2Favh7QdO8P2K2mk2yQRDBYjlnOOrHufrWtXo0qCp6vc+Vx2YyxPux0j+YUUUVueaFFFFABWbq1+bVUihUPdS52Keijuzew/XpVm9uo7O2eaY/KOgHUnsAO5rmJJpGLyzn9/JywHIQdkH0/U5oGkSRlYHfcxluJD88jYyT6f8A1hV23jDcsDn3xWfapvfccEn9K1oVGBxx/nimyh4jz9KnjTHanovGelShRSERkcU1UOeKlK0qr3oEOCjGD+VUZrFTKZ4D5c3c4yGHow7/AMxV8fpS5oC5UtG8wHI2Opwy5HB/LpVnaPWqiMJb0vEfkQFWPZj6D6VdxQAwovtUUkIbKsAy4wQRkEVZppA/woC54Z8UfCWo6Xczar4Tvb2ylOZJYLado1l9SNpHP8682tPHHinbtXxBqYZeCHmYkH3ya+tLm3juYnhlUFWBGSM+1fNnxd8JNol//alom23eQRzqP4WP3W+h6fWuOvCUfei9D3MuxFOo/Z1Um/NGUPG/iojB1+//AAkxUcnizxJLw+v6t/wG7kX+RrBiJdQRVuGEtyRXJ7SXc91YWkvsL7kPuNQ1K6/4+dRvp89fNuXf+ZqmYBu3FAWPU45/OtRIPaneQfSocmzVU1HZGV5XtQIWPatdLUk9KsJaj0pXL5TEW1Y9qeLQ963ltfanraE9qVx2MAWoFPW1Brf+wg9qDZbegouFjCNnjpUTw7eoreaAjtVO6hIHSgaMllFQSIKuupFQSLTEyta3NzY3sN1YzSQ3UTho5EOGU/57d6+ytGnnudIsZ7yLybmWBHlj6bHKgkfgeK8L+Bfg5dS1KTX9RiDWlq2y1RxkSSjktz1C/wA/92voKvSwsGo3fU+UzivCpVUI/Z6/oFFFFdJ44V5F+0dbeZ4X064Az5V1s+gZT/8AE167Xn/xwt/tHw9vCBnypI3/APHsf+zVnWV4M68DLlxEH5nyyetXbJsMKpsKkgbawrzGfZo6aA5Aq2nArJspwcA1rRkEcVmbPYlU1Kjc1Dinp94UEFxGOKiubG1uuZ7eNyDnJUZ/OpEqShEHn3iW1sItZna2t40aKNRIqgAMcZzj6GuE166SIF1xGQOgOM8V0XxZgm0/Wob23LKl3EAxUnllwD+m2uCjSbVbsQDJ6lvb1ropw+09jCti7Q9jTXv30+Y/QryV58yMfKH8Wf0r0DTdQjjn3qkyWrMFjdyCSfQkD3riLjTLjRkLSxh4ie3Wreh3k8p+yynbCWDAFjtRuzAZ64457VdaEZpyiLLcTVwso0qq1v1/r7j0bR7kR+JnXzSyTx7QM5GQSf64rrCDmuW05Le/KLcoFdBtE8Z2kcdSK0tL1M/bzpt8yNOB+6lB4lGOh965Ej08XG0nLozWxRUzREVEy4oOQq36b7SRfUV0PhHUBc6RbBmzLAPJkHcEdD+WKwJmJRh2wRWX4e1E6fquGP7mVtrA9OvBqkZ1Y80TW8Y2Z07WRdRj9xdfMQOzd/8AGqsU+ACDweldrqljHrGmvbOQrgBkf0PY/wBK81leWyke3mTbJGxUg9jSauGHq6WZtm64qCS4J71km8fsBRbpdX9wkFrFLPPIcLHGpZmPpgdaSibudlqW5rtF6nJ9BT9J0/UvEF8tlpNrJPM3JCdFHqx6Ae5r0Twf8HLu8CXHiSc2cJ5FtFgyEf7TdF/U/SvatC0TTtBsxa6TaRW0I6hRyx9SepPua66eGb1lojxsXm9On7tL3n+B534D+E1npRS88QmK+vQQywDmGP65+8fqMex616sAAAAMAcACloruhCMFaJ87XxFSvLmqO4UUUVRiFFFFABTXdY0ZnIVQCST0Ap1ZGrubiZLJD8uBJP8A7uflX8SD+APrQBn3U73ky3DqVhHEMbcHBHLEeuO3Ye5NU5CC+M59uuTVuYkkv+XHbHrUEKAtk/ePtTKRYt0IwBnJ6kHqa1LdckdQB0FUoYgMYABPTjoK0LcAUhssgYp1RhucVKooJDbS4pwpDQFwqjqcjrCIoDiaU7VP90dz+VXScVTgAnmec9Pux/TufxoAfaRLDEqIMKBgVZFMGAP8KcD/AJ60AOoopCaBDJB/n0Nc1450aDWdBuYZlyskZjY9wD0P4HBrpz6VFJGJI3jk5VlKke1Jq6sXCTi1JdD47treS2uprO4GJoJCjD3Bwa3ba3BUcVf+I2nDTvF32hRhbofN/vqdrfyU1FZYIFeNOPLJo+7w9X2tKM+45bUAdKcLYelWqdUXNyusAFPEYFS0mKAGhR6U4CnBaXFIVxMUEUbhRmnYCCReap3ajaavSVUvDhDQBizqAarxQSXVzDbW67pp5FijHqzEBR+Zqa4bk113wb0r+1PHVtK65hsUa5bPQsMKo+uWz/wGtaceaSRhiavsaUqnZH0B4e0qHQ9EstNtf9VbRiMHGNx7sfcnJPua06KK9jY+Dbbd2FFFFAgrnfiDbfbPBOtQ4yfszuB7qNw/lXRVBdwLc2s0D/clQofoRilJXVi6c+SSl2Z8SSrhmHoTTF4NWr2FobuaKQYdHKkehzzVXvXkn3KfUvWjkMK3rOTPBrm7Y/NW3ZHkVmzXoa4NOXrUak09OtAXLEbHNWaqR/eFWZHWKNnc7VUFiT2GMmhEM88+LEyB9Ohl+4Q7fTlef0rjvBUSxzzyOmC/zKT3FVPGevPrWszSoT5IO2MH+7VnQdSt4o4orpGRl6MBwwz1rocGoWOWhXp/WOZ7L/hjqtWiS5sJUdfmxlTjqa5BmgcpAfkdRznjiuw+0wyoggIdW4z6HFc9rOkyrseQAqDwy/T9Oazpu0j2sXTc6Xu2Ze0bVZbCfNhcbWaNomyAQyspBBBHoSK2Jb1bizhKQhJ7eQSK44IPWuGtA8bkgHcDyMYrrdNeOa364ZhjPTPsadVW1Ry4WfNFxmtT0ywuY76zjnjIIYc+xqO5IWuZ8H3TQPc2jt8v3k9vUVpX96EJ5yazMmrOw+5lCRsxPauYdtzk+pqe7unnOM/L6VseE/CGseKbny9LtiYgcPcyZEUf1bHJ9hk1UYtuyInOMI80nZHp/gnyNf8AD9tOqyfaIF8qQxgnlQOvH0NPv/hwPE+obllewMY+eZrdj5g4wMZHNemeCfDlv4V8PW+mWrF9mWlkIwZHPJb2/wAMV0Fd8cOrJyPl6mYyjN+y26HkmmfBLSIJVa/1G7u1HOxAIlb69T+teiaF4e0nQYimk2EFrkAMyL8zfVjyfxrXoraNOMdkcdXFVq38STYUUUVZzhRRRQAUUUUAFFFFADJZEiieSRgqICzE9APWuYgm8xGnk+WWZjIyk8rkcA+4XaPzrX1s74obUc+e/wAw/wBhRlvwOAv/AAKsXUSiP8zAc7j2GaY0NllJB/nRCctnnAqBMHAQhs+lX7ZBkBu3OPegot24IGc/Me39KuRZB5Gf8arKAOewq1EflBpATDr71MBgVFFyTU1BLFprHtRnP0qOeRY42Z22qBkk9hQIp6ncbVSFTh5Ttz/dGeT/AEq3CqhFCjAAwKoQx+Z5kkgP7zgA9QvYfXv9as2bEZjf769/UdjQMs0c0tBFAgBFOqMHBI/QU7PpQAHpUUjAKcnA7U9iB7nqBVeQb2K9ccEe3XmgZ438XrASi+YL88Di5UjqAQN34c5/CuB0ybcqH1FezfEGFPt9r5q7454mif0Yc7h+RxXiFvE9ncTWrnc1vIUJ9RnGf615eJjabZ9blFXmoqJ0INOqGBtyA1NXKeuFOAptLuxTEx3AqNmoY5ptArBmgmmk4pjPQApaqGoyBUxVh5MAmsi9l3sfSmgKcjZr3b4C6MbPw3c6nMm2W/lwmevlJkD/AMe3n6Yrw7TLC51fVLXTrEBrm6kEceegPcn2AyT7CvrPRdOh0jSbPTrUfubaJYVz1IAxk12YSF3zHhZ3iOWmqK3evyL9FFFegfMhRRRQAUUUUAfIfxHsvsHjnWYAMD7S7KPQMSw/nXMOOa9K+P8AaC28eNMBj7TBHL9cDZ/7LXm55FeXNWk0fbYWfPRhLyQ63Pz1t2PUVhwD5xW7p/asZHVE10XingU1TxTs0h2JoT81cr8Tta/s/RvsULf6TefIAOoT+I/0rqAwXknAFeZeK7G78QeJy9mvmIoEatnKxqDySe3erp2vqc9dtRtHdmN4R8ODU71RNGfJjO6Vu2OcKD6n+VetJbwpCIlijEQTYEwMBfTHpVfR9Oi0vT4rWDkKMs2MF27k1donNyZVCiqcbdTlT4VgsZJrixklwx3GE4IA64FZV/qEaxmAgkDIO7PJ6Ee1d8TisjWtGsdWhZLlCrnLCROCDjgn1/Gpvd6nZRrOjHlitDynUpfKdTA3Pcj09P5V7xo/gpfFvwGsdb03T4bXX7NZCHiAAvEjdgdwHVsA8nnK46GvBr+zl0x5re5XDBsqT1xmvtP9neQSfB3w8VjMYCTDBGM4mcZ/HrXZQgpXTPBzbFyhacNNdj5P0rVnF9AyjDnIP5Guv0bR9V8SX4ttLtJbmY8naMKg9WboB9TXuXiT4LaFrPjGHW1c2VuVzcWdtGFEz5J3bv4c55wOevB5r0bRtI0/RbNbTSrSK1gHO2MYyfUnqT7nmmsK767GNXOo8l4K8n+B5l4P+DNhZCK58STfbrkfN9njJEKn0J6t+g9q9XtbeG1t0htoo4YUG1UjUKqj0AHSp6K64QjD4Tw6+IqV3eo7hRRRVGAUUUUAFFFFABRRRQAUUUUAFFFFAHLeOXuIYbSSzn8mZ2aAEYyA2CxHuAhrjrjSbd9StrYxI7SOAzuNxwBknJz9K7HxGpuNdtI8/LBEZMdsscA/kp/OsWFT/wAJJzz5duSD7k4/pTLiSf2Lp7IM2cSNzgooBxRFYNb82V9cwgfwlvMH5MDj8DWuBiPjPC9mpttGxOWD8kEZINAFD7fqVscTwx3UfdoMhwPdc81taXqdtfDET7XHVG4YfUU37MGIyvf+lLNp8EuDJGCy9HHDD6HtQBswgVIaxoZ7mxXEyvc246Ooy6D3Hf6ir6X1s8DSrNGUUZJz0+vpSJZNLMkUbSSMFRQSSTgAeprNil/tLZMwK2wO5FOQX9Cfb2qpcLLrDDeDHYK2QpHMvoSOwrUiUKmPQcUwHnoMU2X91tm/u8H/AHSamRc9e1SMoK7SMqeCO2KQApHX16Up/wA5qvbgohQnlDtz3x2qwDnHHWgQnT/61HtTuDTWYD+dA7jWGQPfIOKhbPAUc46c4H1/wqRjkNzgdR60xiozxgZyAOSeKAOT+IVuG0NZ+slvKCp74PBz+IzXiHiWEQa+sqj93dxhwfU9D/Ja9o8ea7Z2r2miNIhvdSfaiHB2hQWJI/DFeX/EhUWz0q8GMiTYSp4UEc9umVArhxKTl8j3sqk4JX7mdZn5MVZzVC1kAFWg2a4GfSkuaSkBpaQMKYxpWao2amIRmxULtildwKo3VwFB5p2C4l1OFBGax7i4Ayc0y6uSxJzxVjwnoN34s8QW+l2WVDndNLjIjjB+Zj/h3OBVxhd2RjUqqEXKWyPV/wBn3w/5pufEV1GeCbe0yP8Avth/6Dn/AHq9vqhpGm22k6ZbWFhEIrW3QRxqOwH9fer9etTgoRUUfFYrEPEVXUYUUUVZzhRRRQAUUUUAfP8A+0xbsuraHcgDEkMkee+VYHH/AI/Xjat619DftI2gk8M6Xd4y0N2Y8+gZCf8A2UV88kV51dWmz63K5c2Gj5XJ4B81a1q23FY8LYNaMD8Vzs9OJsxz+tTq4PQ1lpICKnR+ODUlF9sMpVhlSMEHkEUyONIl2RIiKOgUAD8qhWWnebQInyKYXHaoTIT3phkAFAErMTUEsmFqGW4ABOaomaa8uY7eyikmmkYKiIpJY9gB3NNJsTkkjJ8V2EOpRqH4kXOCOv0r6s+C0Etp8LvDtvcQSwSR220pIMH7xwfoev0rlPhr8KI7FotU8Uos16MPHaE7kj9C/wDeb26D37ex16OHpygrs+WzXF067UIa26hRRRXSeQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHL6mxbV75gfuRpGARxnGev/Aqy4VB8Syjrm2XB/4Ea05CX1PVsHjzQODgjEaY/XNZjMY/Elo3QSQsv1wQR/OmUjYxtTkD9fapIlG5cAfr6UyVgM9fqD9KdERvHXr/AFNAy6FIqYJkDNQocjp6VZTpSEx8a8YqrcabbTyiSaBHcEHOOT9fX8aupT6BMrbKcsZxk1KcCgN6/lQIBxSmjijNAFSZvKuEb+CT5D9c8f4VNGxIPPQ/jTbqEXEDoTgkcH0PY1XtJjJH84/eKdrgdm6GgZc3DP6j1pDjnsO5pqttGDwO1UbvVreBjHGTNMP+WcQ3H8fT8aALxUYGf1rI1PVBCTBYgT3hHA/hjHYsew/nSNDqOoKRM/2OA8BI8GQj0LdB+FENjDYAiNNi9WfOS/rz3PPU0DR8xapqV2fiBpmpanKWuUvtkgPGwbiuB+degfEaFZ/Bt9jBaGQSKQvTDBj+neuY+POijSdejvYFKR3IEwx/C6kZH5EV3oH9taIIXUGK+tiqt1ALLx/OvNmmpNM+khOMqcKkO35HmenTCW2jYHqBmr6SYrmNBneNPJmUq6kqwP8ACw4IrfRwwrlasz3Yu6uXRIKXzaqhsU7eKQyYvUMkoAqGa4VR1rMur4DODVJEtlq5ugoPNY11dbieeKr3N2TnJrY8F+DdY8aXuzTo/Ks0bE15ID5aeoH95vYfjgc1cYNuyMKtaNOLlN2Rl6Ppt/4h1aHTdJgM91KeB0CDuzHso9f619TfDzwbZeDdHFtb4lvJcNc3JGDI3t6KOwqbwP4N0vwdpxttMjLzPgzXMuDJKfc+g7DoPrk109ejRoqGr3PlsfmDxL5YaR/MKKKK3PNCiiigAooooAKKKKAPPfjfp1zqfgK4SzheaWCVJiigk7QSDgd8Z/Kvl2vuSuL8Q/Dbwzrskk1xpwguXyTNbMY2JPU4Hyk/UGuetRc3dHrZfmMcNH2c1ofKNPSZl969y1T4EQnLaVrcqei3MQb/AMeUj+Vc1c/BLxJGT5Fxps6+0rKT+BX+tcroTXQ9qGZYaW07ep5yl3jqKsJfL3OK6W7+FXjG3J/4lPmqO8c8Zz/49msubwJ4phOH0DUD/uQlv5ZrN05djdYqlLaa+9FVbxfXIp5vI/Wnp4N8Tnp4f1YfW0kH9K07L4a+MLzGzSJo1PeZ1jA/AnP6Uezk9kU8TSiruS+9GQ92uODVWa+A+7ya9L0f4HaxO4OrajaWsXpDulf6cgAfma9K8M/C7w3oJWUWpv7ociW7w+D7LjaPyz71pDDTe+hx1s2oU17ru/I8K8KeBfEHiyVHt7d7axOCbqcFUx6r/eP0/EivoHwR4C0fwlCrWkXn35XD3coBc+oXso9h+JNdeAAAAMAdhS12U6EYep4OKzGridNl2CiiitjgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5naE1rUh/ekBHH/TNe/1NYuqsI9S0qYEYEpQkcfeX/wCtW/qiCPV2dQMtGhxnBJ+YHH5LWJ4oQixWUZJikDjPoG55+lMpGrMxDkA/54p0bHcDn/PBqFD5oBHsc+xBqdCFAJ9P6fSgbL0RPQ81ajPAqnG/Q/jVhGyMUhFmNqkJqCEcmrFAhMZppAzT6aRQAzcMcU4HimEEHA7U5TgUAHPesfWUnjlje1n8jziI5GCg89jz+Wa2c8Z7Vi30h1C6+x2/+rRg08nYYIIUe/FAEkOm5AF5cTXHQEOcA/UDr+NXI4IoUCRRoijBAUAD0NTKuD+Y/wAKCvIz7g+uKABQeccc5H8/60yRQcZGSDjPoP8AJqQZOM/Qj/Gh+noD1oA8u+OGi/b/AAXcSiMPLa4mXHYZO4Aem3Ncx8J9RN54dsIXBKQZhd1IypB4yPpg5r2LWrZbyzlt5UDLKpRlPcHg59Bgsa+Yfh7fS6J4ruNNkdEWWUxr5pIAkUkYJ7Zx+dcmJVmpHs5fLnpSp9tfvNj4jaOdA8YS3CLtsNRPmBscJL3H49fzrGWUr3r2zULGz8U6TJpOsRuueY5e6nsQ3qD614LqsFzoWrXek35BuLSQoXHRxjgj2IINclSF/eR7OCxN17OW6ND7Vgdarz3+B1rGmvgB1rc0LwV4o8Qsp0/SblYW58+4HlR49QWxkf7uaiNNvY6qteNNXk7GVcXxP8VV7SK81S8S0063murmQ4WKJSzH3x6e9eyeG/gQ7bZfE2q47/Z7Efzdh+gX8a9e8M+GNI8NWn2fRbGK2Q/ecDLv7sx5P411QwzfxaHkYjOKUNKfvP8AA8m8BfBUI0V94wcSMPmWwibKg/8ATRx1+i8e5HFe2WVpb2NrHbWUMVvbxjakUShVUegA4FWKK7IQUFZHgV8TUxEuaowoooqzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMPxEhEttIByweLGAcnAYZ/74I/GsvVYln0th2ZcH8Rit7xBCZdKnZBmSICVcdcqd2PxxisqHbc2ZC42snABOMdRigaM3w7MbnS4Xb78YCP9VJ/wrTdiuAePT9RWPoLfZNRvrNh8r4nXjr/AHh+fP41tTDgZxn6D0plC28gIBPXgEfpV2InIrLibDkE8Hnr+dacJ4570gLqEcVOMEVTU5XHcVYhYEYoEyXNNOaXikJoJGPkE0gYN8w6evtVa+vbazGbiQKT90dSx9AOpNZUgvdU/wBYHs7M87Af3rj0J/hHsOaBk17qD3V2bLT2BZcebMORGD0A9T7VcsoktYUijHA6k8lj3JPrWbZWkVndyJbqEVolYAeuTzWiuT9f8mmwLgPyg/j+PSnkdv1pqAAY6980ueB+VIBAQc/nmhuVI6H1phf5xjv0/wA/jTQwcHPTHQetAFaY5CuANu8EkcDqM/Xq1fJXxChFj4y1gr8mLgTJwOCcN/OvrLUrlIIGZ/kVRuOTgYz6/n/9auG034dafrfiqTxLrKNLGGBt7VhhGIORI3qPQdPXNZVYc6sjuwOJjh5uUtrEfgxNc1XRLS61Pw7LaSuoYFJlQsMcNsJyueuDWlqHw00bxHqr6pr1vOJiqxiGObaNq5wWK9Tz2PTFeiUUKlFGUsXUbvHT0Od0PwZ4c0Iq+l6PZwyr0lKb5B/wNst+tdFRRWiSWxzylKTvJ3CiiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFca/m6Hdi1MDy27gtC0TfMFBHylTxxkDg8iuyrJ1uJXutPZhnLun/jhP/stAI5O+v7SPVLS4ikCybwjI6lGAbg8ED2P4VtvKJM4OMcY96qapaiWF4wSAQQBgHt1FYEWpanaXX2doreVmQsCwIOOOuDTRZ0LSbSp5w3HetCCcbOevp/OudW5v3AZraxVj3LMec+mK0IF1J0OZ7aFf9iIn9Sw/lQBtLMM8ZyKU3sUHzSyIi/7RArFe1mlbE17cOmcEIQoP4gZ/WrGn6bbQuGjhG/Gd7cnP1JJosI101ASD9xFK47EjA/M/0qGVb+6480Wyd/L5b8yOPwqzGNpGatJjHFIRm2ekQW0hlC75z96WQlnP41eKDaR0x0qbFJgZ+tAXMS7Uw6lasfuyK0ZHvww/k1Xol5HvUWuL/ofnY+aCRZfwBw3/AI6WqwrADj2oAnHGO+OgprZx16Gmhh1J9jUUkx3EDoM4A6njp7UAOkwSU6nuB1qneahBbJuJ3SE7VRASWJBIAHc/T61Se8uL67eDTEEm04eQ5EUZx3P8R9h+OK1NP0qK0l8+R3nuiMGV/wCEeijoo+n4k0BcrQ6c9/MlxqkYVEIMdvnIz/ef1PsOB7npuUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs3XBiK2l/55zof++sp/wCz1pVT1dPM0u6XGT5bED3AyKAMa8GG647kVhapsint5iv8flkj0OQP1xW/dOrhJEwyOAQf1BrG1aE3FnIi/eK5U+h6j9aZoiaFMY47k5NXkbBKgIMEjgc9Kj05luLGGXHEiBv0/wDr1cSEBycdcGgTGA78EDOcHnpVyCPAyOn5CokTaMemRVlDkY6+9DETKMgVKhxTB92k3c0gLVNJ/wAikU5HrQTzjr7CgRDcIJYZIzjDqVI68YP+NUdPYvaQlj84Uq3rkdf1FXJXKZx2PIHp9awGupPtk9pYwSXFwr7iBwiBvmBLfj9aANS7ukgh8yaRIogTlm4H4evWqtvaT6qd8wltrDtGcrJN7t3Vfbqe9S6ZorJOLvU5RcXQO5EGfLiP+yD1PufwArdoBvsRW8MVvCsUEaxxKMKijAAqWiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBAIwaKKAOUhR7ZXs2XP2c7AO+z+Bh6jH6g1HIodDjnIz/AJFdHfWMN4o8zerqCFkRirr64IrPGiXC8DUDIB0MsQJ/Egrn8qZSZi6G+2z8nP8AqpHT8Axx+lbKYIHToR1rJtrSS0ubyGUxsyy7iUGMggEHGTj061cjfbwMkdeMHFA9y8OpPHY0qN83XPUegquzfLkenGaaWPJx0OR/+qgC+ZgFAHLEHgUqyEkHr9Kzdzc9evGeBSpOV+UMWcfwopYj8BSA2TKFUHt3qG4uo4VZpHCqBzngVFFaSzxKZGeIHkhsFv58VZTT7ZSrNEJGXkNJ8xH0z0oJ0RQgM2otvTckOMBmGA3uB/Wr2n2MdkZmQlpJm3OzdScYH0GBV2igQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGdqek2eo4a5hzIBhZUJR1+jDms5PD88A2wai8iZyBcRhz+YIroqKAOeXSbwN962wDxjcO3entpF3Im03UUR7FFJ/qK3qKdx3MqHRYV5nlluD6O2APwGP1zWjDDFAm2GNY164UYFSUUhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFUdX1XT9GsnvNXvraxtU+9LcSLGg/EmvB/Hn7T3h7S/Mt/CdnLrN0OBPJmG3B9Rn5m/ID3oA+hqz9X1nTNGg87V9RsrCHrvup1iH5sRXwb4q+O3j/xFKxOtyaZAekOmjyAP+BA7z+LGvNb27ub65e4vbia4uHOWklcuzfUnrQB9+6x8d/hzpZZZPEkNxIP4bSGSbP0ZVK/rXLXv7UfgSBiIbXXbn/ajtowP/HpAf0r4jooA+y2/at8KZ+XQ9cI9xED/wCh1atv2qPBUjATaZ4ghz38iJgPyk/pXxrFp97LH5kVpcPH13LGxH54qsylWIYEEdQeKAPvXS/2h/hxfkLJrM1k56C5tJB+qqQPzrvdA8ZeGvEO0aJr2mXzn/lnDcozj6rnI/KvzLpwJBBBwRzkUAfqlRX5x+Gvip438ONH/ZniXURFH92GeUzR49Nj5A/CvcPAv7VLApB420cEcA3em8Y92jY/mQ30FAH1ZRXN+D/G/hzxhaifw5q9re8ZaJXxKg/2ozhl/EV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVjeK/Eel+FNFuNW127S1soBlnY8seyqP4mPYCgDWkdYo2eRgqKCzMxwAPWvn34q/tJ6RoJm0/wZHHrGoqSrXbH/RYz7EcyH6YHua8R+Mfxx1r4gGbTrENpnh3ccWyN+8nHYyt+u0ceu7ANePUAb/i/xdrnjDUmvvEWpT3k2TtDnCRj0RBwo9gKwK9V+FvwR8T+PRFdrENM0ViD9uulPzj/AKZp1f68D3r6r+HvwN8HeC2S4isjqmpLyLu/xIVP+wmNq/XGfegD5A8EfCHxr4yVJtJ0eWKybkXd2fJiI9VJ5Yf7oNey+Gv2V4YY45vGXiZI8/egsFAA+kkn/wARX05dXMzXP2WyCiRQGkkflYwenHcn0/E9sst9JijLSSf6RO/3pJeSfYeg9hQBwOgfAb4d6OEdNBS/lH/LS9labd9VJ2f+O13ul+G9D0lQNK0bTbIDoLa1SPH5AVTm0GOPcbO6vrJRyEt5jsB9kPA+grntTstesne5S+m1K37oZ5IWX6BSBTsOx6HVO/02x1GPZqFlbXSf3Z4lcfkRXL+G71NWRhBf6jbXMRG+GSQOVH/Agcitv7Ze2Zzcxrd2w6yQKRIg9WTnd9V59qQNWOZ1z4PfD/Wg32vwtp0bH+K1Q2x+uYyteX+KP2VfD92Hk8N6zf6dIckRXKrcR/QfdYD6k19FW1xFdQJNbyLJE4yrKcg1LQI+DPF/7PPjzw9C88FlDrFupOW05zI4H/XMgMfooNeS3NvNazvBcxPDPGSrxyKVZT6EHoa/U2uR8c/Dvwv44t/L8RaVDPMFwlynyTJ9HHOPY5HtQB+cdhe3WnXkV3YXE1tdRMGjmhco6H1BHQ19H/Cv9pq9sjFp/j+F762xhdRt0AmT03pwGHuMH2Y1n/Ez9mfWNESW+8GzvrNkoJa1kAFyg9scP+GD6A189zwyW8zxTxtHKjFWRwQVI6gjtQB+nfh3XtL8R6VDqWh30F9Yyj5ZYmyM9wR1BHocEd61K/Nz4dfELX/h/qv2zQLnbGxHn2suWhnHoy56+4wR619wfCL4paN8SNHElm62urRKDdWDtl0PTcv95Pft0ODQB6HRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZXiTXNP8OaJeavq8629haIZJXP6ADuScADueKAKPjrxfpHgnQJ9Y125EVvGMJGCC8z44RF7sf06nAya+B/ip8R9Z+ImvSXupyvHZIx+y2KtmO3T2HdvViMn6YAn+MnxHvviP4pe/nDQabBmOxtc/6qPPU+rN1J/DoBXE2lnc3gm+yW804hjMsnloW2IOrNjoB6nigCfRdKv9b1S207SbSW7vbhtkUMS5Zj/h6noBya+v/g3+ztpnh6GLU/G0VvqmrMMraEb7e3+o6SN7ngdgetfHFheXOn3sF3YzyW91A4kiliYqyMDwQexr7g/Z/wDjNbePbJNI1x47fxPAnI4VbxQOXQdmHdfxHGQoB7QiKiKiKFQDAAGABWPrWrG1k8i2I80Dc7kZCDsMep/Qcntmt4t8ZaJ4UtxJq94ElYZjt4/mlk+i+nucD3rg9O16PXNDiura48+ZmaSUAgtGxYnBHbA4/lS5le19TRUp8vPbQ7XR9SVH8hmZ2kYuzuRkknnjt+HSulMipy7YH1ryC11Iw6vau5LYypz2yQc/pXf3F8st3LCG5XGPxH/16pktG+ZQ8ZKsD7+lVp/3JUgnBznHIx6mqOnSkXBXOAeB746/qa05VWRTuAIx/nvSFY5HVrMWGs2urWPEJJiuFUcbSThj+NdHbzu8eTx0CvkYPHf3pEgDebC3Mcg2twOetZ1g8ljcf2deNl9waGTs47fjTHuTzynSrlrxFxZyH/SkH8J/56gf+heo57c9D15FUhCJrcpOAVkQq49cjmvMrH4u6Tpc7aRrdtdw3FniB5kAkRyowWPII6ehqZSUdy6dGdX4FdnrVFcv/wAJ14bGnxXzarCtrI21ZGDYz6E44qaHxr4ZlUMmvabg9N1wq/zNJST6idKot4v7joq82+Knwg8OfEK0le6t0sdZx+71GBAJMjoHHG9fY8+hFdb/AMJb4c/6D+k/+Bkf/wAVTT4u8NDr4g0j/wADY/8A4qnzInkl2Z+ffxH+HuvfD7VzZ67bfunJ8i7jyYZx6q3r7HBFc/oWsahoOq2+paPdy2d7btujmibBHt7jsQeCOK+7vi343+Hi+C72HxLeafrFpIuFsreZZZZH7bMH5SM/eyMV8CztE08jQI0cRYlEZtxUdhnAz9cCne4mmtGfe3wL+L1j8R9LFteGO08R2yf6RbA4Eo/56R+q+o6g+2CfWK/L/wAP61f+HtZtNU0e5e2vrWQSRyJ1B9D6g9COhHBr618PftDT67pEb2miW6X0ahbjfcEqHx1VcfdPOMn2qZzUFdmlGhOvLkprU+i6K+dLr4ueKZyfL+wW47eXASf/AB5jWZcfEXxfccNrDop7Rwxr+oX+tYPFwR6UclxD3svn/wAA+nqK+VH8W+JZDltd1LP+zcMB+QNMPijxGf8AmPap/wCBcn+NT9cj2NVkVX+ZfifV1FfKH/CT+I/+g9qv/gXJ/jTv+Eq8Sjpr2p/+BLH+tL65HsH9hVf5l+J9W0V8qR+M/FUB3R69fk/7b7x+TA1bi+K/jK0Pz6hFcgdpbaP/ANlAqli4PoZyySutmn/XofUFFfPulfHbUYmC6tpFrcL03W7tEfrg7s/pXsfg7xPYeLNIGoaYXCbtjxyABkbGcH8xW0KsZ7HDXwVbDq9RaG/RRRWhyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8VftSfFFvFOuv4X0eYf2Jpsp86RTxczjIP1VeQPU5PPFe9/tH/EEeBvAc0VjME1rVM29oAfmRcfPKP8AdB4PqVr4HoAnsbSe/vILSzhknuZ3EUUSDLOxOAAO5Jr75+B/wssvh/4S8i7hin1q/QHUJWAcf9cl4+4M/icn0x5X+yF8OEWF/G2s22ZGJh0xXHQdHlHv/CD/AL3qK+opZEhjeSVwkaAszMQABjqaAPjP9on4H/8ACJ+d4k8Kxs2hM265tRljZknqvrHk49R7jp4JYXlzp97Bd2M8lvdQOJIpYmKsjA8EHsa+rvi98R5PE88uk6S5TQ0JVz0N0fU/7HoO/U9gPnTxZ4dNkTd2SE2rcuo58s/4fyrFVouXKd88uqwpe1f3dTptA8US+Irlzq1w0uqud0kkjEmb3z6j0/Ljp1tgJ7WdZ7OeW2nXgSRMQcenuPY14LDLJDKskbFHU5VgcEGvX/AfiaHWYxaXZRNQQdOglHqPf2/H6c2IpOPvxPXyzHwrJUK2/Tz/AOCeg2utalBse8MdxGANzKpEnXORzgn2716D4d8Rrei2uTMHLZBYZBPYEj8CK81UcY7VQlW9s5PM0+Z053FOqk9+KilipRdp6nTjMqhUV6Ssz6a0q9jklRtwBwAfY9xXQwTRSqdjhuK+efBviklwlxlJiRuUnnjuPUV6ro0rSPA0UmYyN7bTnjGSR7V6MZqauj5ivQnRlyzR17sYwxBwAec8965jxysYvtJuOcPJ5LEHHDEYI9wea6GCQXUG4fKjfMe5x6VzfjdfO0qzlHCwXiMdvYc4/UiqRitza0i6mudM2y/NNGWVjxklTx/KvnX4yaSdK8eTz7R5N7mQD3wA3+NfRegw77SSY9JJnYDpgbjxXjH7R0L/ANraRdAfugrKT75H+FYYhXgz0Mrny4leZ5zpOpS6WJUVRNZT8TQOMgj1A9aj1ewFk0NxbM7WVxkqc58s+hPcYPBqqh5x2NdR4SaC8hudFvP9TcKShP8ACepx79686Lvoz6epDk9+PzOfjBIHzE/jVTXNTttFsGuro5/hRB1dvT/Gk1u9i8NxXI1Jx5sDmMIDzIw6bR78HPpXjmuavdazetcXb57Ig+6g9BWlGi5vXY5MdmEcNC0NZP8ADzYmvavc61fG4uSBjhEXoo9BVjwxoNzr98IYAUhXmWUjhB/j7U7wt4eu/EN8IbdSsKkGWYjIQf1PtXt+kaLBpdjHa2cW2NRye7HuT6muqtWVJcsdzycDgZ4yftavw/meE+I9Im0TVJLWcZUcxvjh17EUeHNYn0TU47uH5l+7JH2de4r2Pxt4YOu6O6xIPtkILwk9Se659D0+uK8JkRo3KuCrg4II5BqqNRVoWfzMcdhpYGspQ23R9D2M8d9Zw3Vu26KVAyn29/erPlH0rzn4Q68Fum0a7f5JMvblj0bqV/HqPfPrXrfkj0rzqsHTlys+oweJjiaSqLfr6mTsPpSbT6VqtD7VE8PtWZ1lEClxUzRkGmEYpgRstVLiMEdKvVBKtAmYk8e019B/s86Bd6doF5qV0xWPUWQwxH+6uRu/HP5CvJPCHh9vEniiy08giAvvuGXOVjH3vxPQe5FfU1owhs2htbdYlgxFFGCAu0AdPQDOPwrswsLvmZ8/nOI5YqjHruaNFYelakdSCRo+/aC8jpwMbjtX6kA5x0wQa3K7k7nzjVgooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK83/aC8Wnwb8LdWvbd9l9dKLK1OcESSAgke6qGb6igD49/aB8ZHxp8TNSu4ZvM060b7HZ46eWh5Yf7zbmz6EVi/CrwfP478dabocDFIpn33Eg/5Zwry7fXHA9yK4+vsf9jfwYuneGLzxXdR/wCl6mxgtiRysCN8xH+84P8A3wKAPoPTbG30zT7axsYkhtLaNYYo14CIoAAH4CvDPjz4/MksvhfR5WCqcX0i8bjwfLB9PX8vWvSPit4tXwh4Vmuoipv5z5Nqh5+c/wARHoo5+uB3r5LLPNK807vJLIxZnY5LEnJJPrXNiKnKuVHs5Vg/aS9tPZbeoIuBVmGHzOCMg8EHpimRIWbFbFlbgAE1wN2PpYq55f418HS6eJNQ09N1kfmdF6xfh/d/lXGW80lvMksLskiEMrKcFT619KbFZCrKGVhggjII9DXkfj/wYdL36hpilrInMkfeI/8AxP8AKuvD4jm9yZ4GZZY6f76jt1Xb0Ou8CeL49bhFpelU1JF5HQSj1Hv6j8R7djjNfNFvNJbzJLC7JIhDKynBU+te3/DrxbDr8Qs71kj1RF6dBMO5Hv6j8Rx0zxGH5fehsdeWZp7VKlWfvdH3/wCCa+swFrYtHlXX5gRwQfrXo/wT1ae80u7N9KWaNxArMcBsnd+eBXL3dqDbOCO1a3wpZVsFhUhNt67MeeThMA/hmlhW1KxebxjOjc980ZkNuIlwTjLEcjrxSa5pyz6NeQRjLyRkoD/exkfqKzfCdwbje4BCngd+PaugvH2Ipxkg9K9NnyexneFpA/h+CQchi7DP+8a80+PUK3XhOaULte0lRwfUEgH/ANC9O1el+GgI7B7RlAMDkYyCCrfMCD9DUPibSLfU9F1KynjBSeIgj8D096ia5k0a0Kns6kZ9mfIsJLKh7kCjUtbh8ORpfSybZEIMSL1dqi8Q3kPhoXAvPvwuYlQdXYEj+leQa9rF1rd8bi7YDA2oi/dQegrz6NFzeux9Pj8whh4WhrJljxh4iu/FGuz6nf7VkkOFRPuooGAB+A696d4U8O3XiLUBBb/JCmDLMRkIP6n2qx4K8KX/AIs1JreyXbFEhkmlPRFAJx7sccCvbvDul2ulWMdrZR7Yl5J6lj6k9zXTWrKkuWO55GX4CWMm6lT4fzLOg6NaaPp8dpZRBYl5JPJc+pNagUelORTipBH615jbbuz62MVFcsdiLaPSvE/jF4fFhrEep26Yt73PmY6LKOv5jn65r3QIKxfGOhp4g8O3lgQPNZd0TH+GQdD/AE+hrWhU9nNM5MfhvrNFxW61R8zWlxJa3UNxA22WJw6H0IORX094f1GLWtGtNQt/uTRgkf3T0YfgQRXy7IjRyMjgqykgg9Qe9evfAnWCy3ujStnb/pMOfTgOP/QT+dduLhzQ5ux4GTYj2db2UtpfmerbPajyQRyKnwKQ9K80+sM+aEGqksGK0ZTzUEg+WkBmMuDiq8/Aq3LwxqskUt3dQ21uu+eaRYox6sxAA/WqW5Mmkrs9e+CWmDTvD9/r00a+bcSCG3LccA4/AFzj/gNdXdQ3xuGms4ZZZkgZUWQlDLuXJyfTLoSPUH0rotI0e207QrPSkQPb28aR8/xFccn6nmtMqGKkgEqcj2r1o07RUT4XE4j21WVTuzG8K6W+k2EsUxDSyTO7Ed+ev4/ePuxrboorRKysc7d3cKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvkj9tnXmk1nw9oMcp8uGB72VAerO21SfcBG/Ovrevz1/aK1k638Y/EkwbMdtOLNB/d8pQjD/vpWP40AcFpFhNqurWWn2wzPdTJBGMZyzMFH6mv018O6Ta6DoOn6TYLttbKBII/ooxk+/evh39lbw+Nd+MGnSyJug0yOS+cHplQFT8ndD+FfZPxP1s+HvAurX8TbZxF5UJHUO5CKR9Cc/hSbsrlQg5yUVuz56+NXigeJfGckVs+7T9O3W8ODkM2fnb8Tx9FFcQi8VDAvGatxLlgK8ucnJts+2o0o0YKnHZFyyhyRxW1CoVapWSYArQUYFYyZ1wWgtOEQlUq6h0YFSCMgjoQRSKMmrsEdSWeNfEXwO+lltR0qJmsDzJGoz5J9f8Ad/lXA208ttPHNbyNHMjBldTgqfUV9YxxK8ZDgMrDBB5BHvXinxL8AyaVJLqmkR7tOJ3SRL1g98f3f5fSvRw9fmXLM+WzPLuRutRWnVdvQ7T4eeOIvEdp9h1ApHqqL04AmGPvKPX1H4jjp3Hw1YRarqlmw+cMs6A+mCD/ACAr5Ntp5baeOa3kaOZGDK6nBU+or2v4W+PPtPiOxlvWWO8CmGbsJl7MPQg4JH4j2p0vZzU47EU8a8TRdGp8XR9/+CfXXhCIQiWNfuJ93p07fpWvezotxDETy3bvWL4PuElkmRB8oA2kdCuODVy4jb+3Udvu7Co+uCa6zxhvhZ/MN2T1BRcfRQKofEnxpo/gTw7LqutzAKAVgt1I8y4fHCoO/Xk9AOTWF4o8daP8PrDUdU1uUhGCrDbx4Mk0mDhVB/Ungd6+JfiV441Xx94ln1bWJCBkrb26sSlvH2Rf6nueaGDKHjDxJd+KteutUvgqPO5YRR/cjB7Af5zTPDWg3OvXoihGyFOZZSOEH+PtSeG9CudcvBFCCkKkeZMQcJ/9f2r2fSdNttKso7azj2xryT3Y+pNc1esqastz1Mvy+WKlz1PhX4+RqfDW2g0bUhaWqbYvLJOernI5PqeK2b6EWerXUCjCrJlR/skbl/Q1habL9m1m0lBwGfy2+h4/rXVeKoyt3YXWOJojCx/2lOR+jN+Vec7yTfU+kVqVRJaLYZAwZKmqlZv/AA1bzWZ2DqVcUzNKDQKx86/FfSv7L8aXu1dsN1i4TAx9773/AI8Gqp8OdS/svxjpk7NiN5BDJnptf5cn6ZB/CvRPjxp3m6Zp2ooPmhkaFyPRhkZ/75/WvFVYqwZTgg5GO1etRftKVmfGY2LwuLco97r8z69pjnANUtFvv7Q0axvB/wAt4ElP1KgkfmasSNkV5T0dj7KLUkmupC5yagmYAU+RworPuZqCiG4k5Ndb8G9M/tLxzbyum6KyRrhiegb7q/jls/hXEStk1798D9COmeGXv512z6i4kGeojXIQfqx+hFdGHjzTR5maV1Sw8u70PSaKKK9Q+NCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBrMEUsxwoGST2r8vNcvn1TWtQ1CT791cSTtn1di39a/S7xdObXwprVwpwYrKaQH6Rk/0r8wqAPq79iHSQIPFGsOvLNDaRn0wGZx+qV6N+0vfeR4Q0+yX711dgn/dRST+pWs39juyFr8I2nxg3WozS59cBE/8AZKp/tPzFrzw5bg8Kk8hH1KAfyNZVnaDO3Lo82JgjxWIYFW7UZeqycCrlmOa80+wRs2y4AqzUMA4FTVkzoWxNAuTWhGuKqWwq6lIGWIvu051V0ZHUMjAqQRkEdCCKbH0p9UYM8M+JngE6Pv1TSFLaeWzJF1MJz29V/lXnMEskEySwuUkQhlZTgg+tfW8iJJGySKHRgVZWGQR3BFeFfFLwSmjT/wBpaUmLCViHiHWJvYf3f5V30K/N7stz53Mcu5L1qS06rsfQv7OXxTsfElrLpuqOsHiRFLYPC3KD+JP9odSv4jj7vo3xE8cab4K0GXWtZf5Y/kgt1IEk8hGQqj9SegHNfnrY3dxYXkN3ZTSQXMLiSOWNtrIwOQQexrY8ZeLta8Y6kl74gvXuZkQIgwFRBgZwo4GcZOOprtueGT+PfGeqeN9cfUdVcDGVhgTOyFM52r/U9TWn8J/h1qfxF8QLZWCtDYQkNe3jDKwp7erHnA/oCah+GPgDVPH+trZ2CNFZxnddXbKSsS+g9WPYfyGTX3T4K8M6b4R0U6LoUYhtEjDA8F3bGC7EDljgc/0pAeKfE/w7pXguHw9o+hwCG0jEhJJy8jYUF3PGWPr+A4xXMjpXb/tDWFy9zpepRLI8EavG4wTt5BB/SvPtPuVuIAQfmHWvNxKfO2fX5TJfV0iWclcMOqsGH1zmvQfFEfmeHZJk5+zulyP93OG/8dZq4CUZUj2r1CxhW+8O28bfMtzZbD7kpg1jHc6MVpZo4+2OHzWiDxWNpshe0gdvvFBn64wf1rVjbKisnudsHdXJKBRRSKOa+Jdn9u8D6sgGWjj84H02EMf0Br5pr6u1xBLot/Ew3K9vIpHqCp4r5Rr0sE/daPl8+hapCXdH0X8LLk3PgbTdxy0YeI/g5x+mK6eVgB1rz/4Nz/8AFHyKT9y6dR/3yp/rXYTzE9646qtUZ7mClzYeD8kFzKMGsuaXmp5XyDUFjZXWqX8VnYQtPcSthUUZJP8AQe54FQlc3lJJXZq+CtBm8TeIrWwiBERbfM4/gjBG4/0+pFfVdvDHbwRwwIEijUIqjoAOAK5f4d+ELfwno4jwsl/MA1xMO5/ujP8ACO35111epQpezjrufH5ljPrVS0fhW3+YUUUVuecFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGB8QFLeA/Eir1Om3IH/fpq/Mqv1G1y1N9ouoWgGTPbyRD/gSkf1r8u6APvH9k+VJPgnpKp96Oe4Vvr5rH+RFcp+0u+fFWjp2WzLfm5/wq3+xdqAuPhtqdkTl7TUnOPRXjQj9Q9U/2lB/xV2lH1sv/ajVhiPgZ6OVf7yvn+R5OOlXLLqKpnpVm0bDCvPZ9Yjfg+7U9Q2y5QGpytZM6EWLY1dSs2Jtpq/CwOKQMuJ0p1MQ8U+qMGQXlylrA0smdo4AHJJ7AVX1bUNL8K6aNZ8VODOykW9ggDSNkdMdj6k8AfrR8Y6xY6HpJvdQYkowMKIcM8nYD+ee1fOviTXb3xBqD3eoSs7HIRSxIQdcDNdmFpp+8zxM3xLhFUovfcq6xdw32qXV1bWkVlDNIzpbxElIwTnaM9hVGuk8FeFrzxTqyWtt+7hBBmnYcIv9T14rsviN8KbrQdJbWtHEtzpcWFuAeXi6AMeOVPf0PtXefO2Z7J+y5410W90W38LxW9vp2rWyvIUBwL04++CTy+Oo9BkccL9BLalbiOZPumIqR+IxX5mWN5cafewXdjPJb3UDiSKWNirIwPBB7Gvtv9n/AOMdr460+PRtbeO38S28fTgLdqB99PRu5X8RxkKBc9I1vRk1O2mWVA6smAGGecH/ABr5e8VaM/hTxQ9oy7bacCWEjOMZ5APsRX1/EQSAec8V558WvBsXijSTDCm3UIAZrWT1bHKH2IH51hWpc8dNz0MvxboVEpbM8DJyM9jXp3g9lfQtO5yVyp/MivKLGR2hMcylJ4yUdG4IIOCDXo3w9nE2m+SxwYpiv4EAj9a85bn0+K96nzHMxxm1ubq2fhop5Fx7biR+hFXYmwKl8bWz2PieR8furtBIp7bgAGH6Kaz4Zh3qJbm+HlzU0zRElBc1AsgI60ySYLU2NhdQmWOynZ/uiNifpg18p19I+Jr3yNB1GYn7lvIR7nacD86+bq9DBLRnzWfyvKC8mex/CBivhe5HreOR/wB8JXZO+a434YL5XhVWP/LSZ2/LA/pXo3hPwtqviu88rTYtlsjATXUgIjjHcf7Tew/HA5rnqxcqjSPUwk40cJCU3ZWMywsrzV9QhsNNgae6mOFVfTuSew9zX0L8NfA8HhCxeSd1n1WcDzpgOFHXYnt79z+AGn4N8H6Z4UtDHYRl7iQfvbmTBkk9iew9hxXTV2UcOqfvPc8DMMyeJ/dw0j+YUUUV0nlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfmX4/0z+xfHHiDTCu0Wt/PEo/2RIQD+WDX6aV8I/tY6EdI+MF7cqu2HU4IrtMdM42N+O5CfxoA6/9iXWRB4m8Q6M7Y+12sdygJ7xsVOPwk/Su+/aat9ur6BcY4khljz/usp/9mr5q+BXiEeGfit4dv3YrA1wLab02SgoSfpuB/Cvrj9pLT/P8K6dfL961utp/3XUg/qq1lXV4M7suly4mJ88HpUlu2HFMxxTVODXmn151Fk4MYq5WLpk3G0mtdGzWTNlsDcHNSwykHrTGU4qMcGkUa8MwIqh4l8RWXh7THu76QDAIjiB+aVvRR/XtWXruvWmgacbq9frxHGv3pG9AP69q8H8S67d+INTe7vW/2Y4wcrGvoP8AHvXVQoupq9jyMwx0cMuWOsvyHeJ/EN94i1Jru/kJ6iONSdka+gH+c1Z8HeF7zxRqQgtgUtkIM05GVjH9T7Ung3wveeKNS8i2/d28eDNOwyIx/U+1fRmhaRZ6HpsVjp8WyJOSTyXP95veuqtWVJcsdzx8Fgp4uftau35lbStLtNAt7Kz0+PyokcAnu5PBZvevbvCkEB04QTRo8LqVkRwCrAjnI7jB6GvFPEEoihjIPzlhgV6F4M8QL+7juP3auoDBgeGx6dqnCz5k0zbNqCg4yitLW+48V/aH+DA8Nzy+JPCNs76DJl7m2jBY2bdcgf8APP8A9B+mK8HsLy50+9gu7GeS3uoHEkUsTFWRgeCD2NfpLYFGDwzYeOTIKkZBHcGvlD9oL4Kz+HLm+8ReFrXfoO7zLi1jGWs89SB/zzz/AN8/Tmus8Rqx7F8AfjHb+OrSPSdbeO38TQLkgYC3agffT0bHVfxHGdvsGpWiXKIWVN6NhWIyVzxkccGvzHsLy50+9gu7GeS3uoHEkUsTFWRgeCD2NfbvwB+Mtt49sU0jW3it/E8KcjhUvFH8aDsw6lfxHGQoFzkvixoX9keLhexoFt9SQuwUYAlXh8fXg/nVDwNdmDVJ7XtOm5ecfMp/wJr0z4726SeDnu8ZksrtGBxjhjtI/IivE4LprHULa8Q48twxP+z0P6GvNxEVCeh9Xl1R18Lyy6aHq3iixTWNKKLg3CAPGR1DD/OK8ximOSjgo6nBB4IPoa9Pkn8hIpovnR13KfVa4TxhaiO5bUYV2xucSAfwnsx/l+VYyVzbC1OR8r2KPnMB1pjSk9TVSOcSFVQb2PAC8kn2FdLo/gnxLrBU2uk3McZ/5aXI8lcevzYJH0BqVBvZHbOtCmrzkkedfEi9+z+FbhN2GndYh+eT+imvFa9d/aC0m48N6vpui3lzBNdiD7VMkGSse4kKMkDJwpPQdRXmOh6dPrGtWGmWgzcXs6W8Y/2nYKP1Nenh4OELPc+RzTERxFe8HdJWPrP4HfCR7vwno9/4hk8uxmhW4itoz80qv84LN/CMN0HPuK+iNPsrbT7SO1sYI7e3jG1I41AVR7Cl060i0/T7aztxtgt41hjHoqgAfyqzWkYRjqjkq4ipVSUnotkFFFFWYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzT+2r4aN14e0XxHCpLWUzWk2P7kgypPsGXH/Aq+lq5/x94cg8XeDdX0G62hb2Bo1ZhkI/VG/Bgp/CgD8zkdkYMhIYEEEcEGvviw1Nfij8BBerh76az3SKvUXMXLD2yyfk1fB2o2VxpuoXNlexNDdW0jQyxtwUZSQR+Yr6J/Y28aGw8QX/AITvJcWuoKbm1DHAWZB8wA/2kGf+AUmrqxUJOElJbo5xMFQR0NNIwa6HxzpH9heMdX05V2xRTloh2EbfMgH4MBWDIvOa8pqzsfcQmpxUlsyzYOVkFb8DfLmuatD+9FdBbNlazkdEHoXlYEVj+I9atdC097u7Of4Y4x1kb0H+Pal17WbXQ9Pe6vHxgERxg/NI3oP88V4X4g1u81y/a5vHz2SMfdQeg/zzW1Cg6ju9jzswzCOFjyx1k/w9RfEWt3evagbq9boNqRr91F9BVrwj4au/EuoiCAFLdCDNMRwg/qfam+E/Dl34j1AQ24KQKQZZiMhB/U+1fQWhaTaaNp8VnYxhIkHJ4y5/vN6muqtWVJcsdzxcFgp4yftqvw/mS+H9LtdE0+OysI9kSDJJ5Ln+83vV7R54byZodUuobCZXICSdJF7FWJA/DrQtQajYJewFJFB44rhUtby1Pop03yctN8p6Npvg3Trryp1jt7sqASZS4OfbDYH5Vc1XRNPgaKWe2ubYEgF4yrID0GTj+ZrzfwT40vfC15Hpupnfp7HbFM2cx+gJ7r/KvY0uhJH5kajy5B8yHlG/CvUouLXunyuNhWhO1V37CaIrSuBbz+cseAwcYde2SO/1FdP5SMJ4ZUWRJcRsrAEEEcg+oxXLR2IgvYb3SSI3HEluTgMP9k/0rpY5g0b3AzguMjHKnAHIrQ4m7nyF+0N8E/8AhFHn8ReFonbQmfM9tyxtCe6+sfbnke46eEWF5c6fewXdjPJb3UDiSKWJirIwPBB7Gv01v1jnjEc0YlimyrI4BDDHII7j2NfIP7QnwXbw3JL4j8KWsj6E5LXNvGCxs267gP8Anmf/AB36YoJOhs/i7b+OfhRrGl626Q+J4kibHAW6VZFPmJ6N6r+I4yF5+MhrRPM/uDJP0rwKORo5FdGKsDkEdQa+iv2eI9F8eaubLxLqGy9txvj08DYLwAckNntjlRzjkcZxy16MptNHtZZj6eGhKNT1PQ/hfp2sa54UklS2Se2gmMMBdtjSKByVJ4IB47fpXSWvgPV7y5C3UUVpbkjcXcOcewBPP1r1eztYLO0itrSKOGCNdqRxqFVR6AdqsVSw0Vuc08yqOTcUlczNG0TT9FtY4dOtIYVRcblQBj7k960JHWNGd2CooySTgAU+vGf2o/HA8KfDqbT7SXbqms5tYgp+ZIsfvH/I7fq3tW6Vtjz3Jyd2fIPxZ8Sjxf8AEXXdaRi0FxcEQE/88lAVP/HVBrtP2UvDw1z4uWVxLGWt9Lie9Y9gwG1P/HmB/CvG6+3f2RvBx0H4fSa1dxbL3W5BKuRgiBciMfiSze4IpiPd6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+Lf2vPAj6J4wTxPZx/8AEu1ghZiOkdyo5B/3lG76hq8K0fUrrR9VtNS0+UxXlpKs0Ug6qynINfpD8RfCdn438IahoWoABLlP3cneKQco4+h/MZHevzk8QaNe6BrV7pWqQmC9s5TFKh7EenqD1B7jmgD6L8f+JbHxpFoHinT8Ib6z8m5iHWKeJjvU/wDfa49RtPeuUbla8w8Ka7Lps628zn7C7bmB6IxGNw/IZ9h7V6bG4ZAQcg9CK8/ERanfufV5XVVSgo9V/SJLNcy/Sreq61aaFYG6vH68JGv3pD6D+prJv9Ut9HtHubk57Ig6u3pXlWv6xda3em4u26Daka/dQegqaVD2ju9isdmEcLHljrJ/gO8Ra1da7qT3V22M8JGDwi+g/wA81Y8KeHbrxFf+Tb/JCmDLMRkIP6n2o8J+HLrxHqAhtwUgQgzTEcIP8favetD0m10ewjtLKPZEnUnkufUnua6K1ZUlyx3PKwOBnjJ+1q/D+YaFpFro9jHaWUeyJOSTyXPqa2B0qJRzUgNec227s+o5VFJR0RNEPWptwFQKaXNAjK8UW6zafI2PmUZzXqXw7u3uNBsUkYsVjRgOp27QRXk/ia4Z1ttPg5uLuQRKB2BPJ/Ac13Vrff2K1q1shEMSrERk/dAAHNd+DT1PCzhp8sep7VYx20iH5Ru6GrItVD5T5QRtI7EVhaHfJeWcNxCMJJjkY9D15rdimK43j6fSuw+fZlJI6MYJxh4ZMgjoyHpV4BSjpKA8TDaysAQ2egI9O1W5YY7hS2PmIxmqtyyQQsGIyU3Y4zgdaBHx3+0H8F5fDdxceI/C0BfQpGLz2qDLWZ7kAdY+/wDs9DxzXhVheXOn3sF3YzyW91A4kiliYqyMDwQexr9NrG1hurSCaX97HJCRsflWV8E5GTn/AAr5E/aJ+B//AAifneJPCsbvoTNuubUZY2ZJ6r6x9vUe46Aj2X9n/wCM1t49sk0jXHjt/E8CcjhVvFA5dB2Yd1/EcZC+11+WlheXOn3sF3YzyW91A4kiliYqyMDwQexr7g/Z/wDjNbePbJNI1x47fxPAnI4VbxQOXQdmHdfxHGQoB7LczRW1vJPcSLHDEpd3c4CqBkknsMV+e/x18ev8QfHlzqEJYaXbD7NYowwfLBPzEerHJ+mB2r3b9rX4npYae/gnRpgby5UNqLqf9VGcERZHdup/2eP4q+Q6AOt+F/hG58c+N9N0O1U7JpA1w/aKFTl2/LgepIHev0gs7aGztIbW1jWK3hQRxxqMBFAAAHsAK8V/ZZ+HQ8KeEBruoxEazrEavhlwYYOqJ6gnhj/wEdq9xoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+fP2p/hZ/wAJLox8UaFaltbsFxcxxLlrmADrjuydR3IyOcCvoOigD8q67Lw14oWysnt77cwjXMRHf/ZP+NeyftOfBqTS7m58W+FLTOlyZkv7WIc2795FUfwHqR2PPTp801M4KaszehiJ4eXPA0dX1O51W7M10+eyqOij0FXvCnh268RagIYAUgQgyzEZCD+p9qy9OhjuL2GKeZbeN2w0jZwvvXvvh22sdN06K3sVAiAznqXP94+prGtV9lG0TuwGDeNqOdR6LfuzQ0XTLXR9Pjs7KMJEg5Pdz/eb1NaKmqvnKehp6yj1rzG23dn1sYqC5YrQtA0/Iqp5qj+IUn2qIcFqBMv7gBxTWfHJOKoPfRgcMKz7zVEUHDZNFhNlnSyl342gLYYxwS+X/vfL/Qmu4ChoSGHIA/P8q82+Hk4m+IVikvSSQoufVhgfzr2zVfD32C1e8v547eFjgBiAWPYAY5NephvgPl81f7/5I1/h/Mi2UkKSgsXyVIycdBiunub7zHIgIKrkH1BzXmem31vYyLF9rtwzYYImXI9BwOfrjFdjpdwjOyi4jaQZZiXHTjPeuix5Uu5t6VeS+aUdt64BDfnwR2put+et1ZSKP3InKOPVWHPf1yKbp0tgSzLcRblXBJIAA57+lNuNQe6nWHShHfBiASuTHGc53M/T8ByfSgSNrRk8rTYYu0WYl/3VJUfoBVieKO4hkinjWSKRSro4BDAjBBHce1OiTy41Xrgcn1NPpEnxj+0Z8E28MTzeI/CVqz6DIS1zbRgsbJvUD/nmf/HfpivArC8udPvYLuxnkt7qBxJFLExVkYHgg9jX3T8bfjVo3gO1n0u1SLU/EEkZAtcgxw5HBmwfx29SPQHNfCt1Mbi5lnZY0aRy+2NQqrk5wAOAOeg6UAO1C8udRvZ7y+nkuLudzJLLI25nYnJJPrXtf7Mfwq/4TLXf7e1qDOgac4KxyL8t1N1C+6r1b8B3OOS+C3ww1H4k+IREge30a2YG9vMcKP7i+rkfl1Pv99aBo9hoOj2mmaTbJbWVogjijQcAfXuc8k9SeTQBpAADAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGOiyoyOoZGGCCMgivjf43fs/ahocl/r3hBPtej7mmkskH722XOTtH8SD25A7EDNfZdFA7n5V10Xh/xPeaQBFkzW2f9WxPy/Q9q+sfjT+z5p3ieObV/B8cOma3yz2w+SC5P0H3G9xwe/rXyF4i0DVfDepyafrthcWN4nWKZNpI9QehHuMg1MoqSsy6VadGXPB2Z6fpXiCPUYg9rOGYDLI3DL+FaH2+f+9XiEEskMgkhdkcchlOCK77wR4202zvBH4wsLzULI4HmWcwjlT8CMN9Mj61yTwuvunvUM6ja1Va+R15vZz/ABmmNPK3VjXs3gSx+DnimNDpl+JrlsD7Le3jwTA+gTK7vquR716jafDrwjagCPQLJ8f89VMv/oRNJYWXcuWdUlsmfJ2nWl9qdyLfTre5u5z/AMs4EaQ/UgDgV6R4Y+C+v6kVl1mSLSoDyVfEspHsoOB+Jz7V9G2VpbWMIhs7eG3hHRIkCKPwFWa1jhor4tTirZxVnpTVvxZ55oXwn8OaNBm2jlfUNysL6QhpUIII28YXpjgZx3rrbPRYIJGluZJb2Yrt8y5IbavoowAB9Bz3rWoroilFWR5U6kqj5pu7M650XTbqMJPYWrqOQPLAI+h7Vky+CtKdiUNzGp/hWTI/8eBP6109FO5BgWXhPSbWRXMD3DKcr57lwD67Tx+OK3gMDAGAPSsPxN4u8P8AhiBpfEGsWNgAu4LNKA7D/ZT7zfgDXz/8Qv2pLK3V7XwLp5u5en269UpGPdY/vN+OPoaAPo3XNY0/Q9Nl1DWL2Cysohl5pnCqPb6+3U18qfFz9pW51BLjSvAKSWdqfkbU5RiZx/0zX+Ae559lNeEeMPGPiDxhffavEmq3F84JKI7Yjjz2RB8qj6CsKCKSeZIoUaSV2CqigksT0AHegAnmkuJnlnkaSV2LM7EksT1JPc16V8GfhHq/xI1NZAHstBhbFxfMvX1SMHhm/QdT2B9D+C/7Ol3qxh1jx7FNZafw8WncrNN/10PVF9vvH/Z7/W+l6dZ6Tp8FjpltFa2cChIoYlCqg9AKAKPhPw3pfhPQrbR9DtltrGAYVRyWPdmPdj1JNbNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+NPBegeNdM+w+I9OivIhny3PEkRPdHHKn6cHvmukooA+NPiJ+zHr2lSzXXg65TV7AZZbeVglyo9Oyvx3BBPpXgWp6de6VeyWmp2lxZ3cZw8M8ZR1+qnkV+pFYXinwnoPiyy+y+I9KtdQhHC+anzJ7qw+ZT7gigD8yK7fwr8U/GvhVEj0bxFex26YC28zCaID0COCB+GK+kvFP7K/hy9Z5PDurX2lu3IimAuI19h91h+LGvI/En7Nfj3SmdtOhsdXhHINrOEbHusm3n2BNAHQ6B+1X4itQq67oWm6go43W7tbufcn5x+QFd5pf7VvheVQNT0PWLV+/k+XMB+JZT+lfLur+APF2jFv7T8M6xbqOrtaOU/76Ax+tc3JG8TlJUZGHZhgigD7dX9p7wEVJMetAj1tVyf/H6pX/7U/gyFP9D03XLmTsDFHGv5l8/pXxXRQB9Q65+1leOGXQvDFvCe0l5ctJn/AICoX/0KvMPFHx3+IPiAOkmuNYQP/wAstOQQAfRx8/8A49XD6V4W8QasQNK0PVL0n/n3tJJP5Cu98P8A7P8A8RNZKsdEGnwt/wAtL6ZY8fVcl/8Ax2gDy65nluZ3muJZJZXOWeRizMfUk9ajAJIAGSeMCvqzwx+yhEAr+KPEbsf4odOiAA+kjg5/74Fe2+CPhX4P8FbJNE0aD7Yv/L3cfvZs+oZvu/8AAcCgD5B+H3wD8ZeLlhuZrVdG01yP9Ivsq7L6rH948euAfWvq34X/AAe8L/D5Ensbc3ur7cNqF0AXGeoQdEH05x1Jr0qigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACoLi1t7lcXMEUy+kiBh+tT0UAZTeHtFY7m0fTifU2qE/yq1babY2hBtbK2hI7xxKv8hVuigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perihepatic packing&nbsp;compresses the liver tissue from multiple directions by placing laparotomy pads into the space between the diaphragm and liver, between the lateral abdominal wall and liver, and between the liver and hepatic flexure of the colon. Intrahepatic packing should",
"    <strong>",
"     not",
"    </strong>",
"    be used because it can cause increased bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12723=[""].join("\n");
var outline_f12_27_12723=null;
var title_f12_27_12724="Tropicamide: Patient drug information";
var content_f12_27_12724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tropicamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8100?source=see_link\">",
"     see \"Tropicamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/32/10755?source=see_link\">",
"     see \"Tropicamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mydriacyl&reg;;",
"     </li>",
"     <li>",
"      Tropicacyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diotrope&reg;;",
"     </li>",
"     <li>",
"      Mydriacyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an eye exam.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703096",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tropicamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear sunglasses. Sunlight may bother your eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12145 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12724=[""].join("\n");
var outline_f12_27_12724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232088\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232089\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016224\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016223\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016228\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016229\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016231\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016226\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016227\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016232\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016233\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8100?source=related_link\">",
"      Tropicamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/32/10755?source=related_link\">",
"      Tropicamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_27_12725="Precision and validity";
var content_f12_27_12725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Precision and validity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Dartboard illustrating high precision but low validity. The darts can be interpreted as representing studies attempting to measure the true effect (the bullseye). The studies closely approximate an estimate, but it is not the \"true\" effect.",
"    <br>",
"     (B) Dartboard illustrating low precision but high validity. As in the previous example, the darts can be interpreted as representing studies attempting to measure the \"true\" effect (the bullseye). In this case, the studies closely approximate the \"true\" effect (the bullseye), but the studies vary in their individual estimates. Interpretation of group of studies like this give a less confident assessment that they have revealed the \"truth\" compared with the group of studies that gave highly precise estimates (arrows tightly clustered within the bullseye).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12725=[""].join("\n");
var outline_f12_27_12725=null;
var title_f12_27_12726="Edetate calcium disodium (calcium EDTA): Drug information";
var content_f12_27_12726=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Edetate calcium disodium (calcium EDTA): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/17/276?source=see_link\">",
"    see \"Edetate calcium disodium (calcium EDTA): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31557?source=see_link\">",
"    see \"Edetate calcium disodium (calcium EDTA): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Disodium Versenate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Chelating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lead poisoning:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Available guidelines recommend chelation therapy with blood lead levels &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated with blood lead levels &ge;100 mcg/dL and/or symptoms (Kosnett, 2007). Depending upon the blood lead level, additional courses may be necessary; at least 2-4 days should elapse before repeat treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Blood lead levels &lt;70 mcg/dL and asymptomatic:",
"     </i>",
"     I.M., I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Blood lead levels &ge;70 mcg/dL or symptomatic lead poisoning (in conjunction with dimercaprol):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose:  I.M., I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"     <b>",
"      or",
"     </b>",
"     25-50 mg/kg/day for 5 days; a maximum dose of 3000 mg has been suggested (Howland, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Lead encephalopathy (in conjunction with dimercaprol):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose: I.M., I.V.: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"     <b>",
"      or",
"     </b>",
"     50-75 mg/kg/day for 5 days; a maximum dose of 3000 mg has been suggested (Howland, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Lead nephropathy:",
"     </i>",
"     An alternative dosing regimen reflecting the reduction in renal clearance is based upon the serum creatinine;",
"     <b>",
"      Note:",
"     </b>",
"     Repeat regimen monthly until lead levels are reduced to an acceptable level: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     2-3 mg/dL: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 24 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     3-4 mg/dL: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 48 hours for 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;4 mg/dL: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F164149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31557?source=see_link\">",
"      see \"Edetate calcium disodium (calcium EDTA): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lead poisoning:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels are &gt;45 mcg/dL (CDC, 2002). The AAP recommends succimer as the drug used for initial management in asymptomatic children when blood lead levels are &gt;45 mcg/dL and &lt;70 mcg/dL. Edetate CALCIUM disodium can be used in children allergic to succimer (AAP, 2005; Chandran, 2010).  Combination therapy with edetate CALCIUM disodium and dimercaprol is recommended for use in children whose blood lead levels are &ge;70 mcg/dL or in children with lead encephalopathy (AAP, 2005; Chandran, 2010). Depending upon the blood lead level, additional courses may be necessary; at least 2-4 days should elapse before repeat treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Blood lead levels &lt;70 mcg/dL and asymptomatic:",
"     </i>",
"     I.M., I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days or 50 mg/kg/day (maximum: 1000 mg/day) for 5 days (Chandran, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Blood lead levels &ge;70 mcg/dL or symptomatic lead poisoning (in conjunction with dimercaprol):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose: I.M., I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"     <b>",
"      or",
"     </b>",
"     25-50 mg/kg/day (maximum: 1000 mg/day) for 5 days (Chandran, 2010; Howland, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Lead encephalopathy (in conjunction with dimercaprol):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose: I.M., I.V.: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"     <b>",
"      or",
"     </b>",
"     50-75 mg/kg/day (maximum: 1000 mg/day) for 5 days (Chandran, 2010; Howland, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6151791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be reduced with pre-existing mild renal disease. Limiting the daily dose to 1 g in children and 2 g in adults may decrease risk of nephrotoxicity, although larger doses may be needed in the treatment of lead encephalopathy (Howland, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcium Disodium Versenate&reg;: 200 mg/mL (2.5 mL, 5 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F164131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.M. or I.V. use; I.V. is generally preferred, however, the I.M. route is preferred when cerebral edema is present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion: Administer the daily dose as a diluted solution over 8-12 hours or continuously over 24 hours (Howland, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     For I.M. injection: Daily dose should be divided into 2-3 equal doses spaced 8-12 hours apart. Procaine hydrochloride or lidocaine may be added to the edetate CALCIUM disodium to minimize pain at injection site. Administer by deep I.M. injection. When used in conjunction with dimercaprol, inject into a separate site.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F164157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, Ringer's injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic acute and chronic lead poisoning",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2932700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       To avoid potentially serious errors, the abbreviation &ldquo;EDTA&rdquo; should",
"       <b>",
"        never",
"       </b>",
"       be used.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       Edetate CALCIUM disodium (CaEDTA) may be confused with edetate disodium (Na",
"       <sub>",
"        2",
"       </sub>",
"       EDTA) (not commercially available in the U.S. or Canada). CDC recommends that edetate disodium should",
"       <b>",
"        never",
"       </b>",
"       be used for chelation therapy in children. Fatal hypocalcemia may result if edetate disodium is used for chelation therapy instead of edetate calcium disodium. ISMP recommends confirming the diagnosis to help distinguish between the two drugs prior to dispensing and/or administering either drug.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"       Edetate CALCIUM disodium may be confused with etomidate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, ECG changes, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fatigue, fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Cheilosis, dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, GI upset, nausea, thirst (excessive), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bone marrow suppression (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase decreased, liver function test increased (mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site (I.M. injection), thrombophlebitis (I.V. infusion when concentration &gt;5 mg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, numbness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glucosuria, microscopic hematuria, nephrosis, nephrotoxicity, proteinuria, renal tubular necrosis, urinary frequency/urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Iron, magnesium, and/or zinc deficiency (with chronic therapy)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active renal disease or anuria; hepatitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Monitor for arrhythmias and ECG changes during I.V. therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: Edetate CALCIUM disodium is potentially nephrotoxic. Renal tubular acidosis and fatal nephrosis may occur, especially with high doses; do not exceed the recommended daily dose. If anuria, increasing proteinuria, or hematuria occurs during therapy, discontinue use. Minimize nephrotoxicity by providing adequate hydration, establishment of good urine output, avoidance of excessive doses, and limit continuous administration to &le;5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebral edema:",
"     <b>",
"      [U.S. Boxed Warning]: Use with extreme caution in patients with lead encephalopathy and cerebral edema.",
"     </b>",
"     In these patients, I.V. infusion has been associated with lethal increase in intracranial pressure; I.M. injection is preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment. Primary care providers should consult experts in chemotherapy of lead toxicity before using chelation drug therapy. Do not permit patients to re-enter the contaminated environment until lead abatement has been completed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; reduced dose recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potential for name confusion: Exercise caution in the ordering, dispensing, and administration of this drug. Edetate CALCIUM disodium (CaEDTA) may be confused with edetate disodium (Na",
"     <sub>",
"      2",
"     </sub>",
"     EDTA) (not commercially available in the U.S. or Canada). Fatal hypocalcemia may result if edetate disodium is used for the treatment of lead poisoning instead of edetate CALCIUM disodium (Baxter, 2008). The CDC and FDA recommend that edetate disodium should never be used for chelation therapy (especially in children) (Mitka, 2008). Death has occurred following the use of edetate disodium for chelation therapy in pediatric patients with autism (Baxter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Edetate CALCIUM Disodium may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6151785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies; there are no well controlled studies of edetate CALCIUM disodium in pregnant women. Lead is known to cross the placenta in amounts related to maternal plasma levels.  Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment.  Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL.  In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels &ge;45 mcg/dL (pregnant women with blood lead levels &ge;70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended.  Encephalopathic pregnant women should be chelated regardless of trimester (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6151787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6151788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If present in breast milk, oral absorption of edetate CALCIUM disodium is poor (&lt;5%) which would limit exposure to a nursing infant. However, edetate CALCIUM disodium is not used orally because it may increase lead absorption from the GI tract. The amount of lead in breast milk may range from 0.6% to 3% of the maternal serum concentration. Women with confirmed blood lead levels &ge;40 mcg/dL should not initiate breast-feeding; pumping and discarding breast milk is recommended until blood lead levels are &lt;40 mcg/dL, at which point breast-feeding may resume (CDC, 2010).  Calcium supplementation may reduce the amount of lead in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F164127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinary output; urinalysis; renal function, hepatic function, serum electrolytes (baseline and daily [severe lead poisoning] or at days 2 and 5 [less severe lead poisoning]); ECG (with I.V. therapy); blood lead levels (baseline and 7-21 days after completing chelation therapy); hemoglobin or hematocrit; iron status; free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Disodium Versenate (AU, HK);",
"     </li>",
"     <li>",
"      Calcium Edetate de Sodium (FR);",
"     </li>",
"     <li>",
"      Edetal-CA (DO);",
"     </li>",
"     <li>",
"      Ledclair (GB);",
"     </li>",
"     <li>",
"      Versenato calcio disodico (CN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium is displaced by divalent and trivalent heavy metals, forming a nonionizing soluble complex that is excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Chelation of lead: I.V.: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M., SubQ: Well absorbed; Oral: &lt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into extracellular fluid; minimal CSF penetration (~5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Almost none of the drug is metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metal chelates or unchanged drug); decreased GFR decreases elimination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Environmental Health, &ldquo;Lead Exposure in Children: Prevention, Detection, and Management,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(4):1036-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/16199720/pubmed\" id=\"16199720\" target=\"_blank\">",
"        16199720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baxter AJ and Krenzelok EP, &ldquo;Pediatric Fatality Secondary to &lsquo;EDTA&rsquo; Chelation Therapy for Autism,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2008, 46(10):1083-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/18949650/pubmed\" id=\"18949650\" target=\"_blank\">",
"        18949650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradberry S and Vale A, &ldquo;A Comparison of Sodium Calcium Edetate (Edetate Calcium Disodium) and Succimer (DMSA) in the Treatment of Inorganic Lead Poisoning,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2009, 47(9):841-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/19852620/pubmed\" id=\"19852620\" target=\"_blank\">",
"        19852620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Deaths Associated With Hypocalcemia From Chelation Therapy --Texas, Pennsylvania, and Oregon, 2003-2005,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2006, 55(8):204-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/16511441/pubmed\" id=\"16511441\" target=\"_blank\">",
"        16511441",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevetion (CDC),",
"      <i>",
"       Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women",
"      </i>",
"      , Atlanta: CDC; 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),",
"      <i>",
"       Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention",
"      </i>",
"      , Atlanta: CDC; 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(RR-8):1-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/17975528/pubmed\" id=\"17975528\" target=\"_blank\">",
"        17975528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chandran L and Cataldo R, &ldquo;Lead Poisoning: Basics and New Developments,&rdquo;",
"      <i>",
"       Pediatr Rev",
"      </i>",
"      , 2010, 31(10):399-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/20889734/pubmed\" id=\"20889734\" target=\"_blank\">",
"        20889734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia RC and Snodgrass WR, &ldquo;Lead Toxicity and Chelation Therapy,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2007, 64(1):45-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/17189579 /pubmed\" id=\"17189579 \" target=\"_blank\">",
"        17189579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland M, &ldquo;Antidotes in Depth: Edetate Calcium Disodium (CaNa2EDTA),&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kosnett MJ, Wedeen RP, Rothenberg SJ, et al, &ldquo;Recommendations for Medical Management of Adult Lead Exposure,&rdquo;",
"      <i>",
"       Environ Health Perspect",
"      </i>",
"      , 2007, 115(3):463-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/17431500/pubmed\" id=\"17431500\" target=\"_blank\">",
"        17431500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitka M, &ldquo;Chelation Therapy Trials Halted,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 300(19):2236.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/19017902/pubmed\" id=\"19017902\" target=\"_blank\">",
"        19017902",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moel DI and Kumar K, &ldquo;Reversible Nephrotic Reactions to a Combined 2,3-Dimercapto-1-propanol and Calcium Disodium Ethylenediaminetetraacetic Acid Regimen in Asymptomatic Children With Elevated Blood Lead Levels,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1982, 70(2):259-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/7099793/pubmed\" id=\"7099793\" target=\"_blank\">",
"        7099793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan JM, &ldquo;Chelation Therapy in Lead Nephropathy,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1975, 68(8):1001-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/125923/pubmed\" id=\"125923\" target=\"_blank\">",
"        125923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osterloh J and Becker CE, &ldquo;Pharmacokinetics of CaNa",
"      <sub>",
"       2",
"      </sub>",
"      EDTA and Chelation of Lead in Renal Failure,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1986, 40(6):686-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/27/12726/abstract-text/3096624/pubmed\" id=\"3096624\" target=\"_blank\">",
"        3096624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9401 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12726=[""].join("\n");
var outline_f12_27_12726=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708725\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164143\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164152\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164145\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164149\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164146\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6151791\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164129\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164114\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164131\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164157\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164130\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2932700\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164150\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164134\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164118\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299251\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220072\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164125\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6151785\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6151787\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6151788\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164127\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038608\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164117\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164133\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/17/276?source=related_link\">",
"      Edetate calcium disodium (calcium EDTA): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31557?source=related_link\">",
"      Edetate calcium disodium (calcium EDTA): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_27_12727="Natural history and treatment of pulmonic stenosis";
var content_f12_27_12727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history and treatment of pulmonic stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12727/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12727/contributors\">",
"     Karen Stout, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12727/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12727/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12727/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/27/12727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all cases of valvular pulmonic stenosis are congenital in origin, and most cases occur as an isolated lesion. Acquired cases of stenosis of the native pulmonary valve are encountered less commonly but may be caused by the carcinoid syndrome or rheumatic fever (in which case pulmonic stenosis is always associated with other valve abnormalities). There are increasing numbers of patients with stenosis of bioprosthetic or valved conduits used in repair of more complex congenital lesions affecting the pulmonary valve, such as tetralogy of Fallot, pulmonary atresia, or truncus arteriosus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link&amp;anchor=H1#H1\">",
"     \"Clinical manifestations and diagnosis of pulmonic stenosis\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital valvular pulmonic stenosis exists in three predominant forms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases involve dome-type pulmonic valve stenosis, which is characterized by a narrow central opening with preserved valve motion. Three rudimentary raphes are generally present without clear-cut commissures. The pulmonary trunk may be dilated due to a medial abnormality. Calcification of the valve can be seen in older patients.",
"     </li>",
"     <li>",
"      Approximately 20 percent of cases involve pulmonary valve dysplasia, with thickened valve leaflets and relative immobility of the valve. Pulmonary artery dilation is not commonly associated with dysplastic valves. Dysplastic pulmonary valves are a common component of Noonan syndrome, occurring in up to half of patients in some studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link&amp;anchor=H1#H1\">",
"       \"Clinical manifestations and diagnosis of pulmonic stenosis\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More complex congenital heart disease, such as cases of tetralogy of Fallot or transposition of the great arteries, may be associated with a unicuspid or bicuspid pulmonary valve, which may be obstructive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\", section on 'Right ventricular outflow obstruction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acquired right ventricular outflow obstruction may occur after surgical reconstruction for congenital cardiac disorders such as tetralogy of Fallot, pulmonary atresia, truncus arteriosus, or transposition of the great arteries with pulmonic stenosis. Reconstruction often entails the placement of a right ventricle-to-pulmonary artery homograft, or valved conduit, which degenerate over time, manifesting as stenosis, regurgitation, or both. Treatment of homograft or conduit dysfunction may be amenable to surgery or percutaneous valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history and treatment of valvular pulmonic stenosis will be reviewed here. While valvular stenosis in the context of other congenital lesions or more complex congenital heart disease may have similarities, the natural history, clinical consequence, and concomitant lesions may not be the same, which may limit the direct extrapolation of diagnostic strategies and treatment options. Diagnosis and evaluation of pulmonic stenosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9858791\">",
"    <span class=\"h1\">",
"     GRADING SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history and approach to therapy of valvular pulmonic stenosis are determined by the hemodynamic severity of the obstruction.",
"   </p>",
"   <p>",
"    The severity of pulmonic stenosis is classified by major society guidelines using the following criteria, which vary depending on which guidelines are used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild pulmonic stenosis is identified by a peak Doppler gradient across the valve &lt; 36 mmHg (equal to peak Doppler jet velocity &lt;3",
"      <span class=\"nowrap\">",
"       m/sec)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]or a peak Doppler gradient &lt;30 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Moderate stenosis is identified by a peak Doppler gradient of 36 to 64 mmHg (peak jet velocity of 3 to 4",
"      <span class=\"nowrap\">",
"       m/sec)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/4-6\">",
"       4-6",
"      </a>",
"      ] or peak Doppler gradient of 30 to 50 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe pulmonic stenosis is identified by a peak Doppler gradient &gt;64 mmHg (peak jet velocity of &gt;4",
"      <span class=\"nowrap\">",
"       m/sec)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/4-6\">",
"       4-6",
"      </a>",
"      ] or peak Doppler gradient &gt; 50 to 60 mmHg or",
"      <strong>",
"       mean",
"      </strong>",
"      Doppler gradient &gt; 30 to 40 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2009 European Association of Echocardiography and the American Society of Echocardiography recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/4\">",
"     4",
"    </a>",
"    ], the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    valve guidelines (with 2008 focused update) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/5\">",
"     5",
"    </a>",
"    ], and the European Society of Cardiology guidelines for the management of grown-up congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/6\">",
"     6",
"    </a>",
"    ] classify the severity of pulmonic stenosis according to the peak (maximum instantaneous) Doppler gradient.",
"   </p>",
"   <p>",
"    Although mean gradients have been less commonly used to quantify pulmonic stenosis, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for management of adults with congenital heart disease include these since they may reflect the catheter-derived peak-to-peak gradients more accurately than do peak Doppler gradients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"     1",
"    </a>",
"    ]. A study of 90 patients with isolated pulmonic stenosis found that the mean Doppler gradient more accurately reflected the catheter-derived peak-to-peak gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/7\">",
"     7",
"    </a>",
"    ]. The peak Doppler gradient averaged 24 mmHg higher than the catheter-derived peak-to-peak gradient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11549750\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines and recommendations for monitoring asymptomatic patients with pulmonic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic patients with peak Doppler gradient &lt;30 mmHg, follow-up physical examination, Doppler echocardiography, and electrocardiogram are recommended at five-year intervals.",
"     </li>",
"     <li>",
"      For asymptomatic patients with a peak instantaneous Doppler gradient &gt;30 mmHg, follow-up Doppler echocardiography is recommended every two to three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of survival in patients with isolated valvular pulmonic stenosis is similar to that of the general population. The majority of patients with valvular pulmonic stenosis are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mild stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild pulmonic stenosis are asymptomatic. If symptoms occur, they should not be attributed to pulmonic stenosis. Some adults with mild stenosis will have been diagnosed during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/9\">",
"     9",
"    </a>",
"    ], but many cases will have gone undetected.",
"   </p>",
"   <p>",
"    The course during adulthood is generally benign with little progression of stenosis and a persistently high functional status in most patients. In the Natural History Study of Congenital Heart Defects (NHS), for example, among patients with baseline peak systolic valve gradient &lt;25 mmHg, 96 percent were free of operation at 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Moderate stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate pulmonic stenosis is often detected in childhood and is frequently symptomatic. Dyspnea on exertion and fatigue may occur due to the limitation of right ventricular cardiac output.",
"   </p>",
"   <p>",
"    A large number of patients with moderate stenosis, particularly symptomatic cases, receive definitive therapy during childhood. These individuals survive into adulthood with life expectancies that are not different from the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ]. Long-term follow-up of patients in the NHS found that only 5 percent who had surgical valvotomy or balloon valvotomy in childhood required reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ]. The prevalence and severity of pulmonary regurgitation was higher in patients who had previous treatment; however, the valvular insufficiency was usually well tolerated for many years.",
"   </p>",
"   <p>",
"    Patients with moderate stenosis treated medically in childhood may fare well into adulthood, although some may show evidence of progression of stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Approximately 24 percent of initially asymptomatic patients in the NHS ultimately required a pulmonic valve procedure for progressive symptoms or right ventricular failure; independent predictors of the need for intervention included more severe elevation in the peak systolic gradient and a reduction in cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, there were few differences between surgically and medically treated patients with moderate pulmonic stenosis in the NHS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ]. Both groups had low levels of cardiac drug use (4 percent) and excellent clinical status as defined by New York Heart Association criteria (97 percent were in class I) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Severe stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe pulmonic stenosis most often presents in childhood and presents with right ventricular failure and cyanosis. They have usually been treated early in life with either surgical valvotomy or balloon valvotomy, regardless of symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/9\">",
"     9",
"    </a>",
"    ]. Their prognosis continues to be good into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with isolated pulmonic valve stenosis generally survive into adulthood even if there is significant obstruction to right ventricular outflow [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/11\">",
"     11",
"    </a>",
"    ]. Isolated pulmonic stenosis is rarely a significant impediment to a successful pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild to moderate pulmonic stenosis is associated with little or no maternal risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/5\">",
"     5",
"    </a>",
"    ] and even severe pulmonic stenosis can be well tolerated during pregnancy despite gestational volume overload imposed upon an already pressure-loaded right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/14\">",
"     14",
"    </a>",
"    ]. However, severe pulmonic stenosis may be associated with increased risk during labor, delivery, and the puerperium. Percutaneous balloon valvotomy performed during pregnancy in women with severe pulmonic stenosis has reduced the peripartum risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/15\">",
"     15",
"    </a>",
"    ]. Mild residual low-pressure pulmonary regurgitation is an unimportant sequel.",
"   </p>",
"   <p>",
"    When surgical repair or balloon dilatation of congenital pulmonic valve stenosis leaves behind little or no obstruction and a competent valve, the mother can anticipate a normal pregnancy.",
"   </p>",
"   <p>",
"    The above cited literature review found the following rates of complications during completed (&gt; 20 weeks gestation) pregnancies among women with combined repaired and unrepaired valvular pulmonic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to the mother, there were no cardiac complications (arrhythmia, heart failure, or other cardiovascular events) in over 100 pregnancies.",
"     </li>",
"     <li>",
"      With respect to the fetus, premature delivery occurred in 16 of 110 pregnancies (14.5 percent), fetal mortality in 1 of 123 pregnancies (0.8 percent), perinatal mortality in 5 of 123 pregnancies (4.1 percent) and recurrent congenital heart disease (of any type) in offspring in 3 of 104 pregnancies (2.8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcomes may not be as good when pulmonic stenosis is associated with other congenital heart lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/16\">",
"     16",
"    </a>",
"    ]. As a rule, patients with cyanotic congenital heart disease tolerate pregnancy less well than those with acyanotic heart disease. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Severe stenosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H5#H5\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Major maternal cardiac risks'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H7#H7\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Cyanosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of recurrence of congenital heart disease in offspring of women with pulmonary stenosis is likely 3 to 6 percent. In patients with pulmonary stenosis due to autosomal dominant genetic mutations such as Noonan syndrome, the risk is higher and may approach 50 percent for Noonan syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease recommendations for intervention in patients with pulmonic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic patients with a domed pulmonic valve and peak instantaneous Doppler gradient &gt;60 mmHg or a mean Doppler gradient &gt;40 mmHg (in association with &lt; moderate pulmonic valve regurgitation), balloon valvotomy is recommended.",
"     </li>",
"     <li>",
"      For symptomatic patients with a domed pulmonic valve and peak instantaneous Doppler gradient &gt;50 mmHg or a mean Doppler gradient &gt;30 mmHg (in association with &lt; moderate pulmonic valve regurgitation), balloon valvotomy is recommended.",
"     </li>",
"     <li>",
"      Surgical therapy is recommended for patients with severe pulmonic stenosis and an associated hypoplastic pulmonary annulus, severe pulmonary regurgitation, subvalvular pulmonic stenosis, or supravalvular pulmonic stenosis. Surgery is also preferred for most dysplastic valves and when there is associated severe tricuspid regurgitation, the need for a surgical Maze procedure or other cardiac surgical procedure that warrants operative intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Balloon valvotomy is less effective in patients with a dysplastic valve (with or without Noonan syndrome), so surgery is generally preferred. However, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines note that balloon valvotomy may be reasonable in patients with a dysplastic pulmonary valve who are either asymptomatic with a peak Doppler gradient &gt;60 mmHg or mean Doppler gradient &gt;40 mmHg or symptomatic with a peak Doppler gradient &gt;50 mmHg or a mean Doppler gradient &gt;30 mmHg. &nbsp;",
"   </p>",
"   <p>",
"    There are no definite indications for intervening on an asymptomatic dilated pulmonary artery, as these are low pressure aneurysms with an extremely low risk of dissection or rupture. Repair for evidence of symptomatic compression of neighboring structures and repair at the time of valve replacement are reasonable approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LONG-TERM SURGICAL FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up of surgical intervention from the era of the NHS cohort, which was before the current use of percutaneous balloon valvotomy, comes from a report of 53 patients who were initially treated between 1951 and 1982 at a mean age of 10 years; their status was determined 33 years later [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/17\">",
"     17",
"    </a>",
"    ]. Forty of the patients were treated with open valvotomy, with infundibular resection in 13. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty-five reinterventions were performed in 28 patients (53 percent), including pulmonary valve replacement for regurgitation in 21, open valvotomy in five, and balloon valvotomy in three. Most of the reinterventions were performed more than 25 years after the initial procedure. The only predictor of the need for reintervention was closed valvotomy.",
"     </li>",
"     <li>",
"      Twenty patients developed an atrial arrhythmia, six of whom had radiofrequency ablation, and three patients developed a ventricular arrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar outcomes were noted at 22 to 33 year follow-up in a later cohort of 90 consecutive patients who underwent surgery between 1968 and 1980 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival was 93 percent at 25 years. At last follow-up, 67 percent of patients were in NYHA class I (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) and maximal exercise capacity was 90 percent of normal.",
"     </li>",
"     <li>",
"      Reintervention was required in 15 percent, primarily for pulmonary regurgitation. Reoperation for pulmonary regurgitation was required in nine percent, particularly after use of the transannular patch technique. At last follow-up, moderate to severe pulmonary regurgitation was present in 37 percent.",
"     </li>",
"     <li>",
"      Supraventricular arrhythmias occurred only in patients with severe pulmonary regurgitation and disappeared after reoperation. There were no major ventricular arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BALLOON VALVOTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When intervention is required and pulmonary valve anatomy is suitable (eg, domed), percutaneous balloon valvotomy is the procedure of choice, with excellent short- and long-term results (",
"    <a class=\"graphic graphic_figure graphicRef88377 \" href=\"UTD.htm?19/59/20410\">",
"     figure 1",
"    </a>",
"    ). As discussed above, the NHS found that intervention was rarely needed in long-term follow-up of patients with baseline mild disease, and that intervention was eventually required in approximately one-quarter of initially asymptomatic patients with moderate disease because of progressive symptoms or right heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"     8",
"    </a>",
"    ]. Children with severe disease are usually treated early in life. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11549788\">",
"    <span class=\"h2\">",
"     Procedural considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of an oversized balloon (approximately 1.2 to 1.25 times the measured pulmonary annulus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/19\">",
"     19",
"    </a>",
"    ]) aids in achieving a successful result (defined as a final peak valvular gradient of &lt;20 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is generally well tolerated. A mortality rate of 0.2 percent and major complication of 0.6 percent were reported by the Valvuloplasty and Angioplasty of Congenital Anomalies registry [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/20\">",
"     20",
"    </a>",
"    ]. Acute complications are generally minor and include a vagal response, catheter induced ventricular ectopy, right bundle branch block, and transient or permanent high grade AV nodal block [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. Other complications include pulmonary valve regurgitation, tricuspid regurgitation, stroke, syncope, pulmonary artery rupture, pulmonary edema, cardiac perforation, and tamponade.",
"   </p>",
"   <p>",
"    Transient severe right ventricular outflow tract obstruction (&ldquo;suicidal right ventricle&rdquo;) has been reported after the pulmonic valvular obstruction has been relieved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. This may be treated by volume expansion and beta blocker therapy and tends to regress with time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/22\">",
"     22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A pooled analysis of studies involving 784 patients of all ages showed that clinical success was achieved with balloon valvotomy in 98 percent, with a fall in the systolic outflow gradient from 71 to 28 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/20\">",
"     20",
"    </a>",
"    ]. Procedural mortality was less than 0.5 percent. Among the 196 patients in whom such data could be obtained, transvalvular and infundibular obstruction were each responsible for about one-half of the total residual gradient. After balloon valvuloplasty, a residual infundibular gradient tended to decline over several months as right ventricular hypertrophy diminished. Other studies reported similar reductions in the systolic outflow gradient (eg, 91 to 38 mmHg and 93 versus 19 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long-term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term efficacy of percutaneous balloon valvotomy was evaluated in a series of 53 adolescent and adult patients 13 to 55 years of age treated between 1985 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/23\">",
"     23",
"    </a>",
"    ]. The systolic pressure gradient across the pulmonary valve fell from 91 to 38 mmHg after the procedure and had fallen further at late follow-up an average of seven years later. In 7 of 53 patients who developed pulmonary insufficiency immediately after balloon valvotomy,",
"    <strong>",
"     none",
"    </strong>",
"    had this complication at late follow-up.",
"   </p>",
"   <p>",
"    In another report, 62 patients 9 months to 44 years of age were followed for 1 to 10 years (mean 6.4 years) after percutaneous balloon valvotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/18\">",
"     18",
"    </a>",
"    ]. The mean transvalvar gradient fell from 93 to 19 mmHg immediately after the procedure, and was 18 mmHg at follow-up. Progressive spontaneous regression of infundibular hypertrophy was noted. Restenosis occurred in less than 5 percent and was more likely in patients with dysplastic valves.",
"   </p>",
"   <p>",
"    Similar findings were noted in a series of 85 patients followed for up to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/26\">",
"     26",
"    </a>",
"    ]. Repeat balloon dilation was required in 11 percent and surgical intervention for subvalvular or supravalvular stenosis in 5 percent. Although residual pulmonary regurgitation was noted in the majority of patients, it was mild and right ventricular volume overload did not ensue.",
"   </p>",
"   <p>",
"    Longer-term follow-up is available after surgical correction than after balloon valvotomy. As noted above, patients who underwent surgical valvotomy had, at 33 year follow-up, a 53 percent likelihood of reintervention; most reinterventions were performed more than 25 years after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/17\">",
"     17",
"    </a>",
"    ]. The applicability of these findings to balloon valvotomy is uncertain. Surgery tended to produce lower long-term gradients but a higher rate of pulmonary insufficiency (45 versus 11 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12727/abstract/27\">",
"     27",
"    </a>",
"    ]. This may be important since pulmonary insufficiency requiring pulmonary valve replacement was the indication for reintervention in three-quarters of the patients in the surgical series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11549897\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The severity of pulmonic stenosis is classified echocardiographically according to either the peak or mean Doppler gradients across the valves. Although peak gradients have been more commonly used, the mean gradients may more accurately reflect catheter-derived peak-to-peak gradients. (See",
"      <a class=\"local\" href=\"#H9858791\">",
"       'Grading severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with valvular pulmonic stenosis have mild stenosis and are asymptomatic. Patients with moderate pulmonic stenosis frequently develop dyspnea and fatigue. Patients with severe stenosis may develop early right ventricular failure and cyanosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated pulmonic stenosis is rarely a significant impediment to a successful pregnancy. However, severe pulmonic stenosis may be associated with increased risk during labor, delivery, and the puerperium. Percutaneous balloon valvotomy performed during pregnancy in women with severe pulmonic stenosis has reduced the peripartum risk. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic patients with a domed pulmonic valve and peak instantaneous Doppler gradient &gt;60 mmHg or a mean Doppler gradient &gt;40 mmHg (in association with less than moderate pulmonic valve regurgitation), balloon valvotomy is recommended.",
"     </li>",
"     <li>",
"      For symptomatic patients with a domed pulmonic valve and peak instantaneous Doppler gradient &gt;50 mmHg or a mean Doppler gradient &gt;30 mmHg (in association with less than moderate pulmonic valve regurgitation), balloon valvotomy is recommended.",
"     </li>",
"     <li>",
"      Surgical therapy is recommended for patients with severe pulmonic stenosis and an associated hypoplastic pulmonary annulus, severe pulmonary regurgitation, subvalvular pulmonic stenosis, or supravalvular pulmonic stenosis. Surgery is also preferred for most dysplastic valves and when there is associated severe tricuspid regurgitation or the need for a surgical Maze procedure.",
"     </li>",
"     <li>",
"      Dynamic right ventricular outflow obstruction has been reported after surgical or percutaneous treatment of pulmonic stenosis and tends to regress with time. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1801371\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Catherine M. Otto for her contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/1\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/2\">",
"      Khambadkone S, Coats L, Taylor A, et al. Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients. Circulation 2005; 112:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/3\">",
"      McElhinney DB, Hellenbrand WE, Zahn EM, et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. Circulation 2010; 122:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/4\">",
"      Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/5\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/6\">",
"      Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/7\">",
"      Silvilairat S, Cabalka AK, Cetta F, et al. Echocardiographic assessment of isolated pulmonary valve stenosis: which outpatient Doppler gradient has the most clinical validity? J Am Soc Echocardiogr 2005; 18:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/8\">",
"      Hayes CJ, Gersony WM, Driscoll DJ, et al. Second natural history study of congenital heart defects. Results of treatment of patients with pulmonary valvar stenosis. Circulation 1993; 87:I28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/9\">",
"      Nugent, EW, Freedom, RM, Nora, JJ, et al. Clinical course in pulmonary stenosis. Circulation 1977; 56 [Suppl I]:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/10\">",
"      Nadas AS. Pulmonic stenosis--indications for surgery in children and adults. N Engl J Med 1972; 287:1196.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff, JK. The Clinical Recognition of Congenital Heart Disease, 6th ed, Elsevier/Saunders, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/12\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/13\">",
"      Hameed AB, Goodwin TM, Elkayam U. Effect of pulmonary stenosis on pregnancy outcomes--a case-control study. Am Heart J 2007; 154:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/14\">",
"      McFaul PB, Dornan JC, Lamki H, Boyle D. Pregnancy complicated by maternal heart disease. A review of 519 women. Br J Obstet Gynaecol 1988; 95:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/15\">",
"      Presbitero P, Prever SB, Brusca A. Interventional cardiology in pregnancy. Eur Heart J 1996; 17:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/16\">",
"      Greutmann M, Von Klemperer K, Brooks R, et al. Pregnancy outcome in women with congenital heart disease and residual haemodynamic lesions of the right ventricular outflow tract. Eur Heart J 2010; 31:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/17\">",
"      Earing MG, Connolly HM, Dearani JA, et al. Long-term follow-up of patients after surgical treatment for isolated pulmonary valve stenosis. Mayo Clin Proc 2005; 80:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/18\">",
"      Roos-Hesselink JW, Meijboom FJ, Spitaels SE, et al. Long-term outcome after surgery for pulmonary stenosis (a longitudinal study of 22-33 years). Eur Heart J 2006; 27:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/19\">",
"      Rao PS. Percutaneous balloon pulmonary valvuloplasty: state of the art. Catheter Cardiovasc Interv 2007; 69:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/20\">",
"      Stanger P, Cassidy SC, Girod DA, et al. Balloon pulmonary valvuloplasty: results of the Valvuloplasty and Angioplasty of Congenital Anomalies Registry. Am J Cardiol 1990; 65:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/21\">",
"      Ben-Shachar G, Cohen MH, Sivakoff MC, et al. Development of infundibular obstruction after percutaneous pulmonary balloon valvuloplasty. J Am Coll Cardiol 1985; 5:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/22\">",
"      Fawzy ME, Galal O, Dunn B, et al. Regression of infundibular pulmonary stenosis after successful balloon pulmonary valvuloplasty in adults. Cathet Cardiovasc Diagn 1990; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/23\">",
"      Chen CR, Cheng TO, Huang T, et al. Percutaneous balloon valvuloplasty for pulmonic stenosis in adolescents and adults. N Engl J Med 1996; 335:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/24\">",
"      Jarrar M, Betbout F, Farhat MB, et al. Long-term invasive and noninvasive results of percutaneous balloon pulmonary valvuloplasty in children, adolescents, and adults. Am Heart J 1999; 138:950.",
"     </a>",
"    </li>",
"    <li>",
"     Mullen MP, Landzberg MJ. Care of adults with congenital heart disease. In: Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease, 2nd ed, Antman E (Ed), W.B. Saunders, Philadelphia 2002. p.1062.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/26\">",
"      Rao PS, Galal O, Patnana M, et al. Results of three to 10 year follow up of balloon dilatation of the pulmonary valve. Heart 1998; 80:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12727/abstract/27\">",
"      Peterson C, Schilthuis JJ, Dodge-Khatami A, et al. Comparative long-term results of surgery versus balloon valvuloplasty for pulmonary valve stenosis in infants and children. Ann Thorac Surg 2003; 76:1078.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8118 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12727=[""].join("\n");
var outline_f12_27_12727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11549897\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9858791\">",
"      GRADING SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11549750\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mild stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Moderate stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Severe stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LONG-TERM SURGICAL FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BALLOON VALVOTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11549788\">",
"      Procedural considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long-term efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11549897\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1801371\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8118|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/59/20410\" title=\"figure 1\">",
"      Balloon valvuloplasty in pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8118|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_27_12728="Accelerated partial breast irradiation";
var content_f12_27_12728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Accelerated partial breast irradiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Frank A Vicini, MD, FACR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Thomas B Julian, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Hilary Shapiro-Wright, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12728/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/27/12728/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3016688\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated partial breast irradiation (APBI) refers to the use of limited focused adjuvant radiation therapy (RT) as an alternative to conventional whole breast irradiation (WBI) for selected patients with early breast cancer following breast conserving surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/1\">",
"     1",
"    </a>",
"    ]. Since APBI delivers radiation to a limited volume of tissue (partial breast irradiation), a higher dose of radiation can be delivered in a shorter period of time (hypofractionated accelerated RT) than with WBI. There are several techniques for APBI delivery, including external beam RT, interstitial or intracavitary brachytherapy, and intraoperative RT.",
"   </p>",
"   <p>",
"    The rationale, efficacy, and techniques of APBI are presented here. The role of radiation therapy in breast conserving therapy and the techniques, dosing, and complications of whole breast radiation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3016695\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the equivalence of breast conserving therapy (BCT) and mastectomy in long-term survival of early stage breast cancer has been established, radiation therapy (RT) is essential to reduce the risk of local recurrence after breast conserving surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The importance of RT was demonstrated in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 trial in which the local recurrence rate was significantly lower for patients who received postoperative RT than for patients not treated with RT (14 versus 39 percent after 20 years of follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Rationale'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although conventional WBI is the standard administration schedule for breast cancer patients who require RT, it is costly and may be inconvenient for some patients because of the duration of treatment, especially if travel for treatment is required. In addition, most local recurrences after breast conserving therapy with surgery and postoperative radiation are within one to two centimeters of the original surgical site (",
"    <a class=\"graphic graphic_table graphicRef78033 \" href=\"UTD.htm?6/24/6542\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This observation led to the concept of accelerated partial breast irradiation (APBI), which targets radiotherapy to the region of the tumor bed and a 1 to 2 cm surrounding margin, rather than the whole breast.",
"   </p>",
"   <p>",
"    APBI has been evaluated in patients with early breast cancer and a low risk for recurrence in an effort to achieve comparable local control with a shortened treatment duration and decreased toxicity. As a result of reducing the volume of breast tissue that receives the tumoricidal dose of RT, it is possible to safely use a larger than standard dose of radiation with each treatment, thereby reducing the duration of treatment.",
"   </p>",
"   <p>",
"    The advantages of APBI include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A potential for reduced toxicity due to sparing of normal tissue.",
"     </li>",
"     <li>",
"      A markedly shorter treatment duration (five days or less compared with five to six weeks with conventional WBI), which can translate into lower health care costs, less patient inconvenience, and increased use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    APBI also has potential disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the reduced treatment volume",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poorly defined target volume and dose, the risk of local recurrence may increase due to occult foci of cancer in the untreated breast.",
"     </li>",
"     <li>",
"      The higher radiation dose per fraction may increase late toxicity and adversely impact on cosmesis.",
"     </li>",
"     <li>",
"      According to the delivery technique used, there is also the potential for one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dose inhomogeneity (which can increase toxicity)",
"     </li>",
"     <li>",
"      Infection (with open technique intracavitary brachytherapy catheter insertion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344339\">",
"    <span class=\"h1\">",
"     INDICATIONS AND PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole breast radiation is the preferred choice for most women following breast conserving surgery for breast cancer. Many consider APBI investigational at this time if performed outside of certain criteria. However, given promising preliminary results, we acknowledge it is being used in the absence of prospective data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H7#H7\">",
"     \"Breast conserving therapy\", section on 'Patient selection for BCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If APBI is considered, we agree with the guidelines put forth by the American Society for Radiation Oncology, American Society of Breast Surgeons, and American Brachytherapy Society for appropriate patient selection (",
"    <a class=\"graphic graphic_table graphicRef51382 \" href=\"UTD.htm?9/51/10044\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. APBI should be limited to patients at least 45 years of age with small, lymph node negative tumors and negative surgical margins. It should be noted that some evidence suggests that these criteria do not sufficiently distinguish between patients at low- and high-risk for local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2057268\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to accelerated partial breast irradiation (APBI) have included multicentric breast cancer, positive lymph nodes, primary tumor &gt;3 cm, positive margins, and lymphovascular space invasion. Patients who are younger than age 50 and who have hereditary breast cancer",
"    <span class=\"nowrap\">",
"     (BRCA1/2",
"    </span>",
"    mutation) are considered &ldquo;unsuitable&rdquo; for off-protocol use of APBI at the present time. Other features that may also make patients less than optimal candidates for off-protocol use of APBI include ductal carcinoma in situ, invasive lobular carcinoma, and hormone receptor negative",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    human epidermal growth factor receptor 2 (HER2)-positive tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/8-10,15\">",
"     8-10,15",
"    </a>",
"    ]. However, most of these patients can be considered as candidates for clinical trial participation.",
"   </p>",
"   <p>",
"    Standard contraindications for conventional breast irradiation also apply, especially pregnancy. Although a history of collagen vascular disease, prior therapeutic irradiation to the breast region, and cardiovascular and severe pulmonary disease are commonly held as contraindications to irradiation, successful treatment has been reported with targeted intraoperative radiotherapy in patients with systemic lupus erythematosus, motor neuron disease, Parkinson disease, ankylosing spondylitis, morbid obesity, prior therapeutic irradiation, and cardiovascular or severe respiratory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Contraindications may also vary by APBI technique, such as extremely small breast size as a contraindication for intracavitary brachytherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2058343\">",
"    <span class=\"h1\">",
"     DELIVERY OF APBI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the delivery of APBI include brachytherapy, intraoperative radiotherapy, or external beam radiation. Conformal external beam radiation is the most commonly used delivery system in the US at the present time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3623108\">",
"    <span class=\"h2\">",
"     External beam techniques for APBI",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiotherapy with conformal technique can be used to deliver APBI. The radiation is delivered postoperatively and thus, after the pathology is reviewed and clean surgical margins are ensured. In addition, the treatment is noninvasive, and standard dosimetry and treatment equipment are employed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3623115\">",
"    <span class=\"h3\">",
"     Conformal external beam radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional conformal external beam radiotherapy provides a noninvasive method for APBI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This technique combines multiple radiation treatment fields to deliver a specific dose of radiotherapy to the tumor bed region while sparing the majority of normal surrounding tissue and solid organs.",
"   </p>",
"   <p>",
"    APBI with conformal external beam radiotherapy typically delivers 35 to 38.5 Gy in 10 fractions, twice a day, over one week [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/18\">",
"     18",
"    </a>",
"    ]. Computed tomography images and sophisticated treatment planning computer software are required for radiation planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3623122\">",
"    <span class=\"h3\">",
"     Intensity modulated radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensity modulated radiotherapy uses a linear accelerator to deliver precisely focused small beams of radiation that follow the exact contours of a tumor or target volume. Higher radiation doses can be used because the damage to surrounding tissue is limited, possibly resulting in more effective treatment. Computer imaging is used to evaluate the tumor throughout the course of treatment, permitting the most precise dose and treatment changes based on the changing tumor characteristics.",
"   </p>",
"   <p>",
"    Intensity modulated radiotherapy requires special equipment that is available at most hospitals and radiation centers, but its use in breast cancer for APBI delivery has been limited [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The interim analysis of a phase III clinical trial has shown that intensity modulated radiotherapy can be used to deliver APBI safely with low toxicity, however a prospective study suggested increased risk of poor cosmesis with this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. More study of IMRT for breast cancer is needed. General information about intensity modulated radiotherapy is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3016702\">",
"    <span class=\"h2\">",
"     Brachytherapy techniques for APBI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy is the temporary or permanent placement of radioactive material into body tissues for local radiation treatment. Brachytherapy can be delivered with interstitial, intracavitary, or intraoperative delivery systems. In addition, the strut-adjusted volume implant (SAVI) device delivers interstitial brachytherapy directly into the lumpectomy cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific issues related to brachytherapy techniques are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3625111\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy can be delivered with either low or high dose rate techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Low dose rate radiotherapy",
"      </strong>",
"      &ndash; Low dose rate radiotherapy consists of approximately 45 to 50 Gy delivered to the target site at a rate of 30 to 70",
"      <span class=\"nowrap\">",
"       cGy/hour.",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       High dose rate radiotherapy",
"      </strong>",
"      &ndash; High dose rate radiotherapy is completed as an outpatient procedure over a five day period. This technique typically delivers a total dose of 34 Gy to the target site at a dose of 3.4 Gy twice daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, other fractionation schedules have also been used with good success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345073\">",
"    <span class=\"h3\">",
"     Interstitial brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For interstitial brachytherapy, several small hollow catheters are placed into the breast surrounding the partial mastectomy site (",
"    <a class=\"graphic graphic_figure graphicRef68329 \" href=\"UTD.htm?40/54/41839\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/26\">",
"     26",
"    </a>",
"    ]. Potential disadvantages of this approach include the risk of infection and poor cosmesis with scarring due to the multiple catheters, although these have been seen in older studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link&amp;anchor=H15#H15\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'RT boost'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Catheter placement &minus;",
"      </strong>",
"      The number of catheters used is dependent upon the size and shape of the target. The placement of the catheters is determined using radiation treatment planning software along with stereotactic mammography, ultrasound, or computed tomography guidance.",
"     </li>",
"     <li>",
"      <strong>",
"       Radioactive seed insertion",
"      </strong>",
"      &ndash; High or low dose radioactive seeds are inserted into the catheters as described above. The catheters are removed after five days, when treatment is completed. (See",
"      <a class=\"local\" href=\"#H3625111\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3016723\">",
"    <span class=\"h3\">",
"     Intracavitary brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For intracavitary brachytherapy, a radiation delivery device is placed into the partial mastectomy site [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/27\">",
"     27",
"    </a>",
"    ]. Single lumen and multi-lumen balloon catheter and non-balloon devices have all been used successfully (",
"    <a class=\"graphic graphic_picture graphicRef66278 \" href=\"UTD.htm?36/41/37534\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef59722 \" href=\"UTD.htm?4/32/4612\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The presumed advantage of the multilumen devices as compared with single lumen catheters is more precise dosimetric planning and safer treatment delivery, avoiding skin and other organ damage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Placement of the device",
"      </strong>",
"      &ndash; Consideration of intracavitary brachytherapy requires a surgical cavity large enough to accommodate the device (",
"      <a class=\"graphic graphic_figure graphicRef54572 \" href=\"UTD.htm?42/4/43087\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H344339\">",
"       'Indications and patient selection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The device can be placed at the time of lumpectomy (&ldquo;open technique&rdquo;) or several days later under ultrasound guidance (&ldquo;closed technique&rdquo;). The closed technique is preferable because, if the device is placed during surgery, final pathology results may require the device to be removed due to involved margins or positive lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/27\">",
"       27",
"      </a>",
"      ]. The device can usually be placed percutaneously in the office setting after final pathology results are available. In addition, infection rates are lower with the closed technique [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/31\">",
"       31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A cavity evaluation device may be placed initially in the operating room and then exchanged for the treatment device (",
"      <a class=\"graphic graphic_figure graphicRef55743 \" href=\"UTD.htm?18/9/18590\">",
"       figure 4",
"      </a>",
"      ). The cavity evaluation device is used to assess the partial mastectomy cavity, evaluate skin spacing, and assist in the selection of the correct balloon size applicator for delivery of intracavitary radiotherapy.",
"     </li>",
"     <li>",
"      <strong>",
"       Verification of conformance",
"      </strong>",
"      &ndash; When the appropriate radiation delivery device is in place, a computed tomography (CT) scan is performed to evaluate tissue conformance, skin spacing, symmetry of the balloon in relation to the central catheter, and the device catheter to determine if treatment can be delivered. Verification of the conformance and integrity of the device are necessary to ensure that the correct dose of radiotherapy is provided to the partial mastectomy cavity and surrounding breast tissue.",
"      <br/>",
"      <br/>",
"      Adequate conformance generally requires that less than 10 percent of the planning target volume is composed of air or fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/1\">",
"       1",
"      </a>",
"      ]. Large air or fluid pockets between the device and tissue may require device removal [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, the device-to-skin distance should be greater than or equal to 7 mm to avoid skin damage, which precludes use of this technique for superficial lesions.",
"     </li>",
"     <li>",
"      <strong>",
"       Radioactive seed treatment",
"      </strong>",
"      &ndash; High or low dose radioactive seeds are inserted into the catheters as described above. The catheters are removed after five days, when treatment is completed. (See",
"      <a class=\"local\" href=\"#H3625111\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343053\">",
"    <span class=\"h2\">",
"     Intraoperative radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative radiation",
"    <strong>",
"    </strong>",
"    therapy condenses the entire therapeutic dose into a single fraction, permitting surgery and radiation to be completed in one day. Potential advantages include accurate delivery of radiotherapy directly to the surgical margins and a decreased dose of radiation to skin and subcutaneous tissue since these can be retracted during treatment. Drawbacks to the use of intraoperative radiation include the extended time in the operating room, the inability to verify the radiation dosimetry, and the lack of final pathology information at the time of radiation.",
"   </p>",
"   <p>",
"    Several devices have been used for intraoperative radiation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A portable, spherical, radiation-generating device is placed into the partial mastectomy cavity just after specimen resection and pursestring sutures are placed within the breast to ensure that the breast tissue is in contact with the applicator surface. &nbsp;Treatment is then delivered with low energy x-rays, with a dose of 20 Gy at the applicator surface and 5 Gy at a depth of 1 cm over 20 to 45 minutes, depending upon the size of the cavity and the device [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Electronic brachytherapy using a portable linear accelerator is used to deliver 21 Gy in one fraction intraoperatively, with a lead shield placed on the pectoralis fascia to protect the lung [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/32,34,35\">",
"       32,34,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1569286\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated partial breast irradiation (APBI) has demonstrated promising results when compared to whole breast irradiation (WBI). However, patients included in trials of APBI were highly selected for the following characteristics: age between 45 and 70 years, with tumors that were unifocal, small (&lt;T2), resected with wide negative margins, hormone receptor positive, low grade (1 or 2), and without adverse histologic features (including lobular carcinoma, ductal carcinoma in situ, and extensive intraductal component).",
"   </p>",
"   <p>",
"    Follow-up is limited (ie, 5 to 10 years), which raises potential concern over long-term safety and efficacy. In addition, there are limited data comparing one APBI technique to another. Until the results from prospective trials comparing APBI to WBI are mature, we recommend against APBI rather than WBI outside of a clinical trial.",
"   </p>",
"   <p>",
"    Longer follow-up to define the rates of local control, survival, and toxicity with APBI compared to WBI are needed before APBI is accepted as an alternative to conventional WBI for breast conserving therapy in all patients with early breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/4,7,32,36-40\">",
"     4,7,32,36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A summary of available data is discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meta-analysis of APBI versus WBI &mdash; A meta-analysis of three phase III trials (n=1140 patients) found that compared to WBI, APBI resulted in [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/41\">",
"       41",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No difference in overall survival",
"      <sup>",
"      </sup>",
"      (odds ratio [OR] for death, 0.91, 95% CI 0.67&ndash;1.23)",
"     </li>",
"     <li>",
"      No difference in risk of distant metastasis (OR 7.4, 95% CI 0.51-1.08) or supraclavicular",
"      <sup>",
"      </sup>",
"      recurrences (pooled OR for recurrence 1.42, 95% CI 0.28-7.20)",
"     </li>",
"     <li>",
"      A significant risk of both local (pooled OR for recurrence 2.15, 95% CI 1.40&ndash;3.31) and",
"      <sup>",
"      </sup>",
"      axillary recurrence (pooled OR 3.43, 95% CI 2.06&ndash;5.72)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several issues limit the applicability of this meta-analysis. First, these trials used different patient selection criteria, APBI techniques, and target volume definition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Second, follow-up ranged from four to eight years without long-term data collected. Third, the techniques used in two of these studies are not currently in use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only one trial in the meta-analysis had a sufficient target volume definition [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/42\">",
"       42",
"      </a>",
"      ]. In this study, 258 patients with T1N0-1mic grade 1-2 nonlobular breast cancer were randomly assigned to APBI (delivered as high-dose-rate multicatheter brachytherapy or electron beam irradiation) or WBI to a treatment volume of 50 Gy. Compared to WBI, 5-year actuarial results associated with APBI were [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/42\">",
"       42",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Similar rate of local recurrence (5 versus 3 percent)",
"     </li>",
"     <li>",
"      No significant difference in overall survival (95 versus 92 percent)",
"     </li>",
"     <li>",
"      No significant difference in cancer-specific survival (98 versus 96 percent)",
"     </li>",
"     <li>",
"      No significant difference in disease-free survival (88 versus 90 percent)",
"     </li>",
"     <li>",
"      Significant improvement in the rate of excellent to good cosmetic results (78 versus 63 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TARGIT-A &mdash;The TARGIT-A was a randomized trial which compared a single dose of targeted intraoperative radiotherapy (RT) with WBI in 2232 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/17\">",
"       17",
"      </a>",
"      ]. Of note, 14 percent of the patients treated with targeted intraoperative RT also received external beam RT for unfavorable features found subsequently in the pathologic examination of the excised tumor. At a median follow-up of 4.5 years, compared to WBI, intraoperative RT resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No significant difference in local recurrence rate (1.2 versus 1.0 percent)",
"     </li>",
"     <li>",
"      No significant difference in severe complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single institution retrospective study of 534 patients treated with APBI, the five-year rate of axillary and regional node relapse was 0.2 and 0.4 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/45\">",
"       45",
"      </a>",
"      ]. No factors were associated with axillary or regional node recurrence on univariate analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results demonstrate that APBI is a promising alternative to WBI. However, we await the results from prospective trials comparing APBI to WBI before APBI can be used as an acceptable alternative to WBI. Such a trial is underway in a combined effort by the National Surgical Adjuvant Breast and Bowel Project and the Radiation Therapy Oncology Group (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00103181\">",
"     NSABP B-39/RTOG 0413",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86961917\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated partial breast irradiation (APBI) may be associated with increased toxicities, including breast pain, edema, erythema, seroma, and hyperpigmentation, while more severe toxicity includes telangiectasia, fat necrosis, fibrosis, and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. In addition, APBI may have greater toxicity than WBI.",
"   </p>",
"   <p>",
"    This was demonstrated in a population-based cohort study of 92,735 women 67 years or older with invasive breast cancer diagnosed between 2003 and 2007 identified from the National Medicare Database [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12728/abstract/51\">",
"     51",
"    </a>",
"    ]. Compared to treatment with WBI, treatment with brachytherapy (n=6952) was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher incidence of subsequent mastectomy at five years (hazard ratio [HR] 2.19, 95% CI 1.84-2.61). This translated into a 2 percent higher incidence of mastectomies (number needed to harm, 56; 95% CI 45-77).",
"     </li>",
"     <li>",
"      A higher incidence of toxicities, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Postoperative infections (16 versus 10 percent, respectively; odds ratio [OR] 1.76, 95% CI 1.64-1.88)",
"     </li>",
"     <li>",
"      Postoperative noninfectious complications (16 versus 9 percent, OR 2.03, 95% CI 1.89-2.17)",
"     </li>",
"     <li>",
"      A statistically significant increase in postradiation complications including breast pain (15 versus 12 percent), fat necrosis (8 versus 4 percent), and rib fractures (5 versus 4 percent), although it is unclear whether these findings were clinically relevant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are limited by several factors. First, the authors relied on an algorithm to determine the type of RT performed, with a possibility that treatment delivery was misclassified. Second, they did not take into account the brachytherapy techniques used, which is important because interstitial brachytherapy can be associated with more skin complications than intracavitary brachytherapy (see",
"    <a class=\"local\" href=\"#H3016702\">",
"     'Brachytherapy techniques for APBI'",
"    </a>",
"    above). Third, without clarifying the indication for subsequent mastectomy, it is unclear whether the higher incidence associated with brachytherapy was due to toxicity or other factors, such as local recurrence. Finally, billing codes were used as surrogates for clinical endpoints.",
"   </p>",
"   <p>",
"    We await results from the prospective",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00103181\">",
"     NSABP B-39/RTOG 0413 trial",
"    </a>",
"    comparing APBI to WBI to inform the risk-benefit profile associated with APBI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=see_link\">",
"       \"Patient information: Brachytherapy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       \"Patient information: Radiation therapy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3016765\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accelerated partial breast irradiation (APBI) refers to the use of limited focused adjuvant radiation therapy (RT) as an alternative to conventional whole breast irradiation (WBI) for selected patients with early breast cancer following breast conserving surgery. Since APBI delivers radiation to a limited volume of tissue (partial breast irradiation), a higher dose of radiation can be delivered in a shorter period of time than with WBI. (See",
"      <a class=\"local\" href=\"#H3016688\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rationale for APBI is based upon the observation that most local recurrences after breast conserving therapy with surgery and postoperative radiation are within 1 to 2 cm of the original surgical site. (See",
"      <a class=\"local\" href=\"#H3016695\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most women should receive whole breast radiation therapy following breast conserving surgery for breast cancer. We consider APBI investigational at this time, although we acknowledge it is being used off-protocol in low-risk patients. (See",
"      <a class=\"local\" href=\"#H344339\">",
"       'Indications and patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current contraindications to off-protocol use of APBI include age &lt;50 years, multicentric breast cancer, positive lymph nodes, primary tumors larger than 3 cm, positive margins, and lymphovascular space invasion. (See",
"      <a class=\"local\" href=\"#H344339\">",
"       'Indications and patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2057268\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall, it is not yet clear which patients are at sufficiently low risk for local recurrence so that the advantages of APBI (short treatment duration, decreased cost, reduced toxicity) outweigh the possibility of an increased risk of local recurrence. (See",
"      <a class=\"local\" href=\"#H1569286\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/1\">",
"      Njeh CF, Saunders MW, Langton CM. Accelerated Partial Breast Irradiation (APBI): A review of available techniques. Radiat Oncol 2010; 5:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/2\">",
"      Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/3\">",
"      Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087.",
"     </a>",
"    </li>",
"    <li>",
"     ACR-ACS-CAP-SSO Practice guideline for breast conservation therapy in the management of invasive breast carcinoma. file://www.acr.org/secondarymainmenucategories/quality_safety/guidelines/breast/invasive_breast_carcinoma.aspx (Accessed on November 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/5\">",
"      Dehnim AC, Boughey JC, Sookhan N. Partial-breast irradiation: Rating today's evidence. Contemporary Surgery Online 2008; 64:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/6\">",
"      Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg 1994; 18:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/7\">",
"      Lehman M, Hickey B. The less than whole breast radiotherapy approach. Breast 2010; 19:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/8\">",
"      Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009; 74:987.",
"     </a>",
"    </li>",
"    <li>",
"     American Society of Breast Surgeons, Consensus statement for Accelerated Partial Breast Irradiation www.breastsurgeons.org (Accessed on July 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/10\">",
"      Arthur DW, Vicini FA, Kuske RR, et al. Accelerated partial breast irradiation: an updated report from the American Brachytherapy Society. Brachytherapy 2003; 2:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/11\">",
"      Zauls AJ, Watkins JM, Wahlquist AE, et al. Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by ASTRO Accelerated Partial Breast Irradiation Consensus Statement Groups. Int J Radiat Oncol Biol Phys 2012; 82:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/12\">",
"      McHaffie DR, Patel RR, Adkison JB, et al. Outcomes after accelerated partial breast irradiation in patients with ASTRO consensus statement cautionary features. Int J Radiat Oncol Biol Phys 2011; 81:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/13\">",
"      Shaitelman SF, Vicini FA, Beitsch P, et al. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer 2010; 116:4677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/14\">",
"      Vicini F, Arthur D, Wazer D, et al. Limitations of the American Society of Therapeutic Radiology and Oncology Consensus Panel guidelines on the use of accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2011; 79:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/15\">",
"      Wilder RB, Curcio LD, Khanijou RK, et al. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status. Int J Radiat Oncol Biol Phys 2010; 78:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/16\">",
"      Thompson N, Cogen C, Forman D, Londerville S. MammoSite Radiation Therapy System. Clin J Oncol Nurs 2005; 9:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/17\">",
"      Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/18\">",
"      Berrang TS, Olivotto I, Kim DH, et al. Three-year outcomes of a Canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys 2011; 81:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/19\">",
"      Shaitelman SF, Kim LH, Grills IS, et al. Predictors of long-term toxicity using three-dimensional conformal external beam radiotherapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2011; 81:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/20\">",
"      Probst H, Griffiths S. Moving to a high-tech approach to the irradiation of early breast cancer: is it possible to balance efficacy, morbidity and resource use? Clin Oncol (R Coll Radiol) 2006; 18:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/21\">",
"      Smith D, MacDougall N, Monk J, et al. First quinquennial review of intensity-modulated radiotherapy at St Bartholomew's Hospital, London. Clin Oncol (R Coll Radiol) 2010; 22:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/22\">",
"      O'Donnell H, Cooke K, Walsh N, Plowman PN. Early experience of tomotherapy-based intensity-modulated radiotherapy for breast cancer treatment. Clin Oncol (R Coll Radiol) 2009; 21:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/23\">",
"      Livi L, Buonamici FB, Simontacchi G, et al. Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial. Int J Radiat Oncol Biol Phys 2010; 77:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/24\">",
"      Jagsi R, Moran J, Marsh R, et al. Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer. Int J Radiat Oncol Biol Phys 2010; 78:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/25\">",
"      Fisher B, Daugherty L, Shaikh T, et al. Tumor bed-to-skin distance using accelerated partial-breast irradiation with the strut-adjusted volume implant device. Brachytherapy 2012; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/26\">",
"      Strnad V, Hildebrandt G, P&ouml;tter R, et al. Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2011; 80:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/27\">",
"      Zannis V, Beitsch P, Vicini F, et al. Descriptions and outcomes of insertion techniques of a breast brachytherapy balloon catheter in 1403 patients enrolled in the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial. Am J Surg 2005; 190:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/28\">",
"      Benitez PR, Streeter O, Vicini F, et al. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg 2006; 192:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/29\">",
"      Jeruss JS, Vicini FA, Beitsch PD, et al. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann Surg Oncol 2006; 13:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/30\">",
"      Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 2008; 112:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/31\">",
"      Cuttino LW, Keisch M, Jenrette JM, et al. Multi-institutional experience using the MammoSite radiation therapy system in the treatment of early-stage breast cancer: 2-year results. Int J Radiat Oncol Biol Phys 2008; 71:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/32\">",
"      Arthur DW, Vicini FA. Accelerated partial breast irradiation as a part of breast conservation therapy. J Clin Oncol 2005; 23:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/33\">",
"      Vaidya JS, Tobias JS, Baum M, et al. Intraoperative radiotherapy for breast cancer. Lancet Oncol 2004; 5:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/34\">",
"      Veronesi U, Gatti G, Luini A, et al. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery. Arch Surg 2003; 138:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/35\">",
"      Ivanov O, Dickler A, Lum BY, et al. Twelve-month follow-up results of a trial utilizing Axxent electronic brachytherapy to deliver intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol 2011; 18:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/36\">",
"      Sauer R, Sautter-Bihl ML, Budach W, et al. Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies. Cancer 2007; 110:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/37\">",
"      Wallner P, Arthur D, Bartelink H, et al. Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. J Natl Cancer Inst 2004; 96:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/38\">",
"      Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/39\">",
"      Buchholz TA. Partial breast irradiation--is it ready for prime time? Int J Radiat Oncol Biol Phys 2003; 57:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/40\">",
"      Prosnitz LR, Marks LB. Partial breast irradiation: a cautionary note. Int J Radiat Oncol Biol Phys 2006; 65:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/41\">",
"      Valachis A, Mauri D, Polyzos NP, et al. Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. Breast J 2010; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/42\">",
"      Polg&aacute;r C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma--5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 2007; 69:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/43\">",
"      Ribeiro GG, Magee B, Swindell R, et al. The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol (R Coll Radiol) 1993; 5:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/44\">",
"      Dodwell DJ, Dyker K, Brown J, et al. A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clin Oncol (R Coll Radiol) 2005; 17:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/45\">",
"      Dekhne N, Shah C, Wilkinson JB, et al. Axillary lymph node failure in patients treated with accelerated partial breast irradiation. Cancer 2012; 118:38.",
"     </a>",
"    </li>",
"    <li>",
"     Norris D, Julian T. Update on the NSABP B39/ RTOG 0413 Clinical Trial. Comparing Partial to Whole Breast Irradiation Therapy. file://accc-cancer.org/oncology_issues/articles/janfeb08/norris.pdf (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     Trial details available at www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=409590&amp;version=patient&amp;protocolsearchid=2096975 (Accessed on February 08, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/48\">",
"      Chao KK, Vicini FA, Wallace M, et al. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the william beaumont hospital experience. Int J Radiat Oncol Biol Phys 2007; 69:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/49\">",
"      Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2009; 75:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/50\">",
"      Chen PY, Vicini FA, Benitez P, et al. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation: a method of radiation delivery by interstitial brachytherapy for the treatment of early-stage breast carcinoma. Cancer 2006; 106:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12728/abstract/51\">",
"      Smith GL, Xu Y, Buchholz TA, et al. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 2012; 307:1827.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14977 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12728=[""].join("\n");
var outline_f12_27_12728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3016765\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3016688\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3016695\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344339\">",
"      INDICATIONS AND PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2057268\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2058343\">",
"      DELIVERY OF APBI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3623108\">",
"      External beam techniques for APBI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3623115\">",
"      - Conformal external beam radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3623122\">",
"      - Intensity modulated radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3016702\">",
"      Brachytherapy techniques for APBI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3625111\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H345073\">",
"      - Interstitial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3016723\">",
"      - Intracavitary brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343053\">",
"      Intraoperative radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569286\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86961917\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3016765\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14977|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/54/41839\" title=\"figure 1\">",
"      Interstitial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/32/4612\" title=\"figure 2\">",
"      Multilumen catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/4/43087\" title=\"figure 3\">",
"      Balloon brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/9/18590\" title=\"figure 4\">",
"      Cavity eval device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14977|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/41/37534\" title=\"picture 1\">",
"      Single lumen catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/24/6542\" title=\"table 1\">",
"      Site of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/51/10044\" title=\"table 2\">",
"      Patient selection guidelines for APBI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=related_link\">",
"      Patient information: Brachytherapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_27_12729="Evaluation of pallor in children";
var content_f12_27_12729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of pallor in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12729/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12729/contributors\">",
"     Char Witmer, MD, MSCE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12729/contributors\">",
"     Catherine S Manno, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12729/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12729/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12729/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12729/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/27/12729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of pallor can be acute and associated with a life-threatening illness, or it can be chronic and subtle, occasionally first noted by someone who sees the child less often than the parents. The onset of pallor can provoke anxiety for parents who are familiar with the descriptions of the presentation of leukemia in childhood. In some instances, only reassurance may be needed, as in the case of a light complexioned or fair-skinned, non-anemic child. In other instances, pallor may occur in patients with nonhematologic conditions such as shock, anaphylaxis, respiratory failure, or hypoglycemia. Even if there is a hematologic cause for the pallor, it often is a temporary condition readily amenable to therapy. However, pallor can portend a serious disease, and when onset is acute, it can herald a true pediatric emergency for which rapid diagnosis and treatment are needed.",
"   </p>",
"   <p>",
"    This topic will review the differential diagnosis and approach to children with pallor. The approach to the child with anemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any condition that decreases the concentration of hemoglobin or alters the distribution of blood away from the body's surface may present as pallor (",
"    <a class=\"graphic graphic_table graphicRef65774 \" href=\"UTD.htm?37/7/38012\">",
"     table 1",
"    </a>",
"    ). Clinically, pallor caused by anemia usually can be appreciated when the hemoglobin concentration is below 8 to 9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (4.96 to 5.56",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    although the complexion of the child and the rapidity of onset may influence this value.",
"   </p>",
"   <p>",
"    The concentration of hemoglobin in the blood can be lowered by three basic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased erythrocyte production",
"     </li>",
"     <li>",
"      Increased erythrocyte destruction",
"     </li>",
"     <li>",
"      Blood loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anemias may also be classified by the size of the red blood cell: microcytic, normocytic, or macrocytic. The most common causes of anemia seen in the emergency department (ED) are iron deficiency, infection, and blood loss, but several less common diseases remain important considerations.",
"   </p>",
"   <p>",
"    Nonhematologic causes of pallor include complexion (\"fair skin\"), hypoperfusion from shock, respiratory distress, hypoglycemia, skin edema, and pheochromocytoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life-threatening causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conditions that are life-threatening and cause pallor can be divided into nonhematologic and hematologic causes (",
"    <a class=\"graphic graphic_table graphicRef65774 \" href=\"UTD.htm?37/7/38012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Nonhematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pallor may be associated with respiratory failure, poor tissue perfusion (shock), and hypoglycemia. Etiologies for shock include sepsis, hypovolemia, traumatic brain or spinal cord injury, heart failure, arrhythmia, or anaphylaxis. These conditions require recognition and intervention prior to knowing the results of hematologic studies (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Severe blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive hemorrhage (eg, severe trauma) is accompanied by signs of hypovolemic shock and is considered an emergency. Rapid fluid resuscitation is required to reverse the hemodynamic abnormalities. The initial hemoglobin and indices are typically normal due to lack of equilibration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pallor caused by autoimmune hemolytic anemia (AIHA) is usually acute in onset and may be associated with severe anemia. On physical examination, the child with AIHA often will be pale and jaundiced. Tachycardia is typically present, as is a systolic flow murmur, reflecting a high-output anemic state. However, cardiovascular compromise (eg, congestive failure) is uncommon unless the hemoglobin concentration is &lt;5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (3.10",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The liver and spleen may be palpable, but the presence of massive organomegaly or lymph node enlargement should suggest another disorder such as malignancy (eg, leukemia, lymphoma) or infection (eg, HIV, malaria, tuberculosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H11#H11\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Physical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of only a moderate anemia (6 to 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [3.72 to 4.96",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    at diagnosis should not detract from consideration of this disease as a hematologic emergency because brisk hemolysis may result in a sudden, additional fall in the hemoglobin level that could be life-threatening. It is usually characterized by a positive direct anti-globulin test (DAT or direct Coomb test) and an increased reticulocyte count. Spherocytes are commonly seen in the peripheral smear (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H9#H9\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology and treatment of AIHA in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H32#H32\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sickle cell anemia with splenic sequestration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequestration episodes of sickle cell anemia and related hemoglobin disorders (SC disease, S-&szlig;0 thalassemia, S-&szlig;+ thalassemia) result from acute pooling of red cells and plasma in the spleen. The sudden and severe anemia and the hypovolemia associated with this complication constitute a true hematologic emergency and, if untreated, may rapidly lead to death. The presence of increased pallor and acute enlargement of the spleen in a patient with a sickling disorder should prompt immediate investigation of a possible sequestration crisis. Although this complication rarely occurs in children with homozygous sickle cell disease or S-&szlig;0 thalassemia after the age of five years, sequestration crises may occur much later in children with milder sickling disorders such as SC or S-&szlig;+ thalassemia, in which early splenic infarction is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Splenic sequestration crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red blood cell destruction in both of these processes is secondary to fibrin deposition resulting in microangiopathic hemolysis with schistocytes, helmet cells, and RBC fragments on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50715 \" href=\"UTD.htm?22/13/22739\">",
"     picture 3",
"    </a>",
"    ). Thrombocytopenia and uremia may lower the hemoglobin concentration even further by causing bleeding, impaired red cell production, shortened red cell survival, and increased plasma volume. In some instances, the anemia may be moderately severe when the uremia is only mild and thrombocytopenia is absent, leaving doubt about the correct diagnosis. In more typical cases, however, the diagnosis is readily apparent from the findings of oliguria, central nervous system (CNS) abnormalities, increased blood urea nitrogen (BUN), and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Clinical and laboratory manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link\">",
"     \"Atypical hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Disseminated intravascular coagulation (DIC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In DIC, abnormal fibrin deposition within small blood vessels results in mechanical injury to the erythrocytes. Thrombocytopenia and clotting abnormalities, which often herald the onset of DIC, also may contribute to the anemia by causing diffuse bleeding. The main diagnostic findings are red cell fragments in the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50715 \" href=\"UTD.htm?22/13/22739\">",
"     picture 3",
"    </a>",
"    ), platelet and clotting abnormalities typical of a consumptive coagulopathy, and the clinical features of a disease such as septic shock, which is associated with DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H13#H13\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H14#H14\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoplastic anemia can be the presenting symptom of childhood malignancies. The pallor can be severe, and although all three cell lines of the bone marrow usually are affected, anemia may be the only notable hematologic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12729/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis can be suspected from the presence of other symptoms or findings such as lymphadenopathy, bruising, limb pain, gum bleeding, or an abdominal mass. Malignancies that can present with anemia include leukemias, lymphomas, and other solid tumors that infiltrate the bone marrow (eg, neuroblastoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Peripheral blood abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\", section on 'Presenting symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Common hematologic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common hematologic conditions that result in pallor can be divided into decreased RBC production, increased RBC destruction, and blood loss (",
"    <a class=\"graphic graphic_table graphicRef65774 \" href=\"UTD.htm?37/7/38012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Decreased RBC production",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Iron deficiency&nbsp;anemia",
"      </strong>",
"      &ndash; Anemia from iron deficiency is usually seen in the first two years of life, at which time the dietary iron content is often insufficient to meet the demands of the rapidly increasing red cell mass. It is the most common hematologic disorder in childhood, affecting approximately 5 to 10 percent of young children. The typical presentation of iron deficiency anemia (IDA) is an otherwise asymptomatic, well-nourished infant or child who has a mild to moderate microcytic, hypochromic anemia (",
"      <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"       picture 4",
"      </a>",
"      ). Much less frequent are infants with severe anemia, who present with lethargy, pallor, irritability, cardiomegaly, poor feeding, and tachypnea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link&amp;anchor=H20317248#H20317248\">",
"       \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For infants presenting with a mild microcytic anemia and a presumptive diagnosis of IDA, a therapeutic trial of iron is the most cost effective strategy. In children older than two years of age, dietary causes of iron deficiency are less likely, and other causes of anemia (eg, chronic blood loss, chronic disease, celiac disease) need to be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link&amp;anchor=H16#H16\">",
"       \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Aplastic episodes in patients with a hemolytic anemia",
"      </strong>",
"      &ndash; Patients with inherited hemolytic anemias such as spherocytosis or sickle cell disease may develop red cell aplasia, usually in association with parvovirus B19 infection. Decreased red cell production in the face of ongoing hemolysis causes an exacerbation of the anemia. The usually elevated reticulocyte count falls to inappropriately low levels, often less than 1 percent. Although the platelets and white cells are generally unaffected, they may be mildly decreased. Red cell transfusions are appropriate if the anemia is associated with cardiovascular signs or symptoms or if continuing reticulocytopenia indicates that the anemia is likely to become severe before the usual spontaneous recovery after three to seven days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\", section on 'Transient aplastic crisis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lead poisoning",
"      </strong>",
"      &ndash; Lead poisoning reduces heme synthesis, but significant anemia is unusual unless blood lead levels are markedly elevated. Iron deficiency is common in children with increased lead levels and usually accounts for the microcytic anemia found in these patients. If a concomitant hematologic disorder cannot be found in the anemic patient with plumbism, particular care should be given to the possibility of severe lead intoxication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H8#H8\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Hematologic'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anemia of chronic disease",
"      </strong>",
"      &ndash; Occasionally, pallor is the only presenting finding of a serious systemic disorder. Chronic inflammatory diseases such as juvenile idiopathic arthritis (JIA) and ulcerative colitis often are accompanied by a normocytic or microcytic anemia related to impaired iron use. The serum iron is reduced. The low iron-binding capacity and normal to high ferritin distinguishes the anemia of chronic inflammation from the anemia of iron deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H9#H9\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Iron studies'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Similar clinical and laboratory findings may be associated with chronic infections such as acquired immunodeficiency syndrome (AIDS) and subacute bacterial endocarditis. Other diseases in which anemia may be a prominent component include chronic renal disease, collagen vascular disease, thyroid deficiency, or thyrotoxicosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H10#H10\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Increased RBC destruction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sickle cell syndromes",
"      </strong>",
"      &ndash; Patients with sickle cell disease have a baseline anemia and pallor. Acute accentuation of the pallor can result from an aplastic crisis, increased hemolysis, or acute pooling of red cells in the spleen. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sickle cell anemia with splenic sequestration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Decreased RBC production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Hereditary spherocytosis",
"      </strong>",
"      &ndash; Patients with hereditary spherocytosis, the most common of the membrane disorders, typically present with anemia, jaundice, and splenomegaly. However, the degree of anemia is extremely variable and may be absent, mild, moderate, or severe to the point of threatening life.",
"      <br/>",
"      <br/>",
"      Because hereditary spherocytosis often is inherited in an autosomal dominant fashion, a family history of anemia, splenomegaly, splenectomy, or cholecystectomy may be helpful. However, a particularly severe form of spherocytosis occurs as an autosomal recessive disorder, and some children with more typical disease lack an informative family history. Consequently, the diagnosis should not be dismissed in the absence of other affected family members, in that only 75 percent will have a family history. The red cell morphology often permits the diagnosis of spherocytosis to be made from the peripheral smear (",
"      <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link&amp;anchor=H2#H2\">",
"       \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chronic blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sudden, massive hemorrhage usually is accompanied by signs of hypovolemic shock, the repeated loss of smaller amounts of blood may be associated with few findings other than pallor. The finding of iron deficiency anemia despite normal dietary iron intake or iron supplementation may be a clue to the presence of chronic blood loss from the gastrointestinal (GI) tract (eg, Meckel diverticulum, peptic ulcer), menorrhagia in menstruating females, or within the lungs (eg, pulmonary hemosiderosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other conditions that cause pallor",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Decreased red blood cell production",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Acquired aplastic anemia",
"      </strong>",
"      &ndash; The clinical presentation of aplastic anemia is variable and includes symptoms and signs related to cytopenia in each of the three cell lineages including fatigue, pallor, and cardiovascular complaints caused by progressive anemia; hemorrhagic manifestations secondary to thrombocytopenia;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fever, mucosal ulcerations, and bacterial infections resulting from neutropenia. A diagnosis of AA is suggested by the presence of pancytopenia with absolute reticulocytopenia, suggestive of bone marrow failure. The condition is often idiopathic but has been associated with exposure to certain drugs and chemicals (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      , benzene, pesticides), radiation, and viral infections (especially hepatitis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link&amp;anchor=H2#H2\">",
"       \"Acquired aplastic anemia in children and young adults\", section on 'Etiology and incidence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Transient erythroblastopenia of childhood (TEC)",
"      </strong>",
"      &ndash; TEC is a condition often associated with a recent viral illness, and it is characterized by moderate to severe anemia caused by diminished red cell production. The mean corpuscular volume (MCV) usually is normal at the time of diagnosis. The white cell count is normal or moderately decreased; the platelet count is normal. The reticulocyte count is decreased, and the direct antiglobulin test (direct Coomb test) is negative. Bone marrow examination shows reduction or absence of erythrocyte precursors initially, followed by erythroid hyperplasia during recovery. TEC that occurs in the first six months of life may be difficult to distinguish from Diamond-Blackfan anemia. Spontaneous recovery ultimately confirms the diagnosis of TEC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H11#H11\">",
"       \"Anemia in children due to decreased red blood cell production\", section on 'Transient erythroblastopenia of childhood (TEC)'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"       Folic acid",
"      </a>",
"      <strong>",
"       and vitamin B12 deficiency or other associated abnormalities",
"      </strong>",
"      &ndash; These nutritional anemias are uncommon in children in the United States and rarely develop in the absence of a grossly altered diet, extended hyperalimentation, intestinal resection, celiac disease, or chronic diarrhea. Unusual alterations of B12 and folic acid absorption and metabolism may cause symptoms similar to those of the nutritional megaloblastic anemias. Megaloblastic anemia is rarely severe enough to be life-threatening. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The condition is characterized by normochromic, macrocytic red blood cells, elevated red cell distribution width (RDW), hypersegmented neutrophils, and an elevated serum level of lactate dehydrogenase (LDH). Leukopenia and thrombocytopenia may be present, but a bone marrow aspirate demonstrates hypercellularity with megaloblastic changes. The diagnosis of nutritional disorders is confirmed by the finding of low serum levels of folic acid or vitamin B12 and the response to vitamin B12 or folate replacement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diamond-Blackfan syndrome",
"      </strong>",
"      &ndash; Diamond-Blackfan syndrome is congenital hypoplastic anemia commonly detected in the first few months of life. The anemia can be severe at the time of diagnosis. The red blood cells are normocytic or macrocytic. The reticulocyte count is low. The white blood cell count is low in 10 percent of affected patients, but thrombocytopenia only occurs rarely. The diagnosis is made by examination of a bone marrow aspirate that shows markedly reduced or absent erythrocyte precursors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H3#H3\">",
"       \"Anemia in children due to decreased red blood cell production\", section on 'Diamond-Blackfan anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dyskeratosis congenita &ndash;",
"      </strong>",
"      Dyskeratosis congenita is an inherited bone marrow failure syndrome secondary to accelerated telomere shortening. It is characterized by oral leukoplakia, hyper and hypopigmentation, and dystrophic nails. Patients are at risk for developing aplastic anemia, myelodysplastic syndrome or leukemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H13#H13\">",
"       \"Inherited aplastic anemia in children\", section on 'Dyskeratosis congenita'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fanconi anemia",
"      </strong>",
"      &ndash; Fanconi anemia is characterized by pancytopenia and associated abnormalities, including hyperpigmentation and hypopigmentation, microcephaly, strabismus, small stature, intellectual disability (mental retardation), and abnormalities of the thumbs and radii. Unlike Diamond-Blackfan, all three cell lines of the bone marrow are affected, and the hematologic abnormalities rarely develop before three to four years of age. The anemia is normochromic and macrocytic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"       \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sideroblastic anemia",
"      </strong>",
"      &ndash; Sideroblastic anemia is a disorder of hemoglobin synthesis resulting in hypoproductive state. This disorder is characterized by a microcytic, hypochromic anemia. Sideroblastic anemia may be inherited (sex-linked) or acquired. Iron use within the developing red cell is abnormal, accounting for the presence of diagnostic ringed sideroblasts in the bone marrow. The serum iron and ferritin levels usually are markedly elevated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=see_link\">",
"       \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thalassemia",
"      </strong>",
"      &ndash; The production of the globin portion of the hemoglobin molecule is reduced or absent resulting in a compensating increase of other globin chains and reduced or absent production of adult hemoglobin A. &szlig;-Thalassemia major (Cooley's anemia) presents with severe pallor usually between 6 and 12 months of age, as the fetal hemoglobin level declines but the normal rise in the adult hemoglobin (HbA) production fails to occur because of reduced or absent &szlig;-globin production. Although &szlig;-thalassemia is often associated with Mediterranean ancestry, this disease and related disorders (eg, E-&szlig; thalassemia, HgH disease) also are seen commonly in children of Southeast Asian, Indian, Pakistani, and Chinese ancestry. The presence of hepatosplenomegaly and characteristic red cell morphology, including marked variation in red cell shape, makes this diagnosis readily apparent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Increased red blood cell destruction",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Erythrocyte membrane defects",
"      </strong>",
"      &ndash; Elliptocytosis, stomatocytosis, and pyknocytosis describe other erythrocyte membrane defects that are less common than hereditary spherocytosis. Moderate or severe anemia is less common in these disorders. Elliptocytosis and stomatocytosis have characteristic findings on peripheral blood smear (",
"      <a class=\"graphic graphic_picture graphicRef63129 \" href=\"UTD.htm?9/61/10199\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef75535 \" href=\"UTD.htm?8/51/9015\">",
"       picture 6",
"      </a>",
"      ). Infantile pyknocytosis is a hemolytic anemia seen during the first few months of life and is characterized by distorted and contracted erythrocytes and burr cells. The disorder may be associated with pallor and hyperbilirubinemia. Spontaneous recovery usually occurs by six months of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of hemolytic anemias in children\", section on 'Hereditary elliptocytosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Erythrocyte enzyme defects",
"      </strong>",
"      &ndash; Erythrocyte enzyme defects such as pyruvate kinase deficiency and certain variants of glucose-6-phosphate dehydrogenase (G6PD), may be associated with pallor from increased red blood cell destruction. In G6PD deficiency, pallor may be accentuated by acute hemolytic crises after exposure to oxidant stress (eg, naphthalene-containing moth-balls, drugs, acidosis). Although alterations in red cell morphology sometimes are found in these enzyme disorders, assays of specific enzymes or substrates are required for definitive diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"       \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=see_link\">",
"       \"Pyruvate kinase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Kasabach Merritt syndrome",
"      </strong>",
"      &ndash; The abnormal proliferation of blood vessels within vascular tumors (most commonly tufted angioma or hemangioendothelioma) may trap red cells or may initiate a localized consumptive coagulopathy, causing erythrocyte destruction. Anemia is rarely severe unless the thrombocytopenia, that is more typical of the disorder, causes blood loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chronic blood loss",
"      </strong>",
"      &ndash; Blood loss can occur in conjunction with disorders of the immune system including inflammatory bowel disease and Goodpasture syndrome. Idiopathic pulmonary hemosiderosis results from slow but intractable hemorrhage into the bronchioles and alveoli resulting in iron deficiency anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link\">",
"       \"Idiopathic pulmonary hemosiderosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial assessment of a child with pallor should include an immediate determination of the degree of illness. If the child with pallor is not acutely ill, a deliberate search for the cause of pallor should be undertaken. A thorough yet relevant history should be obtained with particular attention to the type of onset of pallor. The slow development of pallor, which may be noticed by a family member or friend who sees the child only occasionally, suggests diminished red cell production, as is found in iron deficiency or bone marrow aplasia. However, the acute onset of pallor is consistent with the brisk hemolysis found in autoimmune hemolytic anemia and often is accompanied by jaundice, dark urine, and cardiovascular changes.",
"   </p>",
"   <p>",
"    After establishing the type of onset of anemia, the history can be directed toward more narrow categories of anemia or specific diseases. A detailed dietary history, with particular attention to milk intake, is important in young children with suspected iron deficiency. Vitamin B12 deficiency may accompany strict vegetarian diets from which meat and egg products are excluded for many years and may occur in breast fed infants of vegetarian mothers or mothers with pernicious anemia. Sources of internal or external blood loss should be carefully sought. Chronic gastrointestinal (GI) bleeding may escape detection until iron deficiency anemia develops.",
"   </p>",
"   <p>",
"    Similarly, small pulmonary hemorrhages associated with idiopathic pulmonary hemosiderosis are often mistaken for other pulmonic processes until several recurrences of iron deficiency anemia suggest a hidden site of blood loss. If increased bruising or bleeding accompanies pallor, multiple blood elements are probably affected. The circulation time for platelets is short in comparison with that of red cells. Clinical findings of thrombocytopenia often are present by the time pallor develops in patients with acquired aplastic anemia, Fanconi anemia, and acute leukemia.",
"   </p>",
"   <p>",
"    The family history helps in the diagnosis of hemoglobinopathies and inherited disorders of red cell membranes and enzymes. Because results of previous hemoglobin testing may have been explained inadequately or recalled inaccurately, a negative family history or newborn screening for hemoglobinopathies should not preclude evaluation of the patient's hemoglobin phenotype if a sickling disorder is suspected. A history of splenomegaly, splenectomy, or early cholecystectomy in family members may help identify a hemolytic disorder such as hereditary spherocytosis or pyruvate kinase deficiency. Finally, a well-directed review of systems is essential in looking for systemic disorders such as chronic renal disease, hypothyroidism, or rheumatologic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the examination of the severely anemic patient, pallor of the skin and mucous membranes usually is readily apparent. When anemia is less severe or when the skin color is dark, pallor may be appreciated only in the nailbeds and palpebral conjunctivae.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vital signs",
"      </strong>",
"      &ndash; Blood pressure and pulse should be measured to be sure that hypovolemic shock and high output cardiac failure are neither present nor imminent. If anemia or volume loss is mild to moderate, tachycardia may be present, but normal blood pressure is preserved.",
"     </li>",
"     <li>",
"      <strong>",
"       Eyes",
"      </strong>",
"      &ndash; Scleral icterus suggests shortened red cell survival with hemolysis. Conjunctival pallor, although insensitive, is often noted when the hemoglobin falls below 10",
"      <span class=\"nowrap\">",
"       grams/dL",
"      </span>",
"      (6.21",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac",
"      </strong>",
"      &ndash; A systolic flow murmur is often heard when the hemoglobin level falls below 8",
"      <span class=\"nowrap\">",
"       grams/dL",
"      </span>",
"      (4.96",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Lymph nodes and abdomen",
"      </strong>",
"      &ndash; Lymphadenopathy and splenomegaly may suggest a malignancy or an infectious disease such as mononucleosis. When splenomegaly occurs without lymphadenopathy, however, attention is drawn to hemolytic disorders such as hereditary spherocytosis and autoimmune hemolytic anemia or hemoglobinopathies.",
"      <br/>",
"      <br/>",
"      Careful auscultation of the abdomen and head may detect hemangiomas of the viscera. The finding of an unusually large and firm spleen in the absence of increasing scleral icterus suggests that red cells are being sequestered.",
"     </li>",
"     <li>",
"      <strong>",
"       Skin",
"      </strong>",
"      &ndash; Lack of red color in the palmar creases is associated with a hemoglobin that is less than 7",
"      <span class=\"nowrap\">",
"       grams/dL",
"      </span>",
"      (4.34",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      The presence of large hemangiomas suggests microangiopathic anemia.",
"     </li>",
"     <li>",
"      <strong>",
"       Musculoskeletal",
"      </strong>",
"      &ndash; Bony abnormalities associated with red cell disorders include frontal bossing from compensatory expansion of the bone marrow in hemolytic disease and radial and thumb anomalies found in some patients with Fanconi anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete blood cell count (CBC) with differential and a reticulocyte count is the first step in determining if pallor is due to a hematologic abnormality and, in the anemic patient, the likely cause. The use of hemoglobin, hematocrit, mean corpuscular volume, and reticulocyte count in the evaluation of pallor in a child is presented here. Additional discussion of other indices (eg, red cell distribution width [RDW], mean corpuscular hemoglobin concentration, and peripheral smear) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the child with anemia\", section on 'Laboratory examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hemoglobin and hematocrit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia may be defined as a reduction in red blood cell mass or blood hemoglobin concentration below the standard for age (",
"    <a class=\"graphic graphic_table graphicRef57465 \" href=\"UTD.htm?5/34/5679\">",
"     table 2",
"    </a>",
"    ). In practice, anemia most commonly is defined by reductions in one or both of the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with anemia\", section on 'Definition of anemia'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hemoglobin",
"      </strong>",
"      &ndash; This is a measure of the concentration of the red blood cell (RBC) pigment hemoglobin in whole blood, expressed as grams per 100 mL (dL) of whole blood (or",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      The normal value for HGB in a child age 6 to 12 years is approximately 13.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (8.38",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Hematocrit",
"      </strong>",
"      &ndash; The hematocrit is the fractional volume of a whole blood sample occupied by red blood cells; it is expressed as a percentage. As an example, the normal HCT in a child age 6 to 12 years is approximately 40 percent (0.4 fraction).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mean corpuscular volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean corpuscular volume (MCV) is measured directly by automated blood cell counters and represents the mean value (in femtoliters, fL) of the volume of individual RBCs in the blood sample. Values may be low (microcytic), normal (normocytic), or large (macrocytic).",
"   </p>",
"   <p>",
"    The MCV provides a quick, accurate, and readily available method of distinguishing the microcytic anemias (iron deficiency, thalassemia syndromes) from the normocytic (membrane disorders, enzyme deficiencies, autoimmune hemolytic anemia, most hemoglobinopathies) or macrocytic (bone",
"    <span class=\"nowrap\">",
"     marrow/stem",
"    </span>",
"    cell failure, disorders of B12 and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    absorption or metabolism) anemias.",
"   </p>",
"   <p>",
"    As with hemoglobin and hematocrit, the MCV varies with age, necessitating the use of age-adjusted normal values (",
"    <a class=\"graphic graphic_table graphicRef52224 \" href=\"UTD.htm?18/31/18939\">",
"     table 3",
"    </a>",
"    ). In addition, the measured MCV represents an average value. If microcytic and macrocytic red cells are present in the peripheral blood as, for example, in a patient with combined iron deficiency and B12 deficiency, the MCV may remain normal. Thus, the peripheral smear should be examined carefully to determine whether the MCV reflects a single population of red cells of uniform size or two or more populations of distinctly different size. The red cell distribution width (RDW) is elevated in the presence of increased variation in red cell size. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link&amp;anchor=H8911691#H8911691\">",
"     \"Approach to the child with anemia\", section on 'Red cell distribution width'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Reticulocyte count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reticulocytes are the youngest red cells in the circulation, and are identified via the presence of residual RNA, which gives them a blue tint on standard Wright-Giemsa stains (",
"    <a class=\"graphic graphic_picture graphicRef74294 \" href=\"UTD.htm?35/61/36822\">",
"     picture 7",
"    </a>",
"    ). They are quantitated via staining with vital dyes, such as new",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/61/20438?source=see_link\">",
"     methylene blue",
"    </a>",
"    or thiazole orange, and are reported as a percentage. The reticulocyte count can be performed rapidly and helps to distinguish the various causes of impaired red cell production on the basis of decreased reticulocyte count versus increased reticulocyte count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the reticulocyte count is expressed as a percent of total red cells, it must be corrected for the degree of the anemia. The easiest way to make this correction is to multiply the reticulocyte count by the reported hemoglobin or hematocrit (HCT) divided by a normal hemoglobin or hematocrit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reticulocyte count x",
"      <span class=\"nowrap\">",
"       HCT(pt)/HCT(nL)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a reticulocyte count of 5 percent in a child with severe iron deficiency anemia and a hematocrit of 6 percent is not elevated when corrected for the degree of anemia (5 percent x 6",
"    <span class=\"nowrap\">",
"     percent/33",
"    </span>",
"    percent = 0.9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once anemia is identified, the reticulocyte count and MCV help in the initial classification of anemia but leave the clinician with broad categories of disease, rather than specific diagnoses. In many instances, the history and physical examination, when coupled with these laboratory measurements, permit identification of a particular disorder (",
"    <a class=\"graphic graphic_algorithm graphicRef54266 \" href=\"UTD.htm?6/61/7123\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50361 \" href=\"UTD.htm?12/0/12301\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, the reticulocyte count should be interpreted with caution. Disorders of shortened red cell survival are not always characterized by an increased reticulocyte count. As an example, reticulocytopenia may occur in an autoimmune hemolytic anemia despite active hemolysis and increased erythropoiesis in the bone marrow. Chronic hemolytic disorders, such as sickle cell anemia or hereditary spherocytosis, may first be detected during an aplastic crisis when the reticulocyte count is low. Unless the underlying disorder is recognized, the clinician may be misled by this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to a patient with pallor includes determining if the patient is seriously ill and requires immediate supportive measures (",
"    <a class=\"graphic graphic_algorithm graphicRef69343 \" href=\"UTD.htm?13/36/13890\">",
"     algorithm 3",
"    </a>",
"    ). Afterward, the history should be taken to determine if the pallor was acute or insidious in onset. A complete blood count with differential, mean corpuscular volume (MCV), and reticulocyte count will help further delineate the cause of the anemia:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Increased reticulocytes and low MCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thalassemia syndromes associated with moderate or severe anemia can be recognized by distinctive abnormalities of red cell morphology. In &szlig;-thalassemia major, the red cells generally are small but vary markedly in size and shape. Many cells appear to contain little or no hemoglobin; the central pallor extends to the cell membrane. Nucleated red cells, basophilic stippling, and polychromasia reflect active erythropoiesis. The parents of an affected child usually have a low MCV characteristic of thalassemia trait. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with HbS-&szlig;-thalassemia have microcytic red cells, although the alterations of red cell morphology are not as dramatic as in &szlig;-thalassemia major. Sickled forms are often but not always present. Target cells are common. Hemoglobin electrophoresis reveals HbS and reduced (less than 50 percent) or absent HbA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Increased reticulocytes and normal MCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most membrane disorders can be readily identified by the characteristic changes in the red cell shape that lend their names to the diseases (eg, spherocytosis, elliptocytosis, and stomatocytosis). When the diagnosis of a membrane disorder is uncertain, examination of the parents' peripheral smears may be helpful because, in many cases, the inheritance pattern is autosomal dominant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of hemolytic anemias in children\", section on 'Hereditary elliptocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities of red cell morphology are less striking in erythrocyte enzymatic defects. Blister cells (cells with asymmetric distribution of hemoglobin) may be found during episodes of active hemolysis in G6PD deficiency. If transfusion is necessary, a pretransfusion sample should be saved for assay of specific enzymes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reticulocyte count usually is markedly elevated in autoimmune hemolytic anemia, but it may be normal or only slightly elevated during the first days of the disease. In rare instances, reticulocytopenia persists. Spherocytes usually are present on the peripheral smear. Clumping of red cells from agglutination may be seen. This agglutination causes a falsely elevated MCV because the electronic counter measures the volume of the red cell couplets or triplets. The direct Coombs test is positive in 90 percent of cases. Patients with a negative Coombs test present a challenging diagnostic problem because the initial findings may be similar to those in hereditary spherocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link&amp;anchor=H9#H9\">",
"     \"Autoimmune hemolytic anemia in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Homozygous sickle cell disease usually is recognized by the finding of sickled red cells on the peripheral smear. Rarely, however, such cells are absent, even during an acute illness. Target cells are commonly found in sickle cell disease but are more prominent in HbSC. Hemoglobin electrophoresis reveals the presence of the abnormal hemoglobin(s) and the absence of HgA. The broad application of newborn screening allows for identification of most affected children prior to the onset of clinical signs and symptoms or RBC morphological abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Red cell fragments are found in those diseases characterized by microangiopathic anemia. In HUS or TTP, thrombocytopenia is present, renal or neurologic function is usually impaired, and thrombotic complications may be present. The platelet count also is low in DIC, and clotting studies are abnormal. If intravascular hemolysis is severe, as in anemia associated with certain artificial cardiac valves, hemosiderin may be detected in the urinary sediment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Clinical and laboratory manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link\">",
"     \"Atypical hemolytic uremic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H13#H13\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H14#H14\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Low, normal, or slightly increased reticulocytes and low MCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe iron deficiency anemia, red cells are markedly microcytic and show substantial variation in size and shape. Elongated red cells (pencil forms) are common. Platelets are often increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link&amp;anchor=H20317248#H20317248\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemia is uncommon in lead poisoning but, when present, resembles the anemia of iron deficiency in its red cell morphology. Basophilic stippling is found in a small percentage of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H8#H8\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Hematologic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Low, normal, or slightly increased reticulocytes and normal or elevated MCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of mild macrocytosis, red cell morphology usually is normal in childhood disorders of bone marrow or stem cell failure. Thrombocytopenia and neutropenia are present in aplastic anemia and Fanconi anemia. Although the platelet and white count are occasionally low in patients with Diamond-Blackfan syndrome, the red cells are most severely affected. Erythropoiesis is most severely affected in TEC and acquired red cell aplasia, although neutropenia may accompany the former disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link\">",
"     \"Anemia in children due to decreased red blood cell production\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features at the onset of acute leukemia may closely resemble those of aplastic anemia. Examination of a bone marrow aspirate is required to distinguish these disorders. This procedure is rarely performed in the emergency department. Therapy, such as corticosteroids, which might interfere in the interpretation of the bone marrow aspirate, should be withheld until a definitive diagnosis has been made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The MCV is usually increased in megaloblastic anemias unless other nutritional disorders are present. Hypersegmentation of the polymorphonuclear leukocytes is characteristic. In severe or long-standing megaloblastic anemia, neutropenia and thrombocytopenia also may be found. In such cases, the findings in the peripheral blood may be similar to those of aplastic anemia or even acute leukemia; examination of the bone marrow and measurement of specific nutrients (B12,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    ) are necessary to distinguish these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first priority in evaluating children with pallor is to determine if the patient is seriously ill and requires immediate supportive measures. In stable children, a thorough history, physical exam, and simple laboratory studies (complete blood count, mean corpuscular volume, reticulocyte count, peripheral blood smear) usually identifies the underlying etiology (",
"    <a class=\"graphic graphic_algorithm graphicRef69343 \" href=\"UTD.htm?13/36/13890\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65774 \" href=\"UTD.htm?37/7/38012\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef54266 \" href=\"UTD.htm?6/61/7123\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Many conditions can lead to the development of pallor in a child including diseases that decrease the concentration of hemoglobin or alter the distribution of blood flow from the body's surface. Conditions that cause a decrease in hemoglobin can be separated into three categories: increased red cell destruction, decreased red cell production, or blood loss.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kilbum LB, Siegel SE, Steuber CP. Clinical assessment and differential diagnosis of the child with suspected cancer. In: Principles and Practice of Pediatric Oncology, 6th, Pizzo PA, Poplack DG.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.123.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6447 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12729=[""].join("\n");
var outline_f12_27_12729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life-threatening causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Nonhematologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Severe blood loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sickle cell anemia with splenic sequestration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Disseminated intravascular coagulation (DIC)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Common hematologic conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Decreased RBC production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Increased RBC destruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chronic blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other conditions that cause pallor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hemoglobin and hematocrit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Reticulocyte count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Increased reticulocytes and low MCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Increased reticulocytes and normal MCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Low, normal, or slightly increased reticulocytes and low MCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Low, normal, or slightly increased reticulocytes and normal or elevated MCV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6447|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/12/42178\" title=\"algorithm 1\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?6/61/7123\" title=\"algorithm 2\">",
"      Evaluation of anemia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?13/36/13890\" title=\"algorithm 3\">",
"      Approach to pallor algo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6447|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/1/27670\" title=\"picture 1\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 2\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22739\" title=\"picture 3\">",
"      Helmet cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22232\" title=\"picture 4\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/61/10199\" title=\"picture 5\">",
"      Elliptocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/51/9015\" title=\"picture 6\">",
"      Stomatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/61/36822\" title=\"picture 7\">",
"      Reticulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/7/38012\" title=\"table 1\">",
"      Pallor diff dx child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/34/5679\" title=\"table 2\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/31/18939\" title=\"table 3\">",
"      MCV variation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/0/12301\" title=\"table 4\">",
"      Physical findings in anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=related_link\">",
"      Pyruvate kinase deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_27_12730="What's new in drug therapy";
var content_f12_27_12730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in drug therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/27/12730/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12730/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/27/12730/contributors\">",
"     Jonathan M Zand, PharmD BCPS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/27/12730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following material represents a subset of new drugs, drug approvals, drug warnings, and drugs removed from the market from the past six months. This is",
"    <strong>",
"     not a complete list",
"    </strong>",
"    ; it includes those topics considered by the authors and editors to be of particular interest or importance. For a complete list of new drug approvals, see",
"    <a class=\"external\" href=\"file://www.lexi.com/home/newdrugs/\">",
"     file://www.lexi.com/home/newdrugs/",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    You can check drug interactions by going to the Lexi-Interact drug interactions program included with UpToDate. This program is only available for online users at this time, and can be accessed from the New Search tab or in the Drug Interactions section of the individual monographs in the Lexicomp reference when using UpToDate online.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     CYP2D6 inhibitors, genotypes, and breast cancer treatment with tamoxifen",
"    </span>",
"   </p>",
"   <p>",
"    The antiestrogen tamoxifen is converted to its active metabolites by cytochrome P450 2D6 (CYP2D6) and UDP-glucuronyltransferase-2B7 glucuronidation&nbsp;(UGT2B7).&nbsp;There&nbsp;is concern that concurrent use of strong inhibitors of CYP2D6 (such as antidepressants paroxetine, fluoxetine, bupropion,&nbsp;duloxetine, and sertraline at high doses) can reduce conversion of tamoxifen to its active&nbsp;form and&nbsp;compromise its antitumor&nbsp;effectiveness.&nbsp;An unplanned analysis of a large randomized trial of adjuvant tamoxifen&nbsp;in women with breast cancer showed that CYP2D6 poor metabolizers&nbsp;were at greater risk of&nbsp;a breast cancer event compared to faster metabolizers&nbsp;receiving tamoxifen&nbsp;treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/1\">",
"     1",
"    </a>",
"    ]. Although&nbsp;the relationship between CYP2D6 metabolism and breast cancer survival for women on tamoxifen has not been definitively&nbsp;established, we suggest against use of potent inhibitors of CYP2D6 in women receiving treatment with tamoxifen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link&amp;anchor=H125175232#H125175232\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Altered tamoxifen metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEW DRUGS AND US DRUG APPROVALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dimethyl fumarate for treatment of relapsing-remitting multiple sclerosis",
"    </span>",
"   </p>",
"   <p>",
"    US FDA has approved twice-daily oral dimethyl fumarate (Tecfidera) for treatment of relapsing forms of&nbsp;multiple sclerosis (MS)&nbsp;in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/2\">",
"     2",
"    </a>",
"    ]. Approval was based on results from two large trials, in which an oral formulation of dimethyl fumarate significantly reduced relapse rates and the development of new brain lesions on MRI in patients with active&nbsp;MS&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and that&nbsp;the drug&nbsp;reduces the rate of disability progression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/4\">",
"     4",
"    </a>",
"    ]. The most common side effects were flushing and gastrointestinal symptoms, which may improve over time with continued treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/16/9476?source=see_link\">",
"     \"Dimethyl fumarate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Canagliflozin for treatment of type 2 diabetes mellitus",
"    </span>",
"   </p>",
"   <p>",
"    Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of drugs that block reabsorption of glucose within the renal proximal tubule, increasing urinary&nbsp;glucose excretion, and modestly&nbsp;decreasing elevated blood glucose levels&nbsp;in patients with type 2 diabetes.&nbsp;An oral SGLT2 inhibitor, canagliflozin (Invokana), was approved by US FDA for treatment of type 2 diabetes as monotherapy or in combination with other oral agents or insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/5\">",
"     5",
"    </a>",
"    ]. Another oral SGLT2 inhibitor (dapagliflozin, Forxiga)&nbsp;was available previously in Europe. In meta-analyses of clinical trials, SGLT2 inhibitors reduced hemoglobin A1C by approximately 0.5 to 0.7 percentage points, making them relatively weak glucose-lowering agents, similar in potency to the dipeptidyl peptidase 4 (DPP-4) inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The most common side effects are vaginal yeast infection and urinary tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H457938#H457938\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'SGLT2 inhibitors'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42832?source=see_link\">",
"     \"Canagliflozin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ospemifene for treatment of vulvovaginal atrophy",
"    </span>",
"   </p>",
"   <p>",
"    Ospemifene is&nbsp;the first&nbsp;selective estrogen receptor modulator that is effective in treating dyspareunia resulting from menopausal vulvovaginal atrophy. It&nbsp;is an&nbsp;oral medication and&nbsp;may be helpful for women with symptomatic atrophy that is not relieved with vaginal moisturizers or lubricants and who cannot (severe arthritis, obesity, vulvodynia) or prefer not to use a vaginal product. In a&nbsp;randomized trial,&nbsp;12 weeks of ospemifene was significantly more effective than placebo in improving dyspareunia, although the benefit beyond that of placebo was modest [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/8\">",
"     8",
"    </a>",
"    ]. Ospemifene&nbsp;has been approved by the US Food and Drug Administration, but further study is needed to compare it to vaginal estrogen therapy and to&nbsp;evaluate the risk of long-term adverse effects. It is anticipated to be available for clinical use in June 2013. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link&amp;anchor=H2475847#H2475847\">",
"     \"Treatment of vaginal atrophy\", section on 'Selective estrogen receptor modulators'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     \"Ospemifene: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Novel device for epinephrine self-injection",
"    </span>",
"   </p>",
"   <p>",
"    A novel device for epinephrine self-injection is available in North America that is called Auvi-Q in US and Allerject in Canada. It is a rectangular cartridge, approximately the size and shape of a mobile phone and has audible instructions to guide the user through the self-injection process. Each device contains a single pediatric (0.15 mg) or adult (0.3 mg) dose of epinephrine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link&amp;anchor=H8#H8\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\", section on 'Available autoinjectors'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=see_link\">",
"     \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Regorafenib for refractory GIST",
"    </span>",
"   </p>",
"   <p>",
"    In February 2013, regorafenib, an orally active tyrosine kinase inhibitor (TKI) that targets a variety of kinases including KIT, was approved in the United States for treatment of advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib or sunitinib. The efficacy of regorafenib&nbsp;in&nbsp;this setting&nbsp;was shown in a phase III trial in which 199 patients with imatinib- and sunitinib-refractory GIST were randomly assigned to best supportive care plus regorafenib or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/9\">",
"     9",
"    </a>",
"    ]. Regorafenib was associated with significantly better&nbsp;progression free survival (4.8 versus 0.9 months).&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H355376706#H355376706\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Regorafenib'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32006?source=see_link\">",
"     \"Regorafenib: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pomalidomide for relapsed multiple myeloma",
"    </span>",
"   </p>",
"   <p>",
"    Pomalidomide is a thalidomide analog that was approved by the US Food and Drug Administration in February 2013 for patients with&nbsp;multiple myeloma&nbsp;who have received at least two prior therapies, including bortezomib and lenalidomide, and have demonstrated disease progression on or within 60 days of the completion of the last therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/10\">",
"     10",
"    </a>",
"    ].&nbsp;In this&nbsp;patient population, approximately one-quarter of cases demonstrate at least a&nbsp;partial response to treatment with pomalidomide plus low-dose dexamethasone, with a median duration of response of seven months.&nbsp;Toxicities include cytopenias and their complications (eg, infection), increased risk for venous thromboembolism, and teratogenicity. Pomalidomide is only available through the Pomalyst REMS program.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H349206892#H349206892\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Pomalidomide'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=see_link\">",
"     \"Pomalidomide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     New levonorgestrel-releasing IUD",
"    </span>",
"   </p>",
"   <p>",
"    A lower-dose (13.5 mg) levonorgestrel-releasing intrauterine device (IUD; Skyla) became available in the United States in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/11\">",
"     11",
"    </a>",
"    ]. It is smaller in size than the 52 mg levonorgestrel IUD (Mirena)&nbsp;and thus may be easier to insert in nulliparous women. Because of the lower levonorgestrel dose, it is approved for up to three years of use (the 52 mg dose is approved for up to five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     \"Levonorgestrel: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Apixaban for stroke prevention in nonvalvular atrial fibrillation",
"    </span>",
"   </p>",
"   <p>",
"    The orally-active factor Xa inhibitor, apixaban (Eliquis), was approved by FDA to prevent stroke and systemic embolization (SSE) in patients with nonvalvular atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/13\">",
"     13",
"    </a>",
"    ]. Twice-daily apixaban does not require routine laboratory monitoring, and similar to rivaroxaban and dabigatran, other approved newer oral anticoagulants, it has fewer drug and food interactions than warfarin. Approval was based on the results of the large randomized ARISTOTLE trial, which found that apixaban was non-inferior to warfarin in terms of efficacy and superior in terms of safety [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/14\">",
"     14",
"    </a>",
"    ]. In patients with nonvalvular atrial fibrillation who meet criteria for anticoagulation, we prefer apixaban (or dabigatran or rivaroxaban) to warfarin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H485506384#H485506384\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Indications for and choice of therapy'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Apixaban drug interactions and management suggestions, along with contraindicated combinations according to the prescribing information in various countries, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef87789 \" href=\"UTD.htm?7/56/8078\">",
"     table 1",
"    </a>",
"    ). Dosing and safety issues with the administration of&nbsp;apixaban are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982962#H147982962\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     \"Apixaban: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Crofelemer for antiretroviral-associated diarrhea in HIV/AIDS",
"    </span>",
"   </p>",
"   <p>",
"    Crofelemer (Fulyzaq), a botanical derivative that blocks chloride secretion in the intestinal lumen and accompanying water loss in diarrhea, was approved by FDA for managing noninfectious diarrhea in HIV-infected patients receiving antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/15\">",
"     15",
"    </a>",
"    ]. If the antiretroviral (eg ritonavir) causing diarrhea cannot be substituted, we prefer standard antimotility therapy with loperamide or diphenoxylate-atropine over crofelemer due to its modest efficacy and the limited amount of experience with this agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of the HIV-infected patient with diarrhea\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/56/21379?source=see_link\">",
"     \"Crofelemer: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pasireotide for Cushing's disease",
"    </span>",
"   </p>",
"   <p>",
"    A somatostatin analog pasireotide (Signifor) that specifically blocks release of corticotropin (ACTH) from the pituitary was approved by FDA for treatment of Cushing&rsquo;s disease in patients for whom pituitary surgery is contraindicated or unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/16\">",
"     16",
"    </a>",
"    ]. The twice daily subcutaneous injection was previously approved in Europe and will be available in US beginning in March 2013. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H458568732#H458568732\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Pasireotide'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     \"Pasireotide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lomitapide for homozygous familial hypercholesterolemia",
"    </span>",
"   </p>",
"   <p>",
"    Lomitapide (Juxtapid), a microsomal triglyceride transfer protein, received FDA approval for patients with homozygous familial hypercholesterolemia (FH), a rare inherited disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=see_link&amp;anchor=H4096656#H4096656\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'Lomitapide'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"     \"Lomitapide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bedaquiline for multidrug-resistant tuberculosis",
"    </span>",
"   </p>",
"   <p>",
"    Bedaquiline (Sirturo), a diarylquinoline antituberculous agent with a novel mechanism of action (mycobacterial ATP synthase inhibition), received accelerated approval by FDA as part of combination therapy to treat adults with multidrug resistant pulmonary tuberculosis (MDR-TB) when other alternatives are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/18\">",
"     18",
"    </a>",
"    ]. In clinical studies, the addition of bedaquiline to an optimized regimen resulted in faster and more frequent conversion to negative sputum than did the optimized background regimen only (77.6 versus 57.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A black box warning alerts of potential QT prolongation, and a higher frequency of death among patients receiving treatment with bedaquiline than those treated with background regimens only (11.4 versus 2.5 percent). Therefore, the drug should be used only for patients who lack other treatment options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link&amp;anchor=H3115421#H3115421\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\", section on 'New agents'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12869?source=see_link\">",
"     \"Bedaquiline: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Raxibacumab for inhalation anthrax",
"    </span>",
"   </p>",
"   <p>",
"    Raxibacumab, a monoclonal antibody directed against the protective antigen (PA) component of anthrax toxin, was effective for the treatment and prevention of anthrax in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In phase 2 safety studies in humans, levels of the antibody achieved in humans were equal to or greater than those that provide protection in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/23\">",
"     23",
"    </a>",
"    ]. Based upon these data, raxibacumab received US FDA approval for treatment of inhalation anthrax (in combination with antibiotics) and for the prevention of inhalation anthrax when alternative preventive therapies are not available or are not appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A supply of raxibacumab is held in the US Strategic National Stockpile under Project Bioshield and will be distributed by US Centers for Disease Control and Prevention (CDC) in the event of an anthrax emergency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=see_link&amp;anchor=H64397865#H64397865\">",
"     \"Prevention of anthrax\", section on 'Raxibacumab and other immunotherapeutics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link&amp;anchor=H1061471327#H1061471327\">",
"     \"Treatment of anthrax\", section on 'Raxibacumab'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     \"Raxibacumab: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ponatanib for CML",
"    </span>",
"   </p>",
"   <p>",
"    Ponatinib (Iclusig) is a new",
"    <em>",
"     Bcr-Abl",
"    </em>",
"    tyrosine kinase inhibitor (TKI) that has activity in patients with relapsed or refractory chronic phase chronic myelogenous leukemia (CML), including those with the T315I mutation. High response rates have been reported in patients with heavily pretreated chronic phase CML, including those with the T315I mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Ponatinib was approved by US FDA for treatment of adults with CML resistant to or intolerant of prior TKI therapy. The licensing information includes a boxed warning of the risks of arterial thrombosis and liver toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/29\">",
"     29",
"    </a>",
"    ]. Given the short follow-up of patients treated with ponatinib, and the fact that allogeneic hematopoietic cell transplantation (HCT) offers potential cure in patients with T315I mutation, we suggest that eligible patients with CML resistant to an initial TKI who have T315I mutation be evaluated for HCT. Ponatinib represents an alternative and it is our preferred treatment for HCT-ineligible patients with the T315I mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H12149527#H12149527\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Ponatinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link&amp;anchor=H12150663#H12150663\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\", section on 'Ponatinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link&amp;anchor=H12150432#H12150432\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\", section on 'Ponatinib'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     \"Ponatinib: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Omacetaxine for chronic myelogenous leukemia",
"    </span>",
"   </p>",
"   <p>",
"    Omacetaxine (Synribo), a protein synthesis inhibitor that was previously known as homoharringtonine, was approved by FDA for the treatment of adults with chronic myeloid leukemia (CML) in chronic or accelerated phase that is resistant to or intolerant of two or more tyrosine kinase inhibitors (TKIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Uncontrolled prospective trials have demonstrated modest activity including responses in patients with a T315I BCR-ABL mutation, which is known to be resistant to all available TKIs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H24874435#H24874435\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Omacetaxine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link&amp;anchor=H24874649#H24874649\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\", section on 'Omacetaxine'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     \"Omacetaxine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rivaroxaban for acute pulmonary embolism",
"    </span>",
"   </p>",
"   <p>",
"    Rivaroxaban is an oral factor Xa inhibitor that is administered as a fixed dose; it is as effective as standard dose-adjusted anticoagulant therapy for patients with deep venous thrombosis, but without the need for laboratory monitoring. The safety and efficacy of rivaroxaban in patients with acute pulmonary embolism (PE) was addressed in an open-label trial that randomly assigned 4832 patients with symptomatic acute PE to rivaroxaban (15 mg twice daily for three weeks, followed by 20 mg once daily) or standard dose-adjusted anticoagulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no difference in the incidence of recurrent venous thromboembolism and less major bleeding in the rivaroxaban group. Rivaroxaban is approved in US for treatment of acute PE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/33\">",
"     33",
"    </a>",
"    ]; however we suggest AGAINST the routine use of rivaroxaban for acute PE until the potential benefits are confirmed by additional trials and clinical experience. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link&amp;anchor=H1712277#H1712277\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Dosing, drug interactions and other safety issues with the administration of rivaroxaban are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H14130832#H14130832\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dosing and safety issues'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     \"Rivaroxaban: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Teriflunomide for multiple sclerosis",
"    </span>",
"   </p>",
"   <p>",
"    An orally available T cell immunomodulator teriflunomide (Aubagio), which is an active metabolite of leflunomide, has been approved in United States for once daily use in treatment of adults with relapsing-remitting multiple sclerosis (RRMS) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/34\">",
"     34",
"    </a>",
"    ].&nbsp;US approval was based upon the results of two randomized controlled trials comparing teriflunomide, 7 or 14 mg once daily, with placebo; in both trials, the annualized rate of relapse was significantly reduced in patients receiving either dose of drug, while rates of progression to disability were decreased only among patients receiving the 14 mg dose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].&nbsp;Based upon animal data, teriflunomide is considered teratogenic (FDA pregnancy category X) and may cause hepatotoxicity, including fulminant liver failure, requiring regular monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/34\">",
"     34",
"    </a>",
"    ].&nbsp;We suggest teriflunomide as an alternate option for treatment of RRMS for men or postmenopausal women who do not wish to receive treatment with better established therapies that require injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H104685535#H104685535\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Teriflunomide'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     \"Teriflunomide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ado-trastuzumab emtansine as second-line treatment for HER2-positive metastatic breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    There are multiple options for women with HER2-positive metastatic breast cancer. In February 2013, the US Food and Drug Administration (FDA)&nbsp;approved ado-trastuzumab emtansine (trastuzumab emtansine or T-DM1) for use in&nbsp;women with HER2-positive metastatic breast cancer who experienced disease progression on a trastuzumab containing regimen. FDA approval was based on a phase III trial that assigned almost 980 women previously treated with trastuzumab plus a taxane to treatment with T-DM1 or to capecitabine plus lapatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/37\">",
"     37",
"    </a>",
"    ]. T-DM1 significantly improved the overall response rate, progression-free survival, and overall survival compared to capecitabine plus lapatinib. These data support the administration of T-DM1 for women with disease progression following trastuzumab-containing treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H720673240#H720673240\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Ado-trastuzumab emtansine'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=see_link\">",
"     \"Ado-trastuzumab emtansine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DRUG WITHDRAWALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Peginesatide withdrawn due to serious hypersensitivity reactions",
"    </span>",
"   </p>",
"   <p>",
"    The erythropoietin mimetic peginesatide (Omontys)&nbsp;has been withdrawn from the US&nbsp;market due to serious hypersensitivity reactions, including fatal anaphylaxis reported in approximately 0.02 percent of patients following the first dose of intravenous administration.&nbsp;The overall rate of hypersensitivity reaction reported is approximately&nbsp;0.2 percent of patients treated;&nbsp;one-third required urgent medical attention.&nbsp;Information concerning recall and return&nbsp;of product is available on&nbsp;FDA and&nbsp;manufacturer websites&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link&amp;anchor=H16#H16\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS AND WARNINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Everolimus should not be used within 30 days of liver transplantation",
"    </span>",
"   </p>",
"   <p>",
"    Everolimus is a semisynthetic form of sirolimus that may have a role as an immunosuppressant following liver transplantation. However, because of an increased risk of hepatic artery thrombosis in the early post-transplantation period, the US Food and Drug Administration recommends that everolimus",
"    <strong>",
"     not",
"    </strong>",
"    be used earlier than 30 days after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30922?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of immunosuppression in adult liver transplantation\", section on 'Everolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Erythropoiesis stimulating agents and anemia associated with heart failure",
"    </span>",
"   </p>",
"   <p>",
"    There is increasing evidence that anemia, a frequent finding in patients with heart failure (HF),&nbsp;can worsen&nbsp;cardiac function&nbsp;and that correction may be beneficial. How best to treat anemia in patients with HF is controversial. The available evidence does not support the use of erythropoiesis stimulating agents. In the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial, which randomly assigned 2278 patients with systolic heart failure to treatment with either darbepoetin alfa or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/40\">",
"     40",
"    </a>",
"    ],&nbsp;darbepoetin did not improve rates of death from any cause or hospitalization for worsening HF, and&nbsp;thromboembolic adverse events were more frequent. For patients with HF and chronic anemia, we suggest NOT routinely correcting the anemia by the use of erythropoiesis stimulating agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link&amp;anchor=H15#H15\">",
"     \"Impact of anemia in patients with heart failure\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Azithromycin and torsades de pointes",
"    </span>",
"   </p>",
"   <p>",
"    In 2013, the US Food and Drug Administration issued a warning about the risk of QT interval prolongation and potentially fatal torsades de pointes among patients taking azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients at particular risk include those with existing QT prolongation, hypokalemia, hypomagnesemia, significant bradycardia, and those receiving certain antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The warning was based on a review&nbsp;following the publication of a study that showed an increased risk of death in patients receiving azithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/44\">",
"     44",
"    </a>",
"    ]. Clinicians should assess the risk of torsades de pointes when considering antibiotic treatment options for patients at risk for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/41\">",
"     41",
"    </a>",
"    ]. Other macrolides and certain non-macrolides, such as fluoroquinolones, also have the potential for prolonging the QT interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H22#H22\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Long QT syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hepatotoxicity associated with tolvaptan",
"    </span>",
"   </p>",
"   <p>",
"    Tolvaptan is a vasopressin V",
"    <sub>",
"     2",
"    </sub>",
"    &nbsp;antagonist that is used for the treatment of hyponatremia. Safety concerns were raised by a trial that examined its effect on the progression of polycystic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. A greater than 2.5-fold increase in liver enzymes&nbsp;occurred more frequently&nbsp;among patients who received tolvaptan compared with placebo. Based upon these data, the US Food and Drug Administration issued a safety&nbsp;communication&nbsp;that recommended prompt evaluation of&nbsp;serum transaminase levels&nbsp;in patients treated with tolvaptan who develop&nbsp;symptoms suggestive of liver injury&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/47\">",
"     47",
"    </a>",
"    ].&nbsp;In addition, we&nbsp;suggest that liver function tests be measured three to four months after initiating therapy and then at six month intervals. If liver injury is suspected, tolvaptan should be discontinued and not re-initiated unless&nbsp;an unrelated&nbsp;cause for liver injury is established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Limitations to use of tolvaptan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Patient understanding of acetaminophen dosing",
"    </span>",
"   </p>",
"   <p>",
"    Accidental acetaminophen overdose remains a major cause of morbidity and mortality. According to a prospective study of 500 patients tested about their understanding of acetaminophen dosing at one academic and one community internal medicine practice, up to 46 percent of patients would ingest excessive amounts of acetaminophen because they misunderstand dosing directions or fail to recognize that acetaminophen is found in more than one medication they are using [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/48\">",
"     48",
"    </a>",
"    ]. Such errors occur most often among patients with limited literacy or frequent acetaminophen use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H2#H2\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Statins and myalgia",
"    </span>",
"   </p>",
"   <p>",
"    Despite common clinical experience, higher rates of myalgia with statins, compared to placebo, have not typically been found in randomized trials designed to evaluate treatment for cardiovascular prevention. However, a six-month randomized trial in 420 healthy adults designed specifically to examine the effects of statin therapy on skeletal muscle function has found a higher incidence of myalgia in patients treated with atorvastatin 80 mg daily than with placebo (9.3 versus 4.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/49\">",
"     49",
"    </a>",
"    ]. Although there have been concerns about the effects of statin therapy on exercise tolerance, no statistically-significant differences were seen in muscle strength, muscle endurance, or aerobic performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link&amp;anchor=H4#H4\">",
"     \"Statin myopathy\", section on 'Myalgias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Zolpidem dosing for treatment of insomnia in women",
"    </span>",
"   </p>",
"   <p>",
"    Zolpidem is a sedative-hypnotic that is widely used for treatment of insomnia and known to cause residual daytime sedation, drowsiness, cognitive impairment, and motor incoordination in some individuals. Recent studies analyzed by the US Food and Drug Administration (FDA) suggest that 15 percent of women and 3 percent of men have sufficiently high next-morning zolpidem blood levels to impair driving after a 10 mg bedtime dose. Based upon these findings, FDA has required lowering the recommended bedtime dose of zolpidem in women from 10 to 5 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H947212#H947212\">",
"     \"Treatment of insomnia\", section on 'Nonbenzodiazepines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Avoid dabigatran with prosthetic heart valves",
"    </span>",
"   </p>",
"   <p>",
"    Based upon interim data from the European RE-ALIGN trial, the US FDA issued a safety communication warning of increased rates of stroke, myocardial infarction, thrombosis, and major bleeding in patients with mechanical prosthetic heart valves who received anticoagulation with dabigatran compared to dose-adjusted warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The US prescribing information now contraindicates use of dabigatran in patients with mechanical heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/53\">",
"     53",
"    </a>",
"    ]. We do not recommend the use of dabigatran for the prevention of embolization in patients with atrial fibrillation and valvular heart disease without a mechanical prosthetic valve as it has not been adequately studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link&amp;anchor=H4298909#H4298909\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Oral direct thrombin inhibitors and factor Xa inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H4338483#H4338483\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Serious skin reactions due to telaprevir, peginterferon-alfa, and ribavirin",
"    </span>",
"   </p>",
"   <p>",
"    Rash and pruritus are common side effects in patients receiving telaprevir, peginterferon-alfa, and ribavirin for chronic infection with hepatitis C virus, genotype 1. In most cases the rash is mild to moderate but can be severe in about 4 percent of patients; fatalities have been reported in patients with progressive rash and systemic symptoms who continued to receive medication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Because of this, US FDA issued a safety communication and is adding a black box warning to the licensing information instructing providers to discontinue telaprevir, peginterferon-alfa, and ribavirin immediately in patients who have a rash with systemic symptoms or a progressive severe rash [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/54\">",
"     54",
"    </a>",
"    ]. For patients who develop mild to moderate non-progressive rash, without systemic symptoms, alternative management options can be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148836537#H148836537\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Telaprevir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors and bleeding",
"    </span>",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRIs) are believed to alter platelet aggregation, which increases the risk for bleeding. A meta-analysis of 16 observational studies (n=506,411) found that the risk of intracranial hemorrhage was elevated (relative risk 1.72, 95% CI 1.16-2.55) in patients who received SSRIs compared to controls who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/56\">",
"     56",
"    </a>",
"    ]. In a separate analysis, the risk of brain hemorrhage was higher in patients taking the combination of SSRIs and anticoagulants, compared with anticoagulants alone. However, the clinical significance of these findings is not clear. Based upon the meta-analysis, it was estimated that use of an SSRI may lead to one additional intracerebral hemorrhage for every 10,000 patients treated for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H12543449#H12543449\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Antibiotic exposure and risk for inflammatory bowel disease",
"    </span>",
"   </p>",
"   <p>",
"    Genetic and environmental factors contribute to the risk of developing inflammatory bowel disease (IBD). A new population-based study suggests that exposure during early childhood to antibiotics that target anaerobic bacteria increases the risk for IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\", section on 'Perinatal and early exposures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Meningitis and septic arthritis outbreak from contaminated methylprednisolone injection",
"    </span>",
"   </p>",
"   <p>",
"    A multistate outbreak of fungal central nervous system infection and septic arthritis was detected in the United States in late September 2012 when patients who had received epidural injections of methylprednisolone produced at a single compounding center (New England Compounding Center) developed meningitis with or without posterior circulation stroke and patients who received intra-articular injections of the same drug developed septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Infected patients have presented approximately one to six weeks after receiving a methylprednisolone injection, and some have had only mild symptoms. Although early in the outbreak the majority of patients presented with meningitis, the percentage of patients presenting with epidural abscess, phlegmon, discitis, vertebral osteomyelitis, or arachnoiditis at or near the site of injection has increased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/62\">",
"     62",
"    </a>",
"    ]. Updated information about case counts, diagnosis, and management can be found at the",
"    <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\">",
"     United States Centers for Disease Control and Prevention&rsquo;s website",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19321?source=see_link\">",
"     \"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Pediatric fatalities associated with postoperative codeine use",
"    </span>",
"   </p>",
"   <p>",
"    FDA revised&nbsp;an earlier safety communication&nbsp;and added a boxed warning to the prescribing information for codeine contraindicating its&nbsp;use in children following tonsillectomy or adenoidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/63\">",
"     63",
"    </a>",
"    ]. The analgesic efficacy of codeine depends upon biotransformation to active moieties (mainly morphine) by a cytochrome P450 enzyme (CYP2D6), which is known to be highly polymorphic. After taking a typical dose of codeine, patients who are ultra-rapid metabolizers may have higher than expected initial morphine levels that can lead to an overdose. Three fatalities and one near-fatal reaction were reported in children aged&nbsp;two to&nbsp;five who received postoperative codeine after tonsillectomy for obstructive sleep apnea and were found to be ultrarapid metabolizers of codeine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].&nbsp;Determining which children are ultrarapid metabolizers is difficult, making routine testing impractical.&nbsp;Morphine, oxycodone, or hydrocodone are&nbsp;alternatives for management of pediatric pain in the postoperative setting&nbsp;if an&nbsp;opioid is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link&amp;anchor=H35#H35\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Pain relief'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Hydroxyethyl starch solutions in hypovolemia",
"    </span>",
"   </p>",
"   <p>",
"    Concern has been raised about the potential risks of using hydroxyethyl starch solutions for fluid resuscitation. The validity of this concern was demonstrated in a randomized trial, in which 7000 critically-ill patients were randomly assigned to receive 6% hydroxyethyl starch or isotonic saline for all fluid resuscitation until discharge from the intensive care unit, death, or 90 days&nbsp;post randomization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/66\">",
"     66",
"    </a>",
"    ]. More patients in the hydroxyethyl starch group required renal replacement therapy, although no difference was found in the risk of death at 90 days in the two groups. Thus, saline solutions are preferred over hydroxyethyl starch solutions for most critically-ill patients with hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Combination vaccine for meningococcus and Haemophilus influenzae type b",
"    </span>",
"   </p>",
"   <p>",
"    A combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type b (MenHibrix, HibMenCY) was approved by the US Food and Drug Administration in June 2012 for infants and children 6 weeks to 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In prelicensure trials, this vaccine was safe, immunogenic, and did not interfere with immune responses to routine immunizations. In January 2013, the United States Advisory Panel on Immunization Practices began recommending HibMenCY for certain infants and toddlers at increased risk for meningococcal disease, beginning at two months of age (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. It is the first meningococcal vaccine to be recommended in the United States for use in infants younger than nine months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H937132#H937132\">",
"     \"Meningococcal vaccines\", section on 'Combination conjugate vaccine against meningococcus and Haemophilus influenzae type b'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H182642754#H182642754\">",
"     \"Meningococcal vaccines\", section on 'In infants and toddlers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     2012-2013 seasonal influenza vaccine",
"    </span>",
"   </p>",
"   <p>",
"    The CDC's Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) recommend annual influenza vaccination for",
"    <strong>",
"     all persons &ge;6 months",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. For individuals who reside in the northern hemisphere, the schedule for the 2012-2013 seasonal influenza vaccine varies depending upon age and the number of doses of influenza vaccine received after July 2010&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H9#H9\">",
"     \"Seasonal influenza vaccination in children\", section on 'Schedule'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H775052810#H775052810\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Schedule'",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"    <br/>",
"    <br/>",
"    Adults and children &ge;9 years of age should receive one dose.",
"    <br/>",
"    <br/>",
"    Children six months through eight years of age should receive:&nbsp;",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One dose if they received at least two doses of seasonal influenza vaccine after July 2010.",
"      <br/>",
"     </li>",
"     <li>",
"      Two doses, separated by at least one month, if they are receiving seasonal influenza vaccine for the first time, received fewer than two doses of seasonal influenza vaccine after July 2010, or if the number of doses of seasonal influenza vaccine received after July 2010 is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Influenza infection will occur among some individuals who received the influenza vaccine.",
"    </strong>",
"    &nbsp; Based upon analysis conducted by US Centers for Disease Control and Prevention (CDC) of acute respiratory illness in 2697&nbsp;individuals between December 2012 and mid-January 2013, the overall effectiveness of this season's&nbsp;vaccine is moderate (47 percent against influenza A and 57 percent against influenza B)&nbsp;or poor (9 percent) against H3N2 influenza A in older adults.&nbsp;This highlights the importance of early antiviral therapy regardless of vaccination status, particularly for those at risk for severe or complicated influenza infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H205840196#H205840196\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Effectiveness for the 2012-2013 season'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Egg protein-free seasonal influenza vaccines available",
"    </span>",
"   </p>",
"   <p>",
"    A trivalent inactivated influenza vaccine (Flucelvax) produced using cultured mammalian cells, instead of grown in embryonated hen eggs, was approved by US FDA for individuals &ge;18 years of age for the 2012-2013 influenza season (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The same vaccine (called Optaflu) was previously approved in Europe and elsewhere. A second egg-protein free vaccine (Flublok), made using an insect virus (baculovirus) expression system and recombinant DNA technology, was approved in January 2013 by FDA for adults aged 18 to 49 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/75\">",
"     75",
"    </a>",
"    ]. The efficacy and rates of serious adverse events seen with both egg-free vaccines were comparable to standard available influenza vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/74,76\">",
"     74,76",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    We recommend administration of egg protein-free influenza vaccine, if readily available, in patients &ge;18 years of age with egg allergy. If an egg-free vaccine is not readily available, an opportunity for immunization should not be missed and patients with egg allergy should receive standard available inactivated vaccine with appropriate precautions (eg, observation for 30 minutes following vaccination in patients with mild allergic reactions to egg, and immunization supervised by an allergy specialist for patients with a history of severe egg allergic reactions).&nbsp;",
"    <br/>",
"    <br/>",
"    We do not recommend the use of either egg protein-free vaccine in patients &lt;18 years of age since the",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine appears to be less immunogenic in young children and the immunogenicity of these vaccines and rates of side effects in this population are otherwise not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H8#H8\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Alternative methods of vaccine production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H9#H9\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Options for testing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Tdap recommended during each pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    US Advisory Committee on Immunization Practices (ACIP) now recommends that all pregnant women receive tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, to better protect their infant against pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/27/12730/abstract/77\">",
"     77",
"    </a>",
"    ]. Tdap should be administered after 20 weeks and optimally between 27 and 36 weeks, regardless of prior vaccination status. Previously, Tdap was recommended only for pregnant women who had never received the acellular pertussis vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/1\">",
"      Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19:500.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. FDA approves new multiple sclerosis treatment: Tecfidera. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345528.htm (Accessed on April 10, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/3\">",
"      Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/4\">",
"      Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release: FDA approves Invokana to treat type 2 diabetes, March 2013. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm (Accessed on April 10, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/6\">",
"      Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/7\">",
"      Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/8\">",
"      Portman DJ, Bachmann GA, Simon JA, and the Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/9\">",
"      Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:295.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf?et_cid=31038989&amp;et_rid=463648356&amp;linkid=www.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f204026lbl.pdf (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     file://www.drugs.com/pro/skyla-iud.html (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/14\">",
"      Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves first anti-diarrheal drug for HIV/AIDS patients. Available at: file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm (Accessed on January 04, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Press Release: FDA approves Signifor, a new orphan drug for Cushing&rsquo;s disease (December 2012) file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htm (Accessed on January 16, 2013).",
"    </li>",
"    <li>",
"     FDA approves new orphan drug for rare cholesterol disorder. Available at: file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm (Accessed on January 04, 2013).",
"    </li>",
"    <li>",
"     FDA News Release file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm (Accessed on January 09, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/19\">",
"      Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/20\">",
"      Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/21\">",
"      Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/22\">",
"      Barochia AV, Cui X, Sun J, et al. Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis 2012; 205:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/23\">",
"      Nabel GJ. Protecting against future shock--inhalational anthrax. N Engl J Med 2009; 361:191.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release. FDA approves raxibacumab to treat inhalational anthrax. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     Anti-Infective Drugs Advisory Committee Meeting - 02 November 2012. Human Genome Sciences, Inc. Briefing Document, Raxibacumab - ",
"Treatment of Inhalational Anthrax. BLA 125349. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM326185.pdf (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/26\">",
"      Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/27\">",
"      Kim DW, Cortes J, Pinilla-Ibarz J, et al. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial (abstract 3749). ASH Annual Meeting Abstracts 2012; 120:3749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/28\">",
"      Kantarjian HM, Kim DW, Pinilla-Ibarz J, et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (abstract 915). ASH Annual Meeting Abstracts 2012; 120:915.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf?et_cid=30657199&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203469lbl.pdf (Accessed on December 17, 2012).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf?et_cid=30334780&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203585lbl.pdf (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/31\">",
"      Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012; 120:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/32\">",
"      EINSTEIN&ndash;PE Investigators, B&uuml;ller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287.",
"     </a>",
"    </li>",
"    <li>",
"     FDA expands use of Xarelto to treat, reduce recurrence of blood clots file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm (Accessed on November 04, 2012).",
"    </li>",
"    <li>",
"     FDA approves new multiple sclerosis treatment Aubagio. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm (Accessed on September 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/35\">",
"      O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/36\">",
"      O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/37\">",
"      Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm303659.htm (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/40\">",
"      Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368:1210.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Azithromycin (Zithromax or Zmax): Drug safety communication - risk of potentially fatal heart rhythms. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343350.htm?source=govdelivery (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Zmax (azithromycin extended release) for oral suspension. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262866.htm (Accessed on May 18, 2012).",
"    </li>",
"    <li>",
"     ZITHROMAX (azithromycin tablets) and(azithromycin for oral suspension) - prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/44\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/45\">",
"      Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/46\">",
"      Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.",
"     </a>",
"    </li>",
"    <li>",
"     Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm?source=govdelivery (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/48\">",
"      Wolf MS, King J, Jacobson K, et al. Risk of unintentional overdose with non-prescription acetaminophen products. J Gen Intern Med 2012; 27:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/49\">",
"      Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96.",
"     </a>",
"    </li>",
"    <li>",
"     Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses Including Ambien, Ambien CR, Edluar, and Zolpimist file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm (Accessed on January 20, 2013).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves file://www.fda.gov/Drugs/DrugSafety/ucm332912.htm (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/52\">",
"      Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012; 163:931.",
"     </a>",
"    </li>",
"    <li>",
"     Pradaxa (dabigatran etexilate) US prescribing information file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 (Accessed on November 16, 2011).",
"    </li>",
"    <li>",
"     Incivek (telaprevir) In Combination with Drugs Peginterferon Alfa and Ribavirin (Incivek combination treatment): Drug Safety Communication - Serious Skin Reactions file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332860.htm (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/55\">",
"      Jacobson IM, McHutchison JG, Dusheiko GM. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: Final results of phase 3 ADVANCE study. Hepatology 2010; 52:427A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/56\">",
"      Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/57\">",
"      McGrath ER, O'Donnell MJ. Estimating treatment effects in observational studies. Neurology 2012; 79:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/58\">",
"      Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012; 130:e794.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC Health Advisory. Meningitis and stroke associated with potentially contaminated product. file://www.bt.cdc.gov/HAN/han00327.asp (Accessed on October 11, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Multi-state meningitis outbreak. file://www.cdc.gov/hai/outbreaks/meningitis.html (Accessed on January 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/61\">",
"      Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy &mdash; United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61 (Early release):1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Health Alert Network. Update: multistate outbreak of fungal meningitis and other infections associated with contaminated steroid medication. file://emergency.cdc.gov/HAN/han00335.asp (Accessed on November 22, 2012).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. file://www.fda.gov/Drugs/DrugSafety/ucm339112.htm (Accessed on February 27, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/64\">",
"      Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009; 361:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/65\">",
"      Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 2012; 129:e1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/66\">",
"      Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367:1901.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. News &amp; Events. FDA approves new combination vaccine that protects children against two bacterial diseases. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Menhibrix&amp;utm_content=1 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     GSK receives FDA approval for MenHibrix. file://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1134059.htm (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/70\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/71\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/72\">",
"      Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2012-2013. Pediatrics 2012; 130:780.",
"     </a>",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     FDA news release. FDA approves new seasonal influenza vaccine made using novel technology file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/27/12730/abstract/76\">",
"      Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok&reg;) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733.",
"     </a>",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8360 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-124.240.187.81-3C54767836-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12730=[""].join("\n");
var outline_f12_27_12730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CYP2D6 inhibitors, genotypes, and breast cancer treatment with tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEW DRUGS AND US DRUG APPROVALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dimethyl fumarate for treatment of relapsing-remitting multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Canagliflozin for treatment of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ospemifene for treatment of vulvovaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Novel device for epinephrine self-injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Regorafenib for refractory GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pomalidomide for relapsed multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      New levonorgestrel-releasing IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Apixaban for stroke prevention in nonvalvular atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Crofelemer for antiretroviral-associated diarrhea in HIV/AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pasireotide for Cushing's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lomitapide for homozygous familial hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bedaquiline for multidrug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Raxibacumab for inhalation anthrax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ponatanib for CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Omacetaxine for chronic myelogenous leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rivaroxaban for acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Teriflunomide for multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ado-trastuzumab emtansine as second-line treatment for HER2-positive metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DRUG WITHDRAWALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Peginesatide withdrawn due to serious hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADVERSE REACTIONS AND WARNINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Everolimus should not be used within 30 days of liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Erythropoiesis stimulating agents and anemia associated with heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Azithromycin and torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hepatotoxicity associated with tolvaptan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Patient understanding of acetaminophen dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Statins and myalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Zolpidem dosing for treatment of insomnia in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Avoid dabigatran with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Serious skin reactions due to telaprevir, peginterferon-alfa, and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Selective serotonin reuptake inhibitors and bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Antibiotic exposure and risk for inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Meningitis and septic arthritis outbreak from contaminated methylprednisolone injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Pediatric fatalities associated with postoperative codeine use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Hydroxyethyl starch solutions in hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Combination vaccine for meningococcus and Haemophilus influenzae type b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      2012-2013 seasonal influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Egg protein-free seasonal influenza vaccines available",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Tdap recommended during each pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG/8360\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG/8360|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/56/8078\" title=\"table 1\">",
"      Apixaban drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 2\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 3\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/16/11527?source=related_link\">",
"      Ado-trastuzumab emtansine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=related_link\">",
"      Apixaban: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12869?source=related_link\">",
"      Bedaquiline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42832?source=related_link\">",
"      Canagliflozin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/56/21379?source=related_link\">",
"      Crofelemer: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/16/9476?source=related_link\">",
"      Dimethyl fumarate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=related_link\">",
"      Levonorgestrel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=related_link\">",
"      Lomitapide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=related_link\">",
"      Omacetaxine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=related_link\">",
"      Ospemifene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18746?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19321?source=related_link\">",
"      Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/12/30922?source=related_link\">",
"      Overview of immunosuppression in adult liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=related_link\">",
"      Pasireotide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=related_link\">",
"      Pomalidomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=related_link\">",
"      Ponatinib: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=related_link\">",
"      Prevention of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=related_link\">",
"      Raxibacumab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32006?source=related_link\">",
"      Regorafenib: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=related_link\">",
"      Rivaroxaban: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=related_link\">",
"      Teriflunomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=related_link\">",
"      Treatment of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=related_link\">",
"      Treatment of drug-resistant hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_27_12731="Cytotoxic uses MTX";
var content_f12_27_12731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oncologic spectrum of methotrexate activity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        T-cell large granular lymphocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute lymphoblastic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute promyelocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choriocarcinoma/malignant trophoblastic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-Hodgkin's lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desmoid tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptomeningeal metastases (both intrathecal and high-dose parenteral)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Crain Garrot, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12731=[""].join("\n");
var outline_f12_27_12731=null;
var title_f12_27_12732="Pregnancy class acne meds";
var content_f12_27_12732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pregnancy categories of acne medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical tretinoin",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adapalene",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tazarotene",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azelaic acid",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylic acid",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical erythromycin",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical clindamycin",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzoyl peroxide",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzoyl peroxide/clindamycin (Duac&reg;, Benzaclin&reg;, Acanya&reg;)",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzoyl peroxide/erythromycin (Benzamycin&reg;)",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adapalene/benzoyl peroxide (Epiduo&reg;)",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical tretinoin/clindamycin (Ziana&reg;)",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium sulfacetamide",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical dapsone",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral tetracycline, doxycycline, minocycline",
"       </td>",
"       <td>",
"        D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral erythromycin",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        C/D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral azithromycin",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral isotretinoin",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12732=[""].join("\n");
var outline_f12_27_12732=null;
var title_f12_27_12733="Medical history in children with chronic diarrhea";
var content_f12_27_12733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Implications of some aspects of the medical history in children with chronic diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Line of questioning",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical implication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Congenital",
"       </td>",
"       <td class=\"sublist_other\">",
"        Chloridorrhea, Na+ malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abrupt",
"       </td>",
"       <td class=\"sublist_other\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gradual",
"       </td>",
"       <td class=\"sublist_other\">",
"        Everything else",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Coincides with introduction of wheat cereals",
"       </td>",
"       <td class=\"sublist_other\">",
"        Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Stool characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Daytime only",
"       </td>",
"       <td class=\"sublist_other\">",
"        Functional diarrhea (chronic nonspecific diarrhea of childhood)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nocturnal",
"       </td>",
"       <td class=\"sublist_other\">",
"        Organic etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blood",
"       </td>",
"       <td class=\"sublist_other\">",
"        Dietary protein intolerance (eg, milk), inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        White/light tan color",
"       </td>",
"       <td class=\"sublist_other\">",
"        Absence of bile; Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history",
"       </td>",
"       <td>",
"        Congenital absorptive defects, inflammatory bowel disease, celiac disease, multiple endocrine neoplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Dietary history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        \"Sugar-free\" foods",
"       </td>",
"       <td class=\"sublist_other\">",
"        Fructose, sorbitol, or mannitol ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Excessive juice",
"       </td>",
"       <td class=\"sublist_other\">",
"        Osmotic diarrhea/chronic nonspecific diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Raw milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        Brainerd diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Exposure to potentially impure water source",
"       </td>",
"       <td class=\"sublist_other\">",
"        Chronic bacterial infections (eg, aeromonas), giardiasis, cryptosporidiosis, Brainerd diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Travel history",
"       </td>",
"       <td>",
"        Infectious diarrhea, chronic idiopathic secretory diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to thrive/weight loss",
"       </td>",
"       <td>",
"        Malabsorption, pancreatic exocrine insufficiency, anorexia nervosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous therapeutic interventions (drugs, radiation, surgery, antibiotics)",
"       </td>",
"       <td>",
"        Drug side effects, radiation enteritis, postsurgical status, pseudomembranous colitis (C. difficile), post-cholecystectomy diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary gain from illness",
"       </td>",
"       <td>",
"        Laxative abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic illness symptoms",
"       </td>",
"       <td>",
"        Hyperthyroidism, diabetes, inflammatory bowel disease, tuberculosis, mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous drug abuse, sexual promiscuity (in adolescent or in child's parent)",
"       </td>",
"       <td>",
"        HIV disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune problems",
"       </td>",
"       <td>",
"        HIV disease, immunoglobulin deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"       <td>",
"        Obstruction, irritable bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive flatus",
"       </td>",
"       <td>",
"        Carbohydrate malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leakage of stool",
"       </td>",
"       <td>",
"        Fecal incontinence (consider occult constipation)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Fine, KD, Schiller, LR, AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12733=[""].join("\n");
var outline_f12_27_12733=null;
var title_f12_27_12734="Diagnosis of CAPS with APS or aPL";
var content_f12_27_12734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis of catastrophic antiphospholipid syndrome (APS): Patients with APS or persistent positive antiphospholipid antibody",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Catastrophic antiphospholipid syndrome (APS) diagnosis in patients with history of APS or persistent antiphospholipid antibody (aPL)-positivity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10:74. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12734=[""].join("\n");
var outline_f12_27_12734=null;
var title_f12_27_12735="HBIG post liver transplantation";
var content_f12_27_12735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Effect of hepatitis B immunoglobulin after liver transplantation for hepatitis B virus-associated cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 276px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with hepatitis B virus-associated cirrhosis were randomized to long-term or short-term hepatitis B immunoglobulin (HBIG) or no immunoprophylaxis after liver transplantation. Patients treated with long-term HBIG had both a lower incidence of HBsAg recurrence (left panel) and a higher rate of survival (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Samuel D, Muller R, Alexander G, et al. N Engl J Med 1993; 329:1842.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_27_12735=[""].join("\n");
var outline_f12_27_12735=null;
